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Abbreviations
α2-AP α2-antiplasmin
aa aminoacids
ADP adenosine diphosphate
APC activated protein C
APTT activated partial thromboplastin time
ATIII antithrombin III
AU arbitrary units
BCA bicinchoninic acid
BSA bovine serum albumin
BU Bethesda units
C4BP C4b-binding protein
CHRF megakaryocytic cell line representing the late
stage of megakaryocyte development
COL collagen
CPA carboxypeptidase A
CPB carboxypeptidase B
CPE carboxypeptidase E (= CPH)
CPH carboxypeptidase H (= CPE)
CPI carboxypeptidase inhibitor from potato tubers
CPM carboxypeptidase M
CPN carboxypeptidase N
CPR carboxypeptidase R
CPU carboxypeptidase U
DAMI megakaryocytic cell line representing the
intermediate stage of megakaryocyte development
DD(E) complex of D-dimer non-covalently associated
with fragment E
DESAFIB-X minimally degraded human fibrin
DFP diisopropyl fluorophosphate
DIC disseminated intravascular coagulation
dNTP deoxyribonucleoside triphosphates
DTT dithiothreitol
εACA ε-amino caproic acid
EDTA ethylenediaminetetraacetic acid
EGF epidermal growth factor
ELISA enzyme-linked immunosorbent assay
EPCR endothelial protein C receptor
EPI epinephrine
FCS foetal calf serum
FDP fibrin degradation products
fII prothrombin
fIX factor IX
fV factor V
fVII(a) (activated) factor VII
fVIII factor VIII
fX factor X
fXI factor XI
fXIII factor XIII
FPLC fast protein liquid chromatography
GEMSA guanidinoethyl-mercaptosuccinic acid
HBS Hepes buffered saline
HEPES N-2-hydroxyethylpiperazine-N’-2-ethane
sulfonic acid
HepG2 human hepatoma cell line
HMEC human microvascular endothelial cell
HPLC high performance liquid chromatography
HUVEC human umbilical vein endothelial cell
IIa thrombin
MEG01 megakaryocytic cell line representing the early
stage of megakaryocyte development
MERGETPA DL-2-mercaptomethyl-3-guanidino-
ethylthiopropanoic acid
n.a. not applicable
n.d. not determined
NP normal plasma
PAI plasminogen activator inhibitor
PAP plasmin-α2-antiplasmin complex
PBS phosphate buffered saline
PC protein C
PC L-α-phosphatidylcholine, dioleoyl
PC/PS/PE phospholipid vesicles consisting of
40% PC, 20% PS and 40% PE
PC/PS/C4BPdP protein C/protein S/C4BP triple depleted plasma
PCI protein C inhibitor
pCPB plasma carboxypeptidase B
PE L-α-phosphatidylethanolamine, dioleoyl
plg plasminogen
plt platelets
PPACK H-D-Phe-Pro-Arg-chloromethylketone
PS L-α-phosphatidylserine, dioleoyl
PS protein S
PS/C4BPdP protein S/C4BP double depleted plasma
RT-PCR reverse transcriptase-polymerase chain reaction
scu-PA single-chain urine-type plasminogen activator
SD standard deviation
SDS-PAGE sodium dodecyl sulphate polyacrylamide gel
electrophoresis
SEM standard error of the mean
SERPIN serine protease inhibitor
SUP supernatant
SWARPO peroxidase-conjugated swine antibody against
rabbit IgG
TAFI thrombin activatable fibrinolysis inhibitor
TAFIa activated TAFI
TAFIai inactivated TAFIa
TBS Tris buffered saline
TF tissue factor
TFPI tissue factor pathway inhibitor
TM thrombomodulin
TM4-6 thrombomodulin fragment containing EGF
domains 4 to 6
TNFα tumor necrosis factor α
tPA tissue-type plasminogen activator
TRAP thrombin receptor activating peptide
Tris tris(hydroxymethyl)aminoethane
uPA urine-type plasminogen activator, urokinase
vWF von Willebrand factor
XI-1 an inhibitory  monoclonal antibody against
factor XI
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Thombin Activatable Fibrinolysis Inhibitor
(TAFI, plasma procarboxypeptidase B,
procarboxypeptidase R,
procarboxypeptidase U)
( Thrombosis Research 2001; in press )
Chapter 1
Bonno N. Bouma
Pauline F. Marx
Laurent O. Mosnier
Joost C.M. Meijers
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Introduction
Recently, a new inhibitor of fibrinolysis was described. This inhibitor down regulated
fibrinolysis after it was activated by thrombin, and was therefore named TAFI (thrombin
activatable fibrinolysis inhibitor; EC 3.4.17.20). TAFI turned out to be identical to previously
described proteins, procarboxypeptidase U, procarboxypeptidase R, and plasma
procarboxypeptidase B. In this overview, the protein will be referred to as TAFI. TAFI is a
procarboxypeptidase and a member of the family of metallocarboxypeptidases. These enzymes
are circulating in plasma and are present in several tissues such as pancreas. In this review, we
will describe the properties of basic carboxypeptidases with the emphasis on the role of TAFI in
coagulation and fibrinolysis. It cannot be ruled out however, that TAFI has other, yet undefined
functions in biology.
Carboxypeptidases
Carboxypeptidases are enzymes that hydrolyze carboxy-terminal peptide bonds. The family
of carboxypeptidases consists of serine carboxypeptidases, cysteine carboxypeptidases, and
metallocarboxypeptidases. Serine and cysteine carboxypeptidases have a serine or cysteine
residue, respectively, in their active center, whereas metallocarboxypeptidases carry a zinc atom
that is important for their catalytic action (for an overview of basic carboxypeptidases, see table 1).
The pancreatic metallocarboxypeptidases playing a role in the digestive system are the best-
characterized members of this group. According to their substrate specificity, they are referred to
as carboxypeptidase A (CPA), which preferentially hydrolyzes aliphatic residues, or
carboxypeptidase B (CPB), which preferentially hydrolyzes basic amino residues. A number of
non-digestive carboxypeptidases have been discovered more recently, such as mast cell
carboxypeptidase A, carboxypeptidase E (CPE, also known as CPH) and membrane-bound
carboxypeptidase M (CPM).
Since much is known about the structure and catalytic mechanisms of pancreatic CPB, and
because of its similarity to TAFI, CPB will be discussed here. Pancreatic carboxypeptidase B was
discovered in 1958 (1). It is a digestive enzyme and its level in normal serum is almost
undetectable. Only during pancreatitis, the active enzyme can be found in serum (2). Its half-life
9C
H
A
P
T
E
R
1
in blood is in the order of minutes may be because it is not glycosylated (3). Pancreatic CPB has
a molecular weight of 35 kD and is synthesized in the pancreas in a zymogen form (46 kD) that
is devoid of enzymatic activity. Pancreatic CPB has two distinguishable domains, a catalytic
domain and an activation segment. The activation segment shields the preformed active site. A
salt bridge between Arg-145 in the active center and Asp-41 in the activation segment prevents
binding of the carboxy-terminal carboxyl group of the substrate to Arg-145 (4). Mutation of Asp-
41 into asparagine or alanine resulted in a zymogen with a low intrinsic activity, indicating that
small substrates have access to the substrate-binding site and that the salt bridge between Asp-41
and Arg-145 contributes to the null activity of the zymogen (5). Activation of pancreatic CPB by
trypsin occurs by cleavage at Arg-95 resulting in the release of the activation segment and the
exposure of the substrate-binding site (6). The carboxy-terminal arginine is removed by the
active CPB and the activation segment is further cleaved at Arg-81. Active pancreatic CPB is,
Table 1. Characteristics of some mammalian basic carboxypeptidases
Name Structural characteristics Specificity Site of synthesis and tissue
localization
Function and physiological
substrates
Inhibitors Ref
Carboxypeptidase B
(EC 3.4.17.2)
(CPB)
proenzyme 46 kD (401 aa)
enzyme 35 kD (306 aa)
activation by proteolysis
at Arg-95
Arg > Lys pancreas, intestinal tract involved in the digestive
system
Cd2+, chelators, CPI,
MERGETPA, GEMSA
(120)
Carboxypeptidase N
(EC 3.4.17.3)
(CPN)
280 kD tetramer of
2 x 50 kD (438 aa) and
2 x 83 kD (522 aa)
Lys > Arg liver, present in blood removal of C-terminal basic
residues of proteins and
peptides in plasma, like
bradykinin, kinins,
anaphylatoxins (C3a, C4a,
C5a), fibrinopeptides A and B
Cd2+, chelators,
MERGETPA, GEMSA
(121)
Carboxypeptidase M
MAX.1 monocyte/
macrophage differ-
entiation antigen)
(EC 3.4.17.12)
(CPM)
62 kD (426 aa)
23% carbohydrate content,
6 potential glycosylation
sites
Arg > Lys membrane bound form in kidney,
lung, placenta, intestine, brain,
peripheral nerves and blood
vessels; soluble form in amniotic
fluid, seminal plasma and urine
involved in processing peptide
hormones on cell surface, like
bradykinin, enkephalins,
dynorphin A1-13
Cd2+, chelators,
MERGETPA, GEMSA
(122)
Carboxypeptidase D
(EC 3.4.17.22)
(CPD)
180 kD (1380 aa) Arg > Lys brain, pituitary, placenta,
pancreas, adrenal, kidney, lung,
heart, spleen, intestine, ovary,
testis
role in processing of proteins
and peptides that transit the
secretory pathway
Cd2+, chelators,
MERGETPA, GEMSA
(123)
Carboxypeptidase E
(enkephalin
convertase)
(EC 3.4.17.10)
(CPE = CPH)
enzyme 52-56 kD (434 aa)
2 glycosylation sites
activation by proteolysis
of the N-terminus (14 aa)
Arg, Lys brain, pituitary, pancreatic islets,
other neuroendocrine cells
involved in the production of
peptide hormones and
neurotransmitters
Cd2+, chelators, CPI,
MERGETPA, GEMSA,
p-chloro-mercuriphenyl-
sulfonate, HgCl2
(124)
Carboxypeptidase Z
(CPZ)
71 kD (641 aa)
contains a frizzled domain
Arg > Lys salivary gland, placenta, heart,
brain, lung, liver, skeletal muscle,
kidney, pancreas
chelators, p-chloro-
mercuriphenyl-sulfonate,
GEMSA, Zn2+, Mn2+, Cd2+,
Cu2+, Hg2+, MERGETPA
(125, 126)
Adipocyte-enhancer
binding protein 1
(AEBP1)
79 kD (719 aa)
activation by DNA
binding
Arg > Lys adipocyte role in repression of
transcription
(127, 128)
Thrombin
activatable
fibrinolysis inhibitor
(EC 3.4.17.20)
(TAFI)
proenzyme 55 kD (401 aa)
enzyme 35 kD (309 aa)
activation by proteolysis
at Arg-92
4  glycosylation sites in
the activation peptide.
Arg > Lys liver, present in blood role in coagulation and
fibrinolysis
substrates: hexapeptide
enkephalins, bradykinin,
partially degraded fibrin
Cd2+, chelators, CPI,
MERGETPA, GEMSA,
dithiothreitol, 2-
mercaptoethanol
(129)
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in contrast to activated TAFI, a stable protease (6). The zinc in the active center of pancreatic CPB
is coordinated to His-69, Glu-72 and His-196 (figure 1). Other important groups involved in
catalysis are Arg-127 and Glu-270. Arg-145 is important for substrate binding in which it is
assisted by Asn-144 and Tyr-248 whereas Asp-255 is likely to determine the specificity for basic
amino acids since for instance carboxypeptidase A contains an isoleucine or leucine in this
position (7). Presumably, the negatively charged aspartic acid residue attracts basic amino acids
whereas isoleucine or leucine in CPA attract hydrophobic amino acids. In addition, Gly-207 and
Ile-243 in CPB contribute to the creation of a polar environment. All these amino acids are
conserved at analogous sites in TAFI. The key catalytic residue Glu-270 activates a water
molecule for nucleophilic attack on the substrate carbonyl and subsequent proton transfer is the
general mechanism of catalysis. The zinc ion is involved in water polarization and stabilization
of the tetrahedral intermediate (figure 1).
Carboxypeptidase N
In plasma, the family of metallocarboxypeptidases is represented by carboxypeptidase N
(also known as lysine carboxypeptidase, kininase I, anaphylatoxin inactivator), and TAFI.
Carboxypeptidase N (CPN) is constitutively active whereas the carboxypeptidase activity of
TAFI is generated during blood clotting. CPN was discovered by Erdös and Sloane in 1962 as an
enzyme that inactivated bradykinin by removing its carboxy-terminal arginine (8). CPN was
shown to cleave a large number of endogenous peptides and protein substrates including kinins,
anaphylatoxins (C3a, C4a and C5a), and fibrinopeptides A and B. These peptides exert potent
and potentially deleterious effects, and removal of their carboxy-termini by CPN is an important
regulatory step in limiting and modulating their activities (9). CPN is synthesized in the liver and
is secreted in the circulation in its active form. The concentration in plasma is 30 µg/ml. CPN is
a glycoprotein with a molecular weight of 280 kD. It is a tetramer with two catalytic subunits of
50 kD, and two non-catalytic subunits of 83 kD that are heavily glycosylated. The subunits are
held together by non-covalent interactions (10). CPN contains a zinc ion in its active center and
removal of the zinc by chelating agents such as 1,10-phenanthroline and EDTA results in loss of
enzymatic activity. CPN cleaves a variety of synthetic and naturally occurring substrates
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Figure 1. The role of zinc in the catalytic reaction of TAFIa
A. Enzyme-bound zinc generates a hydroxyl nucleophile from bound water, which attacks the
carbonyl of the peptide bond of the carboxy-terminal arginine as indicated by the arrow. Glu-
271 assists by pulling the proton from the zinc-bound water. Arg-125 polarizes the oxygen atom
of scissile carbonyl group through a hydrogen bond with its guanidinium group, making it more
susceptible to a nucleophilic attack by a water molecule.
B. The positive charges of zinc and Arg-125 stabilize the negative charge that develops on the
oxygen of the tetrahedral carbon in the transition state. The tetrahedral intermediate then
collapses as indicated by the arrows, resulting in breakage of the peptide bond.
C. The carboxy-terminal arginine residue is released and a new carboxy-terminus is formed.
Numbering of amino acid residues as in TAFIa.
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containing carboxy-terminal arginine or lysine with a preference of lysine over arginine. In
contrast to TAFI, CPN does not modulate fibrinolysis and is not inhibited by the
carboxypeptidase inhibitor from potato tubers (CPI). A total deficiency of CPN has not been
described. In one person, a decreased level of CPN (20% of normal) in plasma was detected in
association with repeated attacks of angioneurotic edema (11).
Discovery of TAFI and nomenclature
The presence of a labile carboxypeptidase activity in serum that interfered with the
measurement of carboxypeptidase N was first reported in 1988 (12, 13). The new
carboxypeptidase activity was not present in plasma but appeared after clotting of the blood. The
enzyme differed from CPN in terms of stability, pH optimum and substrate specificity. In
addition, separation of fresh human serum by ion-exchange chromatography yielded 2 peaks
exhibiting basic carboxypeptidase activity. The carboxypeptidase activity in the first peak was
unstable at 37 oC, whereas the carboxypeptidase activity in the second peak was stable at 37 oC.
Because of its instability, the new enzyme was called carboxypeptidase U (CPU, where ‘U’
indicates unstable) (13, 14). Campbell and Okada also showed an increase of arginine
carboxypeptidase activity induced during coagulation (15). The same increase in
carboxypeptidase activity was also found in CPN-depleted plasma and the authors therefore
concluded that the arginine carboxypeptidase activity was unrelated to CPN. The enzyme was
called carboxypeptidase R (CPR, where ‘R’ stands for arginine). Eaton et al. (16) discovered the
same enzyme as a contaminant during the purification of α2-antiplasmin, utilizing plasminogen-
Sepharose affinity chromatography. The cDNA of the enzyme was cloned from human liver and
the amino acid sequence was deduced. The enzyme was called plasma procarboxypeptidase B
(pCPB, where ‘B’ stands for basic) because the active enzyme had a similar activity as pancreatic
carboxypeptidase B. Although the molecular weight of CPU was initially reported to be 435 kD
(14), this was adjusted in subsequent studies to 53-60 kD (17-19). Wang et al. (17) confirmed that
CPU and plasma carboxypeptidase B were identical proteins.
In search of the mechanism behind the profibrinolytic effect of activated protein C (20-24),
Bajzar et al. (18) purified the same enzyme and showed that it can be activated by thrombin and
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that upon activation it inhibits fibrinolysis. They called the enzyme thrombin activatable
fibrinolysis inhibitor (TAFI).
At the moment several names are used for the same enzyme: CPU, CPR, pCPB and TAFI. It
is clear that there is a need for one accepted name. In general it is preferable to name an enzyme
according to its specificity or general catalytic mechanism and not after a single substrate or
biological function. The use of the designation ‘U’ in CPU has the disadvantage that other
unstable carboxypeptidases might be discovered. The ‘R’ in CPR is not specific enough because
the enzyme not only cleaves carboxy-terminal arginine but also lysine residues. The name pCPB
is more specific because it implies that carboxy-terminal basic amino acids can be cleaved off,
however in earlier literature carboxypeptidase N has also been referred to as plasma
carboxypeptidase B or serum carboxypeptidase B. Here, we will use the name TAFI because the
focus in this review is on the properties of the enzyme in the fibrinolytic system. TAFI is the
zymogen form of the carboxypeptidase, whereas the active enzyme will be designated as TAFIa.
Characterization of TAFI
TAFI is synthesized in the liver as a prepropeptide consisting of 423 amino acids. The N-
terminal signal peptide of 22 amino acids is efficiently removed intracellularly (16). TAFI is a
glycoprotein with a molecular weight of 55 kD and an isoelectric point of 5.0. The attachment of
carbohydrates to the protein constitutes approximately 20% of the total mass. TAFI circulates in
plasma at a concentration of 4-15 µg/ml (25, 26).
Activation of TAFI by trypsin, plasmin, thrombin or meizothrombin occurs by a single
cleavage at Arg-92 (figure 2). In analogy with pancreas CPB the substrate-binding site of the
preformed active catalytic unit may be covered by the activation peptide. Release of the
activation peptide uncovers the binding site making the interaction of Arg-143 with the carboxy-
terminal carboxyl group of the substrate possible. The activation peptide contains four potential
N-linked glycosylation sites at Asn-22, Asn-51, Asn-63, and Asn-96. The 36 kD catalytic unit of
309 amino acids is not glycosylated. TAFI contains 8 cysteine residues of which one is located
in the activation peptide, however there are no disulfide bonds between the activation peptide and
the catalytic unit. The glycosylation of the activation peptide may act to stabilize and increase the
14
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half-life of circulating TAFI. Plasma elimination studies in mice suggested a half-life of
circulating TAFI of several hours (27). Pancreatic CPB, which is not glycosylated, has a half-life
of only minutes (3).
Based on its homology with other carboxypeptidases, TAFI is supposed to be a zinc
containing metallocarboxypeptidase (figure 1). Although the presence of zinc has not been
directly proven the zinc chelating agent 1,10-phenantroline inhibited TAFIa (16). Residues of
carboxypeptidase A and B that were implicated in catalysis (Glu-271, Arg-125; residue
numbering of TAFIa), substrate binding (Arg-143, Tyr-249, Asn-142) and zinc binding (His-67,
Glu-70, His-196) are conserved in the 309-amino acid catalytic domain of TAFIa (16). The
presence of Asp-257 may determine the specificity for basic amino acids.
In plasma, TAFI is suggested to circulate in complex with plasminogen (28), although direct
evidence is still lacking. TAFI was identified as a contamination during the isolation of
α2-antiplasmin on plasminogen-Sepharose chromatography (16), and purified plasminogen
preparations were found to contain TAFI (16). TAFI binds with a 10-fold higher affinity to Lys-
plasminogen compared to Glu-plasminogen (Kd 0.035 and 0.3 µM, respectively) (28). The
binding of plasminogen is likely to be mediated by the glycosylated activation peptide of TAFI
since activation of TAFI reduced the affinity for Glu- and Lys-plasminogen by 7 and 10-fold,
respectively (28). Involvement of kringle 1 of plasminogen was suggested since α2-antiplasmin
and 6-amino-n-hexanoic acid (εACA) reduced TAFI binding (28). The observation that TAFI
binds preferentially to Lys-plasminogen would argue against a circulating complex in plasma
between TAFI and plasminogen, but rather indicate that this complex is formed during
plasminogen activation when Lys-plasminogen becomes available. The conversion of Lys-
plasminogen to plasmin is not fibrin specific and complex formation with TAFI may therefore
prevent unlocalized plasmin formation.
Since TAFIa has a reduced affinity for plasminogen and because its molecular mass is below
the glomerular filtration limit (27), the active enzyme may not be retained in the circulation.
Plasma elimination studies in mice indicated however that TAFIa remained in the circulation in
a non-covalent complex with α2-macroglobulin and pregnancy zone protein (27). The catalytic
function of TAFIa was not affected by its binding to α2-macroglobulin. The specific binding of
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TAFIa to these macroglobulins may function as an in vivo shuttle to modulate the clearance of
TAFIa from the circulation (27).
Activation of TAFI by thrombin is an inefficient process (KM 0.5-2.1 µM, kcat 0.0021 s-1) (29-
31) and subsequently large amounts of thrombin are required. The endothelial cell receptor
thrombomodulin stimulates the activation of TAFI by thrombin 1250-fold which is almost
exclusively due to an increase in the catalytic efficiency (k
cat in the presence of thrombomodulin
is 0.4-1.2 s-1) (29-31). Compared to thrombin, the KM for plasmin-mediated TAFI activation is
much lower (55 nM), whereas the k
cat is 5-fold lower (0.0004 s-1) (32). Activation of TAFI by
plasmin is stimulated by glycosaminoglycans about 15-fold (32). Other coagulation and
fibrinolytic enzymes such as urokinase, tPA, activated protein C, kallikrein, and factors VIIa, IXa
and Xa were not capable of activating TAFI (16, 33).
TAFIa has a preference for carboxy-terminal arginine residues above carboxy-terminal lysine
(17). The pH optimum of TAFIa is 7.7 (13). TAFIa is inhibited by zinc chelators such as
1,10-phenantroline and EDTA, by εACA (Ki=0.8 mM), potato carboxypeptidase inhibitor
(Ki=0.4 nM), dithiothreitol, 2-mercaptoethanol, MERGETPA, 4-chloromercuribenzoic acid,
GEMSA (Ki=18 µM), and peptide inhibitor from the leech Hirudo medicinalis (14, 30, 34).
Inactivation of TAFIa
The enzymatic activity of TAFIa is unstable, and inactivation was reported to take place by
proteolytic cleavage and by a spontaneous temperature-dependent process (figure 3) (16, 17, 29,
30). Upon incubation of TAFI with trypsin, TAFIa activity first increased and then decreased.
Identification of the trypsin cleavage sites indicated that TAFI was cleaved at Arg-92 and Arg-
330 (16). The latter cleavage yielded a 25 kD inactive fragment and a carboxy-terminal
polypeptide of 71 amino acids. Similar cleavage patterns were found upon incubation with either
plasmin or thrombin. It was suggested that the inactivation of TAFIa took place by cleavage at
Arg-330. However, a mutant form of TAFIa in which Arg-330 was replaced by Gln was still
inactivated by thrombin-thrombomodulin, indicating that cleavage at Arg-330 was not
responsible for inactivation (35). The same results were obtained when Arg-320 was replaced by
Gln (35). Identification of the cleavage sites in TAFI generated during activation and inactivation
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of TAFIa by thrombin-thrombomodulin indicated that the active 36 kD form of TAFIa was
cleaved at Arg-302 into polypeptides of 25 and 11 kD (19). A TAFI mutant in which Arg-302 was
replaced by glutamine was not proteolyzed into the 25 and 11 kD fragments confirming that Arg-
302 is the major cleavage site of thrombin-thrombomodulin in TAFIa (19, 35). Interestingly, the
Arg-302-Gln mutant of TAFIa was still inactivated (19, 35), suggesting that inactivation of
TAFIa is caused by conformational instability as was reported before (17, 29, 30).
The instability of TAFIa is highly sensitive to temperature; the half-life of TAFIa increased
from 10 minutes at 37 oC, 45 minutes at 30 oC, to several hours at 22 oC. At 0 oC, the enzyme is
stable (30). The decay of TAFIa activity is associated with a substantial decrease in the intrinsic
fluorescence of TAFIa implying that a spontaneous structural change accounts for the loss of
activity of the enzyme (35). TAFIa cannot only be stabilized by decreasing the temperature but
also agents such as εACA, heparin, and GEMSA prevent the thermal decay of TAFIa (28, 32, 35).
εACA and GEMSA also slowed down the proteolytic cleavage at Arg-302, suggesting that the
conformational change that causes the inactivation makes TAFIa a more susceptible substrate for
proteolysis (19, 28, 32, 36). Furthermore, proteolytic cleavage may make inactivation of TAFIa
an irreversible process (35). However, addition of εACA to inactivated Arg-302-Gln mutant
TAFIa did not result in a regain of activity (P.F. Marx et al., unpublished observation). The
mechanism by which εACA stabilizes TAFIa is unknown, but suggests the involvement of
lysine-binding sites in TAFI. Interestingly, TAFI was found to bind to immobilized fibrin
monomers pretreated with plasmin, and this binding could be abolished by εACA or pancreatic
carboxypeptidase B (L.O. Mosnier et al., unpublished observation). Carboxy-terminal lysine
residues in fibrin may have a similar stabilizing effect on the activity of TAFIa as εACA. If so,
TAFIa would be most effective in situations where partially degraded fibrin is present, because
fibrin-bound TAFIa would presumably be resistant to spontaneous loss of activity.
Genomic organization of TAFI
The human TAFI cDNA has been isolated and characterized in 1991 (16). Recently, also the
cDNA of mouse and rat TAFI has been isolated and characterized (37-39). The predicted amino
acid sequence of mouse TAFI showed 85% identity with mature human TAFI including
17
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Figure 2. Schematic overview of TAFI gene and protein
The TAFI gene consists of 11 exons (the colors refer to the different regions of the protein encoded
by the exons; size in bases) separated by introns (size in kbases). TAFI is synthesized in the liver as
a prepropeptide consisting of 423 amino acids. The N-terminal signal peptide (yellow, 22 aa) is
removed upon secretion. TAFI (56 kDa, 401 aa) is proteolytically activated to TAFIa by thrombin,
trypsin and plasmin, by cleavage at Arg-92, which results in release of the activation peptide
(green, 20 kDa, 92 aa) from the catalytic domain (dark blue and purple, 35 kDa, 309 aa). All four
N-linked glycosylation sites (ξ) are located in the activation peptide. TAFIa is inactivated by a
conformational change (TAFIai, light blue and pink) (see Figure 3). Further proteolysis at Arg-302
by thrombin results in 25 kDa (light blue) and 11 kDa (pink) fragments.
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conservation of all sites considered to be involved in substrate binding, glycosylation, zinc
binding and substrate specificity. Also arginine 92, which is the thrombin cleavage site for TAFI
activation, was conserved.
The human TAFI gene was recently characterized and found to span approximately 48 kb of
genomic DNA (figure 2) (36). The gene consists of 11 exons. The positions of intron/exon
boundaries were conserved between the TAFI gene and the rat pancreatic carboxypeptidase A1,
A2, and B and the human mast cell carboxypeptidase A genes, indicating that these
carboxypeptidases arose from a common ancestral gene (36). The human TAFI gene was mapped
to chromosome 13q14.11 (40, 41).
The human TAFI promoter was characterized and found to lack a common TATA sequence
(36). Also, multiple initiation starter sites were described. This is in contrast to other
carboxypeptidase genes, such as the pancreatic carboxypeptidases, which all contain a TATA
box and have unique transcriptional start sites. It was therefore concluded that in the evolution of
the TAFI gene, it evolved to be expressed in the liver and that its promoter region acquired
characteristics commonly associated with the promoters of the vitamin K-dependent coagulation
factor proteins, which are also liver-specific in their expression (36).
Recently, it was observed that TAFI expression was influenced by inflammatory
mechanisms. A correlation between TAFI levels and the acute phase reactants C-reactive protein
and haptoglobin was observed in humans (42), and in mice TAFI was found to be an acute-phase
protein (38).
TAFI polymorphisms
Two isoforms of the TAFI gene have been described with one form varying from the other by
alanine for threonine at position 147 (43). The two isoforms were both found to be present in the
population, suggesting that this is a polymorphism. Both isoforms were expressed in a
baculovirus expression system, and extensively characterized. All functional aspects were found
to be similar between the isoforms indicating that the affected residue does not play a major role
in TAFI function (43). This has been further illustrated by the observation that in mouse TAFI this
residue has been changed to an arginine (37). A silent mutation was observed in the cDNA for
TAFI at position 678 (C to T), but this has not been further investigated (43).
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In a recent study, seven novel polymorphisms were described in the promoter region of the
TAFI gene: -152 A/G, -438 A/G, -530 C/T, -1053 C/T, -1102 T/G, -1690 G/A, and –1925 T/C
(44). Five of the seven polymorphisms were located within or very close to potential binding sites
of several transcription factors. Also, the polymorphisms were associated with TAFI antigen
levels. Furthermore, the polymorphisms appeared to confer a protective effect on the risk of
venous thrombosis, especially in young subjects (44). This has to be further evaluated in larger
studies.
Synthesis of TAFI
Human TAFI is synthesized by the liver (16, 41). Also, mouse TAFI was found to be
expressed in the liver and not expressed in tissues such as kidney, testis, spleen, lung and heart
(37). The human TAFI gene contains an approximately 70 bp fragment that was found to be
crucial for liver-specific transcription (36). In situ hybridization studies indicated that the
(mouse) TAFI mRNA was expressed heterogeneously in the hepatocyte, showing a pericentral
distribution within the liver lobule (37).
Recently, TAFI was also identified in platelets and could be secreted upon stimulation of the
platelets (45). Immunofluorescence microscopy revealed a staining pattern that was consistent
with intracellular localization of the protein in the α-granules. These results imply that TAFI
might play a role in the protection of the clot in the early stages of clot formation by increased
TAFI levels during platelet plug formation.
Recombinant TAFI has been expressed in insect cells (43), baby hamster kidney cells (19,
30), and 293 cells (37). In all cases, recombinant wild-type TAFI could be activated by thrombin-
thrombomodulin, and recombinant TAFIa and plasma TAFIa were very similar with respect to
kinetics of cleavage of small substrates, susceptibility to inhibitors and ability to retard both tPA-
and plasmin-induced fibrinolysis.
The presence of TAFI in pig, rat, guinea pig, rabbit, dog, baboon, and mouse plasma was
demonstrated using clot lysis and/or activity assays (37, 46, 47). However, large differences in
TAFIa activity ranging from 20% (mouse) to 500% (pig) compared to humans were observed. As
in man, TAFIa activity was unstable in all species tested. A role of TAFIa in clot lysis was
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Figure 3. Activation of TAFI and inactivation of TAFIa by the thrombin-
thrombomodulin complex
TAFI is a zinc containing metallocarboxypeptidase that consists of a catalytic domain and an
activation segment, which shields the preformed catalytic site. This conformation is stabilized by
a salt-bridge between the activation peptide and Arg-143 of the catalytic domain. The
thrombin-thrombomodulin complex activates TAFI to TAFIa by proteolysis at Arg-92, which results
in the release of the activation peptide from the catalytic domain and exposure of the
complete active site. TAFIa is a labile enzyme that is inactivated (TAFIai) by a temperature-
dependent conformational change. TAFIai is degraded by proteolysis at Arg-302. The
conformational change may make the protein more susceptible to proteolysis.
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demonstrated using potato carboxypeptidase inhibitor, a specific TAFIa inhibitor, which
shortened the lysis time suggesting that the function of TAFI is conserved during evolution.
Purification of TAFI
Several purification schemes have been described for the purification of TAFI. Eaton and
colleagues (16) identified TAFI as a contamination during the purification of α2-antiplasmin on
plasminogen Sepharose. Bajzar and coworkers (18) isolated the protein from plasma in search of
the missing link for the explanation of the profibrinolytic effect of activated protein C. In all
described procedures, fresh frozen plasma supplemented with protease inhibitors was the starting
material, and partial separation was performed by stepwise ammonium sulphate precipitations
(10, 45 and 70%) (16, 18, 28, 48), although also barium chloride, barium sulphate and aluminum
hydroxide have been used (18, 28, 49). Because of the relative high affinity of TAFI for
plasminogen compared to other plasminogen binding proteins, affinity chromatography of TAFI
on plasminogen-Sepharose provides an efficient step (16, 18, 26, 49, 50). Usually the plasma is
first applied to a lysine-Sepharose to remove plasminogen from the plasma. TAFI is eluted from
the plasminogen-Sepharose by εACA. Another frequently used step is ion exchange
chromatography (18, 19, 28, 48). A typical purification of TAFI from plasma results in a 10,000-
30,000-fold purification and a yield of approximately 10-20% (18, 33). The TAFI concentration
can be determined using the molar extinction coefficient of TAFI (ε1M, 280 nm = 1.28*105 M-1cm-1;
ε1%, 280 nm = 26.4, and M
r
 = 55.5 kD (18)) or the bicinchoninic acid (BCA) detection method, which
gives a slightly higher result.
Also, immunoaffinity chromatography using monoclonal antibodies for the purification of
TAFI has been reported (19, 28, 51). Glycine at pH 2.5-3 was found to be an effective eluent and
did not result in decreased TAFI activity. Immunoaffinity chromatography was followed by
anion exchange chromatography and protein G or A to remove contaminating immunoglobulins.
Methods for the purification of recombinant TAFI from culture medium include those
described here, but also cation exchange was used at pH 6.8 (43). Although reports on the
purification of TAFIa are limited, Tan et al. (28) described that the active enzyme could be
isolated by cation exchange chromatography after activation of TAFI in the presence of εACA.
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A function of TAFI in fibrinolysis
The fibrinolytic system is initiated after the formation of fibrin when both plasminogen and
tPA bind to the fibrin surface (figure 4). The binding is mediated by specific interactions of
carboxy-terminal lysine residues of partially degraded fibrin and lysine binding sites in
plasminogen and tPA (52, 53). Binding of plasminogen and tPA to the fibrin surface results in the
formation of a ternary complex and an increase in the catalytic efficiency of plasmin formation.
Fibrin-bound plasminogen is a better substrate for tPA than free circulating plasminogen. Bound
plasmin is protected from rapid inactivation by α2-antiplasmin (54, 55). Plasmin cleaves fibrin
and thereby generates new carboxy-terminal lysine residues that further stimulate plasmin
formation. TAFIa was shown to inhibit fibrinolysis by removing these carboxy-terminal lysine
residues from fibrin and thereby limits plasmin formation (18, 50, 56). The TAFIa dependent
decrease of plasmin formation seems to increase at lower FDP molecular masses (57). TAFIa
abrogated the DD(E) stimulated plasmin formation and also prevented the conversion of DD(E)
to fragment E and DD, the latter of which can impair fibrin polymerization (58).
Activation of TAFI in plasma during clotting resulted in a removal of carboxy-terminal
lysines from partially digested fibrin, with a concomitant decrease in plasminogen binding and
retardation of clot lysis (59). TAFIa inhibits the activation of Glu-plasminogen and the
conversion of Glu- to Lys-plasminogen (18, 56). The effect of TAFI on fibrinolysis may be
further enhanced by the activation of TAFI by plasmin and the inactivation of plasmin by TAFIa,
although plasmin was also shown to inactivate TAFIa (32, 56).
A role of the intrinsic coagulation system in the activation of TAFI
The activation of TAFI by thrombin implies that the coagulation system plays a role in the
regulation of fibrinolysis and that any disturbance in the generation of thrombin will result in an
increased rate of clot lysis. Patients with a deficiency of factor XI are prone to bleeding from
tissues with a high local fibrinolytic activity (urinary tract, nose, oral cavity, tonsils) (60, 61).
The mechanism behind this clinical observation was unclear. It was hypothesized that factor XI
activation by thrombin (62, 63) might play a role in this process and, therefore, we studied the
effect of factor XI on clot lysis using an assay that determines both the activity of the fibrinolytic
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system and the efficiency of the coagulation system to form thrombin that is necessary to down
regulate fibrinolysis (figure 5) (64). The clot lysis time was prolonged in the presence of factor
XI and the effect of factor XI was dependent on the presence of TAFI (65). High concentrations
of thrombin are needed for both the inhibition of clot lysis and for the activation of TAFI (30) in
contrast to the small amounts of thrombin that are sufficient for fibrin formation and platelet
activation. The high concentrations of thrombin were generated in a factor XI-dependent way in
parallel to the antifibrinolytic effect (64). Trace amounts of activated factor XI (1.25 pM,
representing 0.01% activation) were capable of completely inhibiting fibrinolysis indicating that
continued activation of factor XI by thrombin and the amplification power of the intrinsic system
generates the amount of thrombin needed for the activation of TAFI, thereby determining the fate
of the clot during fibrinolytic attack (65). The link between factor XI dependent thrombin
generation, TAFI activation and down regulation of fibrinolysis was further substantiated by the
correlation between TAFI concentration and clot lysis time in plasma of normal individuals, and
the absence of such a correlation when the clot lysis time was performed in the presence of an
antibody blocking the factor XI dependent feedback loop (26).
A deficiency of any other coagulation factor of the intrinsic pathway will result in an
increased rate of clot lysis. The situation in the presence of thrombomodulin seems to be
different. Thrombomodulin was shown to enhance the activation of plasma TAFI by thrombin
(29). In agreement with this, thrombomodulin corrected the premature lysis of clots from factor
X, IX, VIII, and XI deficient plasmas in vitro, indicating that thrombomodulin increases the
activation of TAFI by the low concentrations of thrombin formed under these conditions (48).
The role of thrombomodulin in the activation of TAFI
The activation of TAFI by thrombin is stimulated 1250-fold by thrombomodulin.
Thrombomodulin also accelerates the activation of protein C by thrombin. Previous studies with
epidermal growth factor (EGF) deletion mutants have demonstrated the functional
thrombomodulin requirements for enhanced protein C and TAFI activation (figure 6). Thrombin
binds to EGF-like domains 5 and 6 (66). EGF-like domain 4 is not required for thrombin binding
but is necessary for enhancement of protein C activation (31). EGF domain 3 is essential for the
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activation of TAFI (31, 67). The smallest mutant capable of activating TAFI contained residues
including the c-loop of EGF-3, EGF-4, EGF-5 and EGF-6. This mutant is 13 residues longer than
the smallest mutant capable of enhancing the activation of protein C that consists of EGF domains
4-6 plus the six residues connecting it to EGF-3 (68). Thrombin also contains distinct domains
involved in the activation of protein C and TAFI. Residues E25, D51 and R89/R93/E94 are
Figure 4. Down regulation of plasmin formation by TAFIa
Fibrinolysis is initiated when plasminogen is converted to plasmin by tissue-type plasminogen
activator (tPA). Plasmin then degrades the fibrin clot into soluble fibrin degradation products.
The formation of plasmin is enhanced by a positive feedback loop. The carboxy-terminal lysine
residues of fibrin (K), generated after limited plasmin cleavage, act as template onto which both
tPA and plasminogen bind. Whereas the binding of tPA to fibrin is primarily mediated by the
finger-like domain and secondarily by the second kringle of tPA, the binding of plasminogen to
fibrin is entirely kringle dependent. As a result of tPA and plasminogen interaction with fibrin, the
catalytic efficiency is 100-1000 fold enhanced. TAFIa cleaves off the carboxy-terminal lysine
residues from partially degraded fibrin and thereby abrogates the fibrin cofactor function in the
tPA-mediated catalysis of plasminogen. Elimination of the carboxy-terminal lysine residues
prevents the formation of the tPA/plasminogen/fibrin complex and thereby inhibits the
formation of plasmin and the degradation of the fibrin clot.
K
Kfibrin fibrin
plasminfibrin
tPA
plasminogenfibrinK
plasmin
K
TAFIa
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important for TAFI activation and are located above the active site cleft of thrombin, whereas
residues R178/R180/D183, E229, R233 are involved in protein C activation but are located
below the active site cleft (69). Thus, different elements are required in both thrombin and
thrombomodulin for efficient activation of TAFI and protein C. Recently the structural basis for
the anticoagulant activity of the thrombin-thrombomodulin complex was resolved (70).
Thrombomodulin was shown to bind to the anion-binding site of thrombin where thrombin binds
fibrinogen. This way, thrombomodulin inhibits fibrinogen binding whereas it binds protein C in
such a way that its activation peptide is correctly placed as a substrate in thrombin’s active site
(70, 71). Thrombomodulin uses its EGF domains to sterically block access of substrates to
thrombin by one EGF domain and uses at the same time other EGF domains to present a novel
substrate to thrombin such as protein C and may be also TAFI.
Thrombomodulin seems to play a dual role; on one hand it dampens the generation of
thrombin by enhancing the activation of protein C by thrombin whereas on the other hand it
makes these low concentrations of thrombin more effective in the activation of TAFI with a down
regulation of fibrinolysis as result. Although activation of TAFI and protein C can occur
simultaneously, the thrombomodulin concentration was found to be the determining factor in the
outcome of the overall effect. TAFI activation was stimulated at low concentrations (5 nM) of
thrombomodulin whereas TAFI activation decreased at higher thrombomodulin concentrations
(10 nM) (72). The reduction of TAFI activation at higher concentrations was shown to be due to
the inhibition of thrombin generation by activated protein C (72). This suggests that
thrombomodulin is an antifibrinolytic agent at low concentrations and profibrinolytic at high
concentrations. This phenomenon of differential regulation of fibrinolysis might play a role in
vivo where the expression of thrombomodulin on endothelial cells varies in different tissues.
Also, the vessel size might be an important factor as the effective thrombomodulin concentration
increases as blood moves from the aorta into the capillaries.
Thrombin induced inhibition of clot lysis independent of TAFI
It should be emphasized that thrombin may also inhibit clot lysis in other ways than only via
activation of TAFI. Thrombin activates factor XIII, which inhibits fibrinolysis by both
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cross-linking fibrin chains and cross-linking of α2-antiplasmin to fibrin (73). A deficiency of
factor XIII results in a bleeding disorder, demonstrating its importance as a fibrinolysis inhibitor.
Thrombin can also convert the single-chain precursor form of urokinase (scu-PA) into an inactive
two-chain form, that is hardly activatable anymore by plasmin (74-76). The observation that the
inactivation of scu-PA and activation of factor XIII require only low amounts of thrombin that
can easily be provided by the extrinsic pathway suggests that these mechanisms do not play a role
in the factor XI dependent inhibition of fibrinolysis. However, recently it was demonstrated that
in plasma higher concentrations of thrombin are needed for the inactivation of scu-PA (77, 78).
Figure 5. Model of blood coagulation
The model is explained in detail in the text. To improve the clarity of the figure, most zymogens
and procoagulant surfaces are not depicted. Abbreviations used are: TF-VIIa, tissue factor-
factor VIIa complex; TFPI, tissue factor pathway inhibitor; Xa+V, factors Xa and V(a) (depicting
the prothrombinase complex); IXa + VIII, factors IXa and VIII(a) (depicting the tenase complex);
IIa, thrombin; APC, activated protein C; TM, thrombomodulin; TAFI, thrombin activatable
fibrinolysis inhibitor; XIa, factor XIa. An uninterrupted line indicates activation, while an
interrupted line indicates inhibition. The uninterrupted line between Xa and TFPI indicates that
factor Xa has to form a complex with TFPI, and that this complex then inhibits TF-factor VIIa.
Reprinted with permission from (82).
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In addition, experiments were described that suggest that the inactivation of scu-PA is dependent
on thrombin that is additionally generated via factor XI (78).
Factor XI independent activation of TAFI
In plasma only a small amount of TAFI is activated by thrombin during and after clot
formation. Using a specific and sensitive assay for active TAFI it was demonstrated that in
plasma, activation of TAFI takes place via both factor XI dependent and factor XI independent
mechanisms (79). A large inter-individual variation in the extent of factor XI independent
activation of TAFI was observed. It was speculated that the extrinsic pathway mediated part of
the thrombin needed for the activation of TAFI. The mechanism for this generation is unclear
because no activator of the extrinsic system was used. However in this setting thrombin could be
important for feedback activation of factor V or for conversion of single chain factor VII to two-
chain factor VIIa. Plasma lipoproteins were also shown to enhance tissue factor-independent
factor VII activation (80). Interestingly during the use of oral contraceptives a factor XI
independent prolongation of the clot lysis time was observed, suggesting that during the use of
oral contraceptives the factor XI independent activation of TAFI is enhanced by an increased
generation of thrombin via the extrinsic pathway (81).
The role of TAFI in a revised blood coagulation model
Based on the results described in recent years, a revised model for blood coagulation was
postulated in which there is no distinction between extrinsic and intrinsic pathways (figure 5)
(82). Coagulation is initiated by the exposure of tissue factor. Tissue factor binds factor VII(a)
and this complex can activate factors IX and X. At high tissue factor concentrations factor X is
mainly activated by the tissue factor-VIIa complex, whereas at low tissue factor concentrations
the contribution of the tenase complex in the activation of factor X becomes more pronounced
(83, 84). Once small amounts of factor Xa have been generated, the extrinsic pathway is rapidly
inhibited by tissue factor pathway inhibitor (TFPI) (85). TFPI first forms a complex with factor
Xa, which then binds to the tissue factor-factor VIIa complex, resulting in a quaternary complex
that can no longer sustain coagulation. However in the mean time, sufficient amounts of thrombin
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are generated to induce fibrin formation. Thrombin formation continues inside the fibrin clot
(65). Most of the thrombin is formed after clot formation (86) and the generation of thrombin
inside the clot is mainly generated via the intrinsic pathway by the activation of factor XI by
thrombin (64). Activation of factor XI may occur on the surface of the clot by fibrin-bound
thrombin. Although only small amounts of activated factor XI are formed, a secondary burst of
thrombin formation is provided by the intrinsic pathway due to the continued activation of factor
XI by thrombin and the amplification power of both the tenase and prothrombinase complex.
These high concentrations of thrombin are needed for the activation of TAFI and the inactivation
of scu-PA, which results in down regulation of fibrinolysis.
The model also explains the profibrinolytic role of activated protein C, because activated
protein C by inactivation of factors Va and VIIIa decreases the generation of thrombin, and thus
inhibits the activation of TAFI (21-24). Evidence for such a mechanism was recently presented
using an animal model (87). In this model, activated protein C was shown to prevent thrombin-
induced thromboembolism in mice by interrupting thrombin-dependent mechanisms that make
the fibrin clots more resistant to lysis. In this way, the intravascular deposited fibrin is removed
Figure 6. Schematic representation of thrombomodulin
The structure of thrombomodulin can be divided in several well-defined domains. The amino-
terminal part of thrombomodulin, which is directed towards the circulating blood, consists of a
relatively large lectin-like domain (residues 1-226), followed by six tandem epidermal growth
factor-like (EGF) domains joined by small connecting peptides. Other regions include a serine/
threonine-rich domain (residues 463-497), a transmembrane domain (residues 498-521) and a
carboxy-terminal intracellular domain (522-557). The EGF domains that are essential for the
binding of thrombin and the stimulation of TAFI and protein C activation are indicated in color.
The EGF domains 5 and 6 are primarily responsible for the interaction with thrombin (indicated in
blue), whereas EGF4 (red) is required for the interaction with protein C. The minimal structure of
thrombomodulin required for protein C activation comprises EGF domains 4 to 6 plus six residues
connecting EGF 4 to EGF 3 (indicated in blue and red). However, this minimal fragment of
thrombomodulin is not capable of stimulating TAFI activation, for which the c-loop of EGF 3 is
required (yellow). Oxidation of methionine-388 (green) abolishes protein C activation but
renders TAFI activation relatively unharmed.
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more rapidly by the endogenous fibrinolytic system. The importance of the recently discovered
factor V R506Q (factor VLeiden) (88) may also be explained by the role of thrombin in the down
regulation of the fibrinolytic system. The R506Q mutation abolishes a cleavage site for activated
protein C, which results in a decreased rate of inactivation of factor Va and consequently in the
formation of more thrombin. This results in an increased rate of activation of TAFI and in a down
regulation of the fibrinolytic system (89). This emphasizes the delicate balance between
procoagulant (antifibrinolytic) and anticoagulant (profibrinolytic) properties of the coagulation
system.
Thrombin is known to possess both pro- and anticoagulant functions. This phenomenon has
been called the Thrombin Paradox (90). An explanation was provided by the observation that the
mechanism of action of thrombin was dependent on its concentration (91). In vivo, continuous
activation of the coagulation mechanism at a basal level generates these low levels of thrombin,
resulting in inhibition of coagulation by activated protein C (92). Activation of coagulation by
exposure to tissue factor will result in higher levels of thrombin that overcome the anticoagulant
effect of protein C resulting in clotting. It can be concluded that at high concentrations thrombin
will not only become procoagulant, but also antifibrinolytic which enhances its thrombotic
potential.
Bleeding abnormalities in deficiencies of the intrinsic coagulation
factors: a role for TAFI?
The revised coagulation model may provide an explanation for the bleeding abnormalities of
factor XI deficient patients. These patients are prone to bleeding from tissues with a high local
fibrinolytic activity and it is at these sites that the down regulation of fibrinolysis is not provided
for by the factor XI dependent generation of thrombin and TAFI activation.
However our model could not explain the variation in expression of the bleeding tendency in
factor XI deficient patients. The variation in the factor XI independent activation of TAFI may
provide an explanation for this (79).
A defective activation of TAFI might also contribute to the severity of the bleeding disorder
in factor VIII and IX deficiency (haemofilia A and B). These patients have a reduced thrombin
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formation via the extrinsic pathway at low tissue factor concentrations and a reduced secondary
burst of thrombin generation via the intrinsic pathway. Because of this, the activation of TAFI
and thus the down regulation of fibrinolysis by the intrinsic pathway is defective. This results not
only in an inadequate haemostatic response, but also in the case fibrin had been formed, it will
dissolve more rapidly leading to destabilization of the haemostatic plug.
Thrombosis risk associated with high levels of intrinsic coagulation
factors: a role of TAFI?
The role of the intrinsic pathway of in coagulation is two-fold: it contributes via thrombin
generation to the (further) formation of fibrin, and - again via thrombin generation - it helps to
protect the fibrin from rapid proteolysis (Figure 5). With high levels of intrinsic coagulation
factors, it can therefore be hypothesized that the secondary thrombin generation would be
enhanced or sustained leading to a prolonged down regulation of fibrinolysis and therefore to a
thrombotic risk. Indeed high levels of factor VIII, IX and XI have been found to be associated
with approximately two-fold increased risks for venous thrombosis (93-95).
Measurement of TAFI and TAFIa
Several assays have been developed for the measurement of TAFI in plasma. TAFI antigen
is measured using sandwich ELISA assays with monoclonal and polyclonal antibodies (26, 96).
Also, rocket immunoelectrophoresis has been used for the quantification of TAFI in plasma (49).
TAFIa activity is measured after activation of TAFI with thrombin-thrombomodulin. That way
the total amount of TAFI that can be activated is measured. Activated TAFI is then determined
using the substrate furoylacroleyl alanyl-arginine by the change in absorbance at 336 nm (14, 50, 59).
Other methods detect the released hippuric acid from hippuryl-Arg by TAFIa either by HPLC
(97), by colorimetric quantification with cyanuric chloride (26), or by change in absorbance at
254 nm (14, 18). The carboxypeptidase activity is measured in the presence and absence of potato
carboxypeptidase inhibitor in order to be able to correct for the constitutively active CPN. TAFIa
activity is detected as the activity that is sensitive to inhibition by the potato carboxypeptidase
inhibitor. Recently, a sensitive and specific assay was described in which the Hippuryl-Arg was
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added directly to the plasma before the clotting was initiated without the addition of
thrombomodulin. With this assay the activation of TAFI during the clotting of plasma could be
demonstrated (79).
Clot lysis assays were also used to detect TAFIa. In these assays, clotting is initiated by
thrombin or tissue factor. Clot formation and lysis is followed in time by measuring the change
in turbidity. The clot lysis time is dependent on the amount of additional thrombin generated by
the coagulation system and on the activation of TAFI. The role of TAFIa in the clot lysis can be
demonstrated by performing the test in the presence and absence of the potato carboxypeptidase
inhibitor. The TAFIa activity tests, the antigen assays and the clot lysis assay showed a good
correlation (Mosnier et al., unpublished observations).
The carboxypeptidase inhibitor from potato tubers (CPI)
The carboxypeptidase inhibitor from potato tubers has been frequently used in both in vitro
(26, 97) and in vivo (98-100) studies concerning TAFI function. Because of its specific property
to inhibit TAFIa activity but not CPN activity (50) the assessment of carboxypeptidase activity
specific for TAFIa was greatly facilitated and therefore some characteristics of CPI are discussed
here. CPI naturally occurs in potatoes and homologous carboxypeptidase inhibitors have been
found in tomatoes and squash. There are 5 highly homologous isoforms of CPI of which CPI-II
is the most abundant but all 5 isoforms are strong competitive inhibitors with a Ki in the nM range
(101). Besides TAFIa, CPI inhibits a broad range of digestive tract, intracellular and microbial
carboxypeptidases (101). In a plasma environment, CPI is specific for TAFIa, whereas outside
the circulation CPI can inhibit other carboxypeptidases.  CPI contains 39 amino acids and has a
molecular mass of 4295 Da. Because of its 3 disulfide bridges the protein has a compact structure
and belongs to the family of knottins (102). CPI consists of a globular core (Cys8-Cys34) and two
flexible terminal regions (Glu1-Ile7 and Glu35-Gly39) (102). Especially the carboxy-terminal
tail of CPI is important for the inhibition of carboxypeptidase activity and the role of Pro36
appears to be mainly the restriction of the mobility of the CPI carboxy-terminal tail. The
mechanism of inhibition presumably involves the docking of the carboxy-terminal tail of CPI in
the active site of the carboxypeptidase, leading to a stopper-like inhibition mechanism (103).
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The interaction of Val38 of CPI with CPA residues was found to contribute to approximately
50% of the required binding energy (102, 104). X-ray crystallographic analysis of the CPI-CPA
complex revealed that the Val38-Gly39 peptide bond is cleaved in the complex, and that Gly39
of CPI appears to be trapped in the binding pocket of the enzyme (101). After removal of Gly39
by CPA, Tyr37 of CPI becomes an essential residue for the stabilization of the CPI-CPA
interaction (104) and enzymatic activity of CPA was not required for association with CPI.
If a similar mechanism occurs for the inhibition of TAFIa by CPI is not known.
Since CPI is used in a number of in vivo studies as an inhibitor of TAFIa and this will probably
only increase in the near future it is important to realize that CPI might have additional effects in
an in vivo model system. Although the exact biological role of CPI is unclear, it is probably
involved in plant defense against fungal and phytophagous plagues (103). In addition, CPI has
been found to be protective against radiation-induced transformation of embryonic cultured cells
after internalization, and inhibit tumor cell growth by acting as an antagonist of epidermal growth
factor (105, 106). No toxic effects of CPI were found in mice (106) and its half-life in rabbits was
estimated to be 10 minutes. Known contaminants of CPI are endotoxin and an inhibitor of
plasmin activity, which can be effectively removed by reverse phase chromatography (100). Two
abbreviations are used for this carboxypeptidase inhibitor, CPI and PCI (Potato
Carboxypeptidase Inhibitor), however since the abbreviation PCI is also used for protein C
inhibitor, CPI is the preferred abbreviation.
A role for TAFI in disease?
In several studies the level of TAFI was measured in normal individuals. A broad range of
TAFI levels was found in the normal population (26, 96). In normal individuals, the TAFI antigen
levels correlated with TAFI activity and clot lysis assays (26). No difference in TAFI antigen
concentration was found between men and women (49). Analysis of the effect of age showed no
increase of TAFI levels in men and an age dependent increase in women (49, 96). Using an
activity test, Schatteman et al. (97) reported a positive correlation between the TAFI
concentration and age in men, and women not receiving hormonal therapy. Hormonal therapy
including oral contraceptives were found to increase the level of TAFI whereas pregnancy had no
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effect on the TAFI concentration (49, 81, 97). The mean TAFI antigen level of a black African
male group was significantly lower than the value of age matched Caucasian men (96).
A role of TAFI in thrombotic disease was found in the Leiden Thrombophilia Study (49).
Elevated TAFI levels were found to be associated with a mild risk for venous thrombosis. The
increased risk for venous thrombosis might be explained by the induction of a hypofibrinolytic
state by the increased TAFI levels. Increased TAFI levels were found in patients with stable
angina pectoris and coronary heart disease (42). In this study, TAFI levels correlated with factor
VII amidolytic activity and protein C activity, suggesting a common mechanism for modulating
the plasma levels of these proteins. Sera of patients with rheumatoid arthritis were reported to
have reduced levels of an arginine carboxypeptidase which was unrelated to carboxypeptidase N
and thus is most likely TAFI (107).
A role for TAFI in inflammatory disease has been suggested. TAFI levels in plasmas of
normal individuals were found to correlate with markers of the acute phase response (C-reactive
protein and haptoglobin) (42), and in mice and rats, TAFI was identified as an acute-phase
reactant (38, 39). An increase in the TAFI plasma concentration is associated with an increased
formation of TAFIa by thrombin, since the KM for TAFI activation by thrombin is far below the
TAFI plasma concentration. This suggests that increased TAFI levels during inflammation
contribute to the prothrombotic- and antifibrinolytic state that is characteristic for disseminated
intravascular coagulation (DIC), the haematologic manifestation of inflammatory disease. In
addition, a number of observations suggest a shift towards stimulation of TAFI activation.
Plasma levels of soluble thrombomodulin are elevated in patients with DIC (108) and soluble
thrombomodulin was found to stimulate TAFI activation (109). TNFα down regulates
thrombomodulin expression in the endothelial cell (110) and decreasing concentrations of
thrombodulin are accompanied by increased TAFI activation (72). Endotoxin induces down
regulation of protein C mRNA (111) and protein C antigen decreased progressively during the
initial stages of DIC in humans (112) suggesting that the inhibition of TAFI activation by the
protein C pathway is decreased (25). Oxidation of Met-388 in thrombomodulin by activated
neutrophils (113) selectively blocks protein C activation but has no effect on TAFI
activation (68).
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The role of TAFI in inflammation can be two fold. On one hand the increased TAFI levels
might contribute to the inactivation of inflammatory mediators such as anaphylatoxins and
inflammatory peptides such as C3a and C5a thereby reducing the susceptibility for septic shock.
On the other hand, the increased TAFI levels could contribute to an increased inhibition of
fibrinolysis and thereby facilitate the deteriorating effects of DIC. Which mechanism will prevail
will have to be determined in future studies.
Decreased levels of TAFI activity were detected in patients with acute promyelocytic
leukemia (114). Interestingly, the TAFI antigen concentration was normal whereas the TAFI
activity level was severely decreased by 60%. The reduction in TAFI was most likely caused by
the action of plasmin on TAFI because in vitro experiments revealed that plasmin slightly
reduced antigen levels but severely reduced TAFIa activity. The acquired functional deficiency
in acute promyelocytic leukemia may contribute to the severity of the haemorrhagic diathesis
because of the impaired capacity of the coagulation system to protect the fibrin clot from
fibrinolysis (114).
A role of TAFI in angiogenesis and tumor growth
The process that leads to the formation of new blood vessels is called angiogenesis. This is a
tightly regulated process that is dependent on both the formation and degradation of an
extracellular matrix. Degradation of the matrix by plasmin disrupts the interaction between the
cells and the matrix and excessive fibrinolysis inhibits both angiogenesis and tumor growth.
Endostatin, a proteolytic fragment of collagen XVIII, and a promising inhibitor of angiogenesis
and tumor growth was shown to stimulate fibrinolysis. Carboxy-terminal lysines in endostatin
were essential for plasmin generation because treatment with carboxypeptidase B or TAFIa
inhibited this effect (115). Both the anti-angiogenic and the anti-tumoral effect of endostatin were
inhibited by the carboxypeptidase B treatment. These results indicated that endostatin inhibits
angiogenesis by enhancing extracellular matrix degradation by plasmin and thereby interferes
with endothelial cell adhesion. Furthermore, these results imply that carboxypeptidases such as
TAFI can affect angiogenesis and tumor growth. The coagulation system may provide a
regulatory role in this process by generating activated TAFI and abrogating the effect of
endostatin on fibrinolyis (115).
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In vivo evidence for a role of TAFI in fibrinolysis: implications for the
treatment of thrombotic disease
In vivo evidence for a role of factor XI and TAFI as an anti-fibrinolytic factor was obtained
in an experimental thrombosis model (99). Incorporation of anti-factor XI antibodies or potato
carboxypeptidase inhibitor in jugular vein thrombi resulted in an almost two-fold increase in
endogenous thrombolysis compared to a control antibody. In this model, systemically
administered anti-factor XI antibodies resulted in a similar increase in lysis as obtained with
incorporation of anti-factor XI antibodies in the thrombi. This suggests that the factor XI
dependent generation of thrombin takes place either within, or on the surface of the fibrin clot,
where it is accessible for inhibition by anti-factor XI antibodies (99). This also suggests that the
activation of TAFI takes place at or near the fibrin surface by clot-bound thrombin. In agreement
with this concept, other studies showed that activation of TAFI resulted in a rapid elimination of
plasminogen binding sites on the surface of partially degraded fibrin (59). Thus, in a factor XI-
deficient plasma milieu, the diminished presence of clot-bound thrombin may facilitate enhanced
fibrinolysis, because of a lower degree of activation of TAFI. Indeed, therapeutic strategies that
inhibited the activity of clot-bound thrombin enhanced endogenous thrombolysis in an
experimental rabbit thrombosis model (116).
Interfering with activation of the intrinsic pathway for instance by inhibition of the thrombin-
mediated factor XI activation may offer an alternative approach for the treatment of thrombotic
complications. At the moment of clotting only a small amount of prothrombin is activated,
whereas continuous generation of thrombin after clot formation results in consumption of a large
part of the prothrombin present within the clot. The amount of thrombin generated in the clot is
markedly affected by factor XI. In vivo, inhibition of the activation of factor XI by thrombin at
the onset of the intrinsic system may therefore result in clots that are not only less thrombogenic
and mitogenic but also more susceptible to fibrinolysis because of a reduced activation of TAFI.
Furthermore the risk for bleeding complications may be low, because this therapy would not be
accompanied by the strong anticoagulant effects seen with heparin and hirudin. Although an
adequate haemostatic response requires thrombin generated by both the extrinsic and intrinsic
pathways, the potential advantage of a therapy with inhibitors of activated factor XI is that some
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haemostatic plug formation may still take place via the tissue factor pathway, whereas continued
thrombin generation via the intrinsic pathway at the site of the clot does not take place. This
makes the clot less thrombogenic and more susceptible for lysis.
Other evidence for an in vivo role of in fibrinolysis comes from studies using thrombolytic
therapy. The generation of TAFIa in dogs undergoing coronary thrombosis and thrombolytic
therapy with tPA was demonstrated (117). During streptokinase therapy of myocardial infarction
a rise in levels of active TAFI was detected in plasma early after the start of the therapy suggesting
activation of TAFI by plasmin (118). At later times a drop in the level of active TAFI was
observed suggesting consumption of TAFI. Several studies showed that TAFI plays an important
role in the susceptibility of a clot for lysis. In a rabbit arterial thrombolysis model and a rabbit
jugular vein thrombolysis model inhibition of TAFI by specific inhibitors enhanced the tPA
induced lysis of a thrombus (98, 100, 119).
In conclusion, although the pathophysiological role of TAFI is still unclear, it is evident that
TAFI provides an important link between coagulation and fibrinolytic cascades. Further insight
in this mechanism will lead to the development of new therapeutic agents that increase the
efficiency of fibrinolytic therapy in the treatment of thrombotic disorders whereas other agents
that improve the efficiency of TAFI to down regulate fibrinolysis might become available for the
treatment of bleeding disorders such as haemophilia A and B.
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Aim of the study
To determine the contribution of the extrinsic- and intrinsic pathway on the formation of
thrombin, the activation of TAFI and the down regulation of fibrinolysis.
To determine the effect of inhibition of thrombin formation by the protein C pathway on the
activation of TAFI and the regulation of fibrinolysis.
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Plasma TAFI Levels Influence the Clot Lysis Time
in Healthy Individuals in the Presence of an
Intact Intrinsic Pathway of Coagulation
( Thrombosis & Haemostasis 1998; 80: 829-835 )
Chapter 2
Laurent O. Mosnier
Peter A. Kr. von dem Borne
Joost C.M. Meijers
Bonno N. Bouma
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Summary
Thrombin Activatable Fibrinolysis Inhibitor (TAFI) is a recently identified fibrinolysis
inhibitor in plasma, that when converted to an enzyme potently attenuates fibrinolysis. It is
activated by relatively high concentrations of thrombin that exceed the thrombin concentration
required for fibrin formation. These high concentrations of thrombin are generated by the
intrinsic pathway via activation of factor XI by thrombin. The down regulation of fibrinolysis by
TAFI can be measured in a clot lysis assay. When the clot lysis times of healthy individuals were
determined, large inter-individual differences were observed. To determine if differences in
concentration of TAFI explain the variation in clot lysis between individuals, specific assays
were developed for the measurement of TAFI antigen and activity in plasma. In normal plasma,
there was a dose-dependent relationship between TAFI antigen and TAFI activity. There was
also a correlation between clot lysis time and plasma TAFI antigen, indicating that the amount of
TAFI that is activated during the clot lysis assay, is dependent on the concentration of TAFI.
In the plasmas of 20 healthy individuals, clot lysis times, TAFI antigen and TAFI activity were
determined. Both TAFI antigen and TAFI activity showed a significant correlation with the clot
lysis time. No correlation between TAFI antigen and clot lysis time was found when the clot lysis
time was determined in the presence of an antibody blocking the factor XI feedback loop. These
results indicate that plasma TAFI levels influence the clot lysis time in healthy individuals in the
presence of an intact intrinsic pathway of coagulation.
Introduction
After injury, a fibrin clot is formed to prevent excessive blood loss from the circulation
maintaining the integrity of the vascular system. The fibrin clot is formed by the coagulation
cascade, a series of linked proteolytic reactions in which zymogens are converted into serine
proteases, ultimately leading to the formation of thrombin, which converts soluble fibrinogen to
insoluble fibrin (130, 131). Another important proteolytic network is the fibrinolytic system, in
which plasminogen is converted into plasmin, resulting in proteolysis of  a fibrin clot into soluble
fibrin degradation products (132, 133). By virtue of its capacity to degrade fibrin, the fibrinolytic
system maintains the patency of vasculature and surrounding tissues (134, 135). During normal
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haemostasis there is a delicate balance between coagulation and fibrinolysis. Disturbance of this
balance may result in a thrombotic tendency or in a bleeding disorder. Although the interplay
between the two systems is not yet well understood, it is obvious that both systems must be
closely regulated and controlled.
Thrombin activatable fibrinolysis inhibitor (TAFI) (18) is a recently identified fibrinolysis
inhibitor in plasma and has to be considered a likely candidate for the link between coagulation
and fibrinolysis. Amino-terminal sequence analysis of TAFI revealed that it is identical to plasma
procarboxypeptidase B previously isolated as a plasminogen binding protein (16). In addition,
a carboxypeptidase had been purified from serum that was called carboxypeptidase U (17),
because of its instability. Later it was found that carboxypeptidase U is similar to activated
plasma procarboxypeptidase B and activated TAFI (TAFIa) (67).
TAFI can be activated by trypsin-like enzymes, such as thrombin and plasmin (16, 18).
However, TAFIa is also rapidly inactivated by thrombin (18) or is inactivated due to temperature-
dependent intrinsic inactivation (17, 29, 30, 136), whereas TAFIa and plasmin reciprocally
inhibit each other (137). For the activation of TAFI by thrombin relatively high concentrations of
thrombin are required (18), however the catalytic efficiency is increased many fold in the
presence of the cofactor thrombomodulin (29). Evidence from both in vitro (64, 65) and in vivo
(87, 99) experiments suggest that in plasma an intact factor XI (intrinsic) feedback loop is
necessary to generate sufficient thrombin for TAFI activation. Thrombin was found to activate
factor XI, even in the absence of a negatively charged surface (62-64, 138, 139), and factor XI was
shown to play a role in the protection of the fibrin clot against lysis (64). TAFI was responsible
for the antifibrinolytic effect of factor XI. In a clot lysis assay activation of TAFI results in down
regulation of fibrinolysis, whereas blocking the factor XI (intrinsic) feedback loop with a
monoclonal antibody prevents TAFI activation and results in the up regulation of fibrinolysis (65).
In plasma another carboxypeptidase is present, carboxypeptidase N (CPN), which is
constitutively active and like TAFI has a specificity for substrates with carboxy-terminal
arginines and lysines (13, 14, 17). In contrast to TAFI, however, CPN is not capable of down
regulating fibrinolysis (50). Both carboxypeptidases have also a different specificity for a
carboxypeptidase inhibitor (CPI) from potato tubers. TAFIa is completely inhibited by CPI at
concentrations were CPN activity is not affected (50).
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The mechanism by which TAFI down regulates fibrinolysis has been suggested to involve the
removal of carboxy-terminal lysines (and arginines) from fibrin.  These carboxy-terminal lysines
are exposed upon limited proteolysis of fibrin by plasmin and act as ligands for the lysine binding
sites of plasminogen and tissue-type plasminogen activator (tPA) (140, 141). Elimination of
these basic groups by TAFIa abrogates the fibrin cofactor function of tPA mediated plasminogen
activation, resulting in a decreased plasmin generation and subsequently down regulation of
fibrinolysis. Addition of purified TAFI or TAFIa to a system of purified components (18, 29, 30)
or to diluted TAFI depleted plasma (25, 142) resulted in a dose-dependent down regulation of
fibrinolysis. The estimated concentration of TAFI in plasma is about 70 nM (25), which is almost
30 fold below the KM (29) for the thrombin mediated TAFI activation, indicating that the TAFI
activation 
 
in plasma occurs well below V
max
 conditions. Hence, the TAFI concentration in plasma
is likely to affect the activation rate of TAFI. This implies that the concentration of TAFI may
determine the up or down regulation of the fibrinolytic system. Clot lysis assays in individual
plasma samples indicated large inter-individual differences, which could not be correlated to
abnormalities in either coagulation factors or components of the fibrinolytic system.
In this study we investigated the possibility that variation in the concentration of TAFI is the
explanation for the large inter-individual differences in clot lysis times in individual plasma
samples.
Materials and Methods
Materials
Fresh frozen plasma was obtained from the local blood bank. Protein G Sepharose, CNBr-
activated Sepharose and PD-10 Sephadex G-25 M were purchased from Pharmacia (Uppsala,
Sweden). Bovine serum albumin (fraction V), L-α-phosphatidylcholine, dioleoyl (PC),
L-α-phosphatidylserine, dioleoyl (PS), L-α-phosphatidylethanolamine, dioleoyl (PE) were
purchased from Sigma (St. Louis, MO).  Tissue type plasminogen activator (531,000 IU/mg) was
obtained from Chromogenix (Mölndal, Sweden). Cyanuric chlorid was from Merck
(Amsterdam, The Netherlands). Hippuryl-Arg and H-D-Phe-Pro-Arg-chloromethylketone
(PPACK) were purchased from Bachem (Bubendorf, Switzerland) and carboxypeptidase
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inhibitor (CPI) was from Calbiochem (La Jolla, CA). Peroxidase-conjugated swine antibody
against rabbit IgG (SWARPO) was from Dako (Glostrup, Denmark). Thrombomodulin was
obtained from American Diagnostica (Greenwich, CT). Purified human thrombin was a generous
gift from Dr. W. Kisiel (University of New Mexico, Albuquerque, NM, USA). Other chemicals
obtained were the best grade available.
Purification of human TAFI
Human TAFI was purified according to the method of Eaton et al (16), with some minor
modifications. Briefly, four units of fresh frozen citrated plasma (1300 ml) was depleted of
plasminogen by affinity chromatography using lysine-Sepharose (143). The flow through was
fractionated with 0.8 M and 2.7 M ammonium sulphate. The pellet of the 2.7 M ammonium
sulphate precipitation was dissolved in and dialyzed against phosphate buffer (0.1 M NaH2PO4/
Na2HPO4, pH 7.4) and then applied to a plasminogen-Sepharose column (14 ml, 6 mg/ml)
equilibrated in phosphate buffer containing 1 mM NaN3, 1 mM DFP and 100 µg/ml aprotinin.
The column was washed with the same buffer containing 0.5 M NaCl until the A280 was less
than 0.01. The bound protein was eluted with a linear ε-ACA gradient (0-50 mM). Fractions
containing TAFI, as identified by SDS-PAGE, were pooled (20 ml) and concentrated in a
Centricon 10 microtube until the volume was 0.5 ml. The concentrated TAFI preparation was gel
filtered on FPLC Superdex 200 HR10/30, equilibrated in 50 mM Tris, pH 7.4, 150 mM NaCl and
3 mM EDTA. Fractions containing TAFI were pooled and stored at -70°C. TAFI appeared as a
single band of about 58 kD on SDS-PAGE. The protein concentration was determined with a
BCA kit (Pierce, Rockfort, IL) using bovine serum albumin as a standard.
Antibodies
A monoclonal antibody against factor XI (XI-1) capable of blocking factor XI activity had
been prepared as described previously (144). Murine monoclonal antibodies against TAFI were
prepared according to standard procedures. Hybridoma cells producing the monoclonal
antibodies were cultured and IgG was isolated from the culture medium using rabbit antibodies
against mouse IgG immobilized on CNBr-activated Sepharose. Five monoclonal antibodies were
44
T
A
F
I
L
E
V
E
L
S
obtained (Ock-6A5, Ock-6D3, Ock-6F3, Nik-2E12 and Nik-9H10). A polyclonal antibody
specific for TAFI was obtained in rabbits. After plasmapheresis, IgG was isolated by
chromatography on protein G Sepharose. The antibody was specific for TAFI as demonstrated by
crossed immunoelectrophoresis using normal plasma and purified TAFI (145).
Plasma samples
Normal plasma samples were obtained from healthy volunteers. Blood was taken from the
antecubital vein, collected into 3.8% trisodium citrate (0.129 M) as the anticoagulant (9:1 v/v).
To obtain platelet poor plasma the samples were centrifuged twice for 15 min at 2500 g, after
which the plasma was stored at -70°C until use. Normal plasma was derived from a donor pool
of 40 healthy volunteers. TAFI depleted plasma was obtained by passing plasma from a healthy
donor over a Sepharose column to which MoAb-2E12 was coupled. The undiluted flow-through
fractions of the column were tested for the absence of TAFI in a clot lysis assay. Fractions
depleted in TAFI were pooled and used as TAFI depleted plasma. This plasma was also shown
to be devoid of TAFI activity as determined by the activity assay (see below) and did not show
a precipitation peak in crossed-immunoelectrophoresis (data not shown).
Phospholipid vesicles
Phospholipid vesicles consisting of 40%PC/20%PS/40%PE were prepared according to
Brunner (146), with some modifications. Briefly, vesicles were obtained by passing
phospholipids diluted in sodium desoxycholate through a Sephadex G-25 column. This method
produces a homogeneous population of bilayer vesicles, with a vesicle diameter somewhat larger
than the average diameter of sonicated vesicles (146). The total phospholipid content of the
vesicles containing fractions was determined by phosphate analysis (147).
Enzyme-linked immunosorbent assay
For the detection of TAFI in plasma a sandwich ELISA was used consisting of a monoclonal
capture antibody and a polyclonal detecting antibody. The MoAb-9H10 (3 µg/ml, 100 µl/well)
was coated overnight at 4°C to 96-well plates (Costar, Cambride, MA) in carbonate buffer
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(50 mM Na2CO3/NaHCO3, 0.02% NaN3, pH 9.6).  After the wells were washed with TBS (50 mM
Tris, 150 mM NaCl, 0.1%Tween, pH 7.4), they were incubated for two hours at room temperature
with blocking buffer (TBS containing 3% BSA, 200 µl/well). Samples were diluted 1/500 and
1/1000 in blocking buffer and allowed to bind for 1.5 hour at room temperature (100 µl/well).
Serial dilutions of normal plasma were used as calibration curve. After washing, the plates were
incubated for one hour at room temperature with the polyclonal rabbit anti-TAFI antibody
(3 µg/ml, 100 µl/well) diluted in blocking buffer. After another washing step, the plates were
incubated with peroxidase conjugated swine anti-rabbit antibodies (SWARPO) diluted 1:1000 in
blocking buffer (100 µl/well). After incubation for one hour at room temperature, the plates were
washed three times with TBS and peroxidase activity was detected with 0.4 mg/ml ortho
phenylene diamine in phosphate citrate buffer (100 mM Na2HPO4, 50 mM citric acid, pH 5.0)
with 0.035 % H2O2  (100 µl/well). Color was allowed to develop after which the reaction was
stopped by the addition of 1M sulfuric acid to each well (50 µl/well) and absorbance was
measured at 490 nm.  Plasma samples and normal plasma controls were tested in two dilutions
in duplicate. Plasma TAFI levels were expressed as a percentage of normal plasma.
Clot lysis assay
Clot lysis was studied in a plasma system in which tPA-mediated fibrinolysis of a thrombin-
induced clot is measured using turbidity as described earlier (64). We observed that the clot lysis
is greatly influenced by the type and composition of phospholipids in plasma (139). Therefore,
plasma samples were centrifuged (10 min at 15,000 g) before use to remove remaining
endogenous phospholipids and reconstituted with PC/PS/PE vesicles. Thrombin (20 nM),
PC/PS/PE vesicles (10 µM), calcium necessary for recalcification (17 mM, resulting in a free
calcium concentration of 2.3 mM), and tPA (30 U/ml) were added to 75 µl of citrated plasma.
The volume was adjusted to 150 µl with Hepes buffer (25 mM Hepes, 137 mM NaCl, 3.5 mM
KCl, 3 mM CaCl2, 0.1% BSA, pH 7.4). After mixing, 100 µl of the reaction mixture was pipetted
in a microtiter plate and then incubated at 37°C during which turbidity was measured in time at
405 nm in a Spectramax 340 kinetic microtiter plate reader (Molecular Devices Corporation,
Menlo Park, CA, USA). The clot lysis time was defined as the time between the maximum
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turbidity and the midpoint of the maximum turbid-to-clear transition that characterizes the lysis
of fibrin. Parallel experiments were performed with plasma that had been preincubated for 30 min
with  250 nM of a murine monoclonal anti-factor XI antibody (XI-1) capable of blocking factor
XI activity (144). Each clot lysis time is the mean of two independent experiments. The effect of
sample collection and circadian rhythm on the clot lysis assay was also determined. Fibrinolysis
assays are known to be sensitive for this. Blood samples were drawn in various ways from three
different individuals. Samples were collected at 9 am and 5 pm using a wide gauge needle with
minimum stasis, discarding the first 5 ml. Samples were also collected after 15 min of venous
stasis by a tourniquet, sampling both the first and second 5 ml. Another sample was taken using
a vacuum collecting system. Tubes were immediately placed on ice and centrifuged as soon as
possible. A sample was also taken which was left at room temperature for one hour before
centrifugation. The different sampling techniques had only minor effects on the fibrinolysis
assay, resulting in an increase or decrease of the clot lysis time of less than 10%. Only the time
of sampling was found to influence the clot lysis time to a larger extent, resulting in a 10 to 20%
decrease of the clot lysis time in samples collected at 5 pm.  Samples tested in this study were all
collected at 9 am.
Assay for the activity of TAFI in plasma
TAFI activity in plasma was measured using a method which was described earlier for the
detection of angiotensin-converting enzyme in serum and is based on the colorimetric
determination of hippurate with cyanuric chloride/dioxan reagent (148-150). The reaction
volumes were scaled down compared to those used previously (148-150) to facilitate multiple
sample determination in 96-wells microtiterplates. The optimal conditions for the coloring
reaction were found to be  0.1 M phosphate, 0.8% cyanuric chloride, pH >6.5 and were essentially
not different from those reported (148, 149). Thrombin (20 nM), thrombomodulin (5 nM) and
CaCl2 (17 mM) were added to 30 µl plasma. The volume was adjusted to 60 µl with Hepes buffer
and the activation was allowed to proceed for 10 min at room temperature. The activation of TAFI
was terminated by the addition of PPACK (20 µl, 150 µM). The substrate for TAFIa, hippuryl-
Arg was added (20 µl, 20 mM) and after thorough mixing substrate conversion was allowed for
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10 minutes. The substrate reaction was stopped by 1 M HCl (20 µl) after which an equivalent
volume of 1 M NaOH was added. Since the colorimetic determination of hippurate with cyanuric
chloride/dioxan reagent requires phosphate, 25 µl of 1M sodium phosphate (pH 7.4) was added
to each sample. Finally, 60 µl of 3% cyanuric chloride dissolved in 1,4-dioxan was added and
color was allowed to develop, during which the samples were extensively vortexed. Denaturated
protein and excess cyanuric chloride were removed by centrifugation (2 min, 14.000 rpm) and
100 µl was transferred to a 96-wells microtiterplate. The absorbance was measured at 382 nm in
a Spectramax 340 kinetic microtiter plate reader. During each experiment a standard curve of the
TAFI activity in normal plasma was determined by serial dilutions of normal plasma in heat
inactivated serum (30 min, 56 °C), whereas plasma samples were determined in duplicate using
two dilutions of plasma in heat inactivated serum (75% and 50% plasma). Dilution of plasma in
heat inactivated serum (keeping the total amount of protein constant) was necessary for
reproducible results, since denaturation of plasma/serum proteins by the color reagent facilitated
the precipitation of excess cyanuric chloride, resulting in clearer supernatants after centrifugation
(148). Heat inactivated serum did not contain activated TAFI nor could TAFI be activated by the
thrombin-thrombomodulin complex. To make a distinction between the constitutive
carboxypeptidase activity (CPN) and inducible carboxypeptidase activity (TAFI) in plasma,
the TAFIa activity was determined as the carboxypeptidase activity sensitive to inhibition by
CPI. In both samples and the standard curve, TAFIa activity was determined in the presence and
absence of the TAFIa inhibitor CPI (25 µg/ml). TAFI activity in plasma samples were expressed
as a percentage of the TAFI activity in normal plasma.
Results
Quantification of TAFI in plasma using an ELISA
A sandwich ELISA was developed for the measurement of TAFI in plasma, using two
antibodies against TAFI, a monoclonal antibody (MoAb-9H10) and a rabbit polyclonal antibody.
The specificity of the ELISA was tested by comparing the dose-response of purified TAFI,
normal plasma and TAFI depleted plasma reconstituted with purified TAFI. TAFI depleted
plasma was used as a control. Purified TAFI, normal plasma and reconstitution of TAFI depleted
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plasma with purified TAFI show a similar dose-response relationship. No TAFI is detected in
TAFI depleted plasma, indicating that the ELISA is specific for TAFI (figure 1). Reconstitution
of TAFI depleted plasma with purified TAFI results in the corresponding TAFI levels. The intra-
and inter-assay coefficient of variation were 11% (TAFI level 99.6 ± 10.6%, n=6) and 13% (TAFI
level 101.5 ± 13.2%, n=6), respectively. Serial dilutions of purified TAFI were used as a
calibration curve for the determination of the TAFI concentration in a normal plasma pool. A
concentration of  275 nM (16 µg/ml) was found which was higher than the previously reported
values (25, 67). TAFI levels in individual plasma samples were expressed as a percentage of a
normal plasma calibration curve. In the 40 individual plasmas comprising the normal plasma
pool, a mean TAFI level of 97.9 ± 19.0% (mean ± SD, range 60 to 138%) was obtained with a
normal distribution (figure 2).
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Figure 1. Dose-response curves of TAFI ELISA
A sandwich ELISA was used for the determination of TAFI levels in plasma, using a murine
monoclonal capture antibody (MoAb-9H10) directed against TAFI and a rabbit polyclonal
detecting antibody. Normal plasma (), purified TAFI (10 µg/ml) (), TAFI depleted plasma ()
and TAFI depleted plasma reconstituted with purified TAFI (10 µg/ml) ().
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Clot lysis assay
The clot lysis time was determined by measuring the turbidity of tPA mediated fibrinolysis
in a thrombin induced plasma clot in the presence and absence of a factor XI inhibiting antibody
(XI-1) to determine the contribution of the factor XI feedback loop on the down regulation of the
clot lysis (64). The reproducibility of the clot lysis assay was tested using normal plasma.
The intra- and inter-assay coefficients of variation were 3.8% and 7.6% (clot lysis times 63.8 ±
2.4 and 59.7 ± 4.6 min, n=10) in the absence of the factor XI inhibiting antibody XI-1. In the
presence of the factor XI inhibiting antibody the intra- and inter-assay coefficients of variation
were 3.2% and 5.9% (clot lysis times 37.9 ± 1.2 and 39.1 ± 2.3 min, n=10). When purified TAFI
is added to either TAFI depleted plasma or normal plasma a linear relation between the clot lysis
time and the TAFI antigen concentration was observed (r=0.94) (figure 3). Even at TAFI
concentrations up to 300% clot lysis times continue to prolong, suggesting that in plasma TAFI
activation occurs well under V
max
 conditions. This indicates that in our assay the TAFI level
determines the lysis of the clot in normal plasma.
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Figure 2. Distribution of TAFI antigen levels in healthy individuals
TAFI levels were determined using a sandwich ELISA specific for TAFI and TAFI levels were
expressed as a percentage of normal plasma. On the left the distribution of the TAFI levels in the
40 individuals comprising the normal plasma pool (,A), and on the right the distribution of TAFI
levels in plasma in the group of 20 volunteers (,B) of which the clot lysis times and TAFI activity
were also determined. The horizontal bar represents the mean of each group.
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An assay for the determination of TAFI activity in plasma
A functional assay was developed for the determination of the activity of TAFI in plasma.
This assay is based on the colorimetic determination of hippurate, which is released from
hippuryl-Arg by TAFIa, using cyanuric chloride. The optimal conditions for the activation of
TAFI in plasma were determined.  Using 20 nM thrombin, TAFI activation in plasma was
maximal at a thrombomodulin concentration of 5 nM, reaching its plateau after 5-10 min. Since
the intrinsic inactivation of TAFIa is promoted at 37° C, all reactions and incubations were
performed at room temperature. Substrate conversion was linear in time and the addition of
hydrochloric acid stopped the reaction instantaneous. Furthermore, the presence or removal of
the fibrin clot was of no influence on the amount of activated TAFI generated in the plasma.
Using normal plasma the intra- and inter-assay coefficient of variation were found to be 5%
(100.9 ± 5.0, n=6) and 14% (98.9±14.3%, n=6), respectively. Purified TAFI was added to either
TAFI depleted plasma or normal plasma and the TAFI activity was measured, as demonstrated
in figure 4.  A dose-dependent increase of TAFI activity was observed (r=0.98), indicating that
the TAFI activity assay is both a functional and quantitative assay.
Figure 3. Effect of TAFI concentration on the clot lysis time in normal plasma
 Purified TAFI was added to TAFI depleted plasma and normal plasma after which the clot lysis
times were determined by measuring the turbidity of tPA mediated fibrinolysis in a thrombin
induced plasma clot. TAFI levels were determined using a sandwich ELISA specific for TAFI, and
were expressed as a percentage of normal plasma.
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Determination of clot lysis time, TAFI antigen and TAFI activity in healthy
individuals
In a group of 20 healthy volunteers clot lysis time, TAFI antigen and TAFI activity were
determined in the individual plasma samples. The clot lysis times were determined in the
presence and absence of the factor XI inhibiting antibody. The mean clot lysis time in the absence
of the factor XI inhibiting antibody was 62.0 ± 11.5 min (range 41 to 82 min) and showed large
individual differences.  In the presence of the factor XI inhibiting antibody a shorter lysis time is
observed 38.7 ± 8.6 min (range 24.5 to 69 min), while the individual differences were less. As a
possible explanation for the differences in clot lysis between these individuals, TAFI antigen and
activity levels were determined in the plasmas of these 20 healthy volunteers. A mean plasma
TAFI antigen level of 111.4 ± 25.2% (range 72 to 154%) (figure 2) and a mean TAFI activity of
114.8 ±31.6% (range 38 to 169%) were observed. When the TAFI antigen and TAFI activity in
these individuals were compared a significant correlation (r=0.665, p=0.0014) was obtained
(figure 5).
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Figure 4. Determination of TAFI activity in normal plasma
Purified TAFI was added to TAFI depleted plasma and normal plasma after which the TAFI activity
was determined as described in materials and methods. TAFI activity and TAFI antigen were
expressed as a percentage of normal plasma.
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Relationship between clot lysis time, TAFI antigen and TAFI activity levels in
normal individuals
In the group of 20 healthy volunteers large individual differences are observed in either clot
lysis time, plasma TAFI antigen and TAFI activity levels. TAFI antigen levels in the individual
plasma samples were compared with the clot lysis times (figure 6a). A significant positive
correlation (r= 0.755, p=0.0001) was observed, suggesting that also in individual plasma samples
the TAFI concentration determines the lysis of the clot. In the presence of the factor XI blocking
antibody there is no correlation between the plasma TAFI levels and the clot lysis time (r=0.437,
p>0.05), as demonstrated in figure 6b. This indicates that the plasma TAFI levels influence the
clot lysis time in plasma only in the presence of an intact factor XI (intrinsic) feedback loop.
Next, the TAFI activity was compared to the clot lysis time (figure 7). A significant positive
correlation was found (r=0.604, p=0.0048), indicating that the TAFI activity elicted in the
presence of thrombomodulin predicts the functional activity of TAFIa in plasma in the absence
of thrombomodulin, as that is measured in a clot lysis assay.
Figure 5. Relationship between TAFI concentration and TAFI activity in plasma
In plasma samples from 20 volunteers, both TAFI antigen levels and TAFI activity were
determined. TAFI activity and TAFI antigen were expressed as a percentage of normal plasma.
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Discussion
The first indication of a direct regulatory link between coagulation and fibrinolysis was the
profibrinolytic effect of activated protein C (22, 23, 151, 152). At that time this could not be
explained by the coagulation scheme and suggested the presence of a previously uncharacterized
fibrinolysis inhibitor which activation could be inhibited by activated protein C. Recently this
observation was explained by the identification of TAFI in plasma (16-18), indicating that indeed
a regulatory link between the coagulation and the fibrinolytic system is present in plasma.
Previous work identified TAFI as a plasma zymogen, that when converted into an enzyme
potently attenuates fibrinolysis (29, 65). Activation of TAFI is mediated either by plasmin or
thrombin, the latter greatly enhanced in the presence of the cofactor thrombomodulin (29).
During coagulation, thrombin is formed in relatively high concentrations that exceed far above
the thrombin concentration required for fibrin formation (64). It was demonstrated that these high
thrombin concentrations, generated by the factor XI (intrinsic) feedback loop result in a down
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Figure 6. Relationship between TAFI antigen levels and clot lysis time in plasma
In plasma samples from 20 volunteers both TAFI antigen levels and clot lysis time were
determined. The clot lysis times were determined by measuring the turbidity of tPA mediated
fibrinolysis in a thrombin induced plasma clot. Clot lysis times were determined in the absence (A)
and presence (B) of a factor XI blocking antibody. TAFI antigen was expressed as a percentage
of normal plasma.
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regulation of  fibrinolysis (64, 65). Blocking the factor XI feedback loop with an antibody against
factor XI resulted in a decreased endogenous thrombin generation and an abrogated TAFI
activation, exhibited as an up regulation of fibrinolysis (65). The thrombin mediated TAFI
activation in plasma is an unfavorable reaction. Considering the kinetics of TAFI activation,
a Michaelis-Menten constant of almost 30 fold above the plasma concentration was found for the
TAFI activation by thrombin, while addition of the cofactor thrombomodulin predominantly
results in an increase in the reaction rate (29).  Although these kinetics were determined in a
purified system and might be different in a plasma system, it suggests that the TAFI concentration
in plasma may influence the amount of activated TAFI formed, since the reaction operates well
below V
max
 conditions.
In the present study, assays were developed to determine both TAFI antigen and TAFI
activity in plasma. Furthermore, a previously developed factor XI dependent clot lysis assay was
used to determine the regulation between coagulation and fibrinolysis in plasma (64).
TAFI antigen in plasma was determined by an ELISA (figure 1)  and in normal plasma the TAFI
concentration was found to be 275 nM, which is higher than the previously reported values (25).
In healthy individuals TAFI levels were normally distributed and varied over a rather broad range
(figure 2). In normal plasma, addition of purified TAFI to normal plasma resulted in a dose
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Figure 7. Relationship between TAFI activity and clot lysis time in plasma
From 20 volunteers both TAFI activity and clot lysis time were determined. TAFI activity was
expressed as a percentage of normal plasma.
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dependent prolongation of the clot lysis time, linear up to 300 % TAFI, supporting the idea that
the activation of TAFI in plasma is an inefficient process and that the amount of TAFIa generated
is greatly influenced by the concentration of TAFI present in plasma (figure 3). An assay was also
designed to determine the TAFI activity in plasma, using the small substrate hippuryl-Arg and a
colorimetic detection system for hippuric acid as described previously (148-150).  Using this
assay, a linear relation between the TAFI activity and TAFI antigen in normal plasma is observed
(figure 4).
The clot lysis time of individual plasma samples were determined by measuring the turbidity
of tPA-mediated fibrinolysis in a thrombin induced clot. The clot lysis times showed large
individual differences which could not be explained by the capacity of the intrinsic pathway,
measured by the APTT (activated partial thromboplastin time), factor XI concentration
or platelet count (by influencing plasminogen activator inhibitor concentration) (153).
TAFI antigen and TAFI activity were determined in the plasmas of these healthy volunteers to
investigate the possibility that these parameters could explain the variable clot lysis times.
When TAFI antigen levels were plotted against the clot lysis time a significant positive
correlation was observed (figure 6a). In the presence of the factor XI inhibiting antibody the clot
lysis times became independent of the amount of TAFI in plasma (figure 6b), indicating the
importance of both plasma TAFI levels and an intact coagulation cascade for the regulation of
fibrinolysis. The TAFI activity in the individual plasmas correlated well with both the TAFI
antigen and clot lysis time in these plasmas (figures 5 and 8). From this it can be concluded that
the TAFI activity assay provides an accurate prediction of the amount of TAFI in plasma and its
functional properties.
Relatively large amounts of thrombin are required for the activation of TAFI which are
generated in our clot lysis assay by the factor XI (intrinsic) feedback loop. TAFI dependent
regulation of fibrinolysis has also been shown in animal models in which inhibition of active
TAFI by CPI as well as inhibition of factor XIa resulted in an up regulation of fibrinolysis
(87, 99, 117), indicating that TAFI and the factor XI feedback loop also play an important role in
vivo in the regulation of fibrinolysis. Previous studies demonstrated that thrombomodulin
corrects the premature lysis of clots from factor X, IX, VIII and XI deficient plasmas in vitro (48).
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This indicates again that in the absence of thrombomodulin an intact coagulation system is
necessary for the down regulation of fibrinolysis but it also shows that in the presence
of thrombomodulin the small amounts of thrombin that are generated, even in coagulation
factor deficient plasmas, can still activate sufficient TAFI to down regulate clot lysis.
The profibrinolytic role of activated protein C can be explained by its inhibitory effect on
thrombin generation resulting in a decreased rate of TAFI activation. However despite the fact
that the thrombin-thrombomodulin complex is a very efficient activator of protein C,
thrombomodulin down regulates fibrinolysis indicating that thrombin is still generated although
at a decreased rate and activation of TAFI still takes place. Further studies are necessary to
understand this mechanism.
In this study we were able to show that the concentration of TAFI effects the rate of clot lysis.
This indicates that increased levels of TAFI might be associated with an increased risk for
thrombosis whereas decreased levels of TAFI might result in a bleeding disorder. However even
if TAFI levels are increased an impaired coagulation cascade might decrease the risk for a
thrombotic tendency by reducing the rate of TAFI activation by thrombin. Similarly a bleeding
tendency caused by decreased levels of TAFI might be prevented by the presence of
thrombomodulin.
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Regulation of Fibrinolysis in Plasma by TAFI
and Protein C is Dependent on the
Concentration of Thrombomodulin
( Thrombosis & Haemostasis 2001; in press )
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Summary
Thrombin activatable fibrinolysis inhibitor (TAFI) is a carboxypeptidase B-like proenzyme,
that after activation down regulates fibrinolysis. TAFI is activated by thrombin in the presence of
the cofactor thrombomodulin (TM). By stimulation of TAFI activation TM down regulates
fibrinolysis, however TM is also a cofactor in the activation of protein C. Activated protein C
(APC) can up regulate fibrinolysis by limiting the activation of TAFI via the attenuation of
thrombin production. We studied these counteracting fibrinolytic properties of TM in plasma  by
measuring the activation of TAFI during tissue factor induced coagulation. TAFI activation was
stimulated at low concentrations of TM but decreased at higher concentrations of TM. Similarly,
the clot lysis times increased at low concentrations of TM but decreased at higher concentrations
of TM. The reduction of TAFI activation at high TM concentrations was found to be dependent
on a functional protein C pathway. The concentration of TM is therefore an important factor in
the regulation of TAFI activation and in the regulation of fibrinolysis. High concentrations of TM
result in up regulation of fibrinolysis, whereas low concentrations of TM have a down regulatory
effect on fibrinolysis. These results suggest that fibrinolysis might be differentially regulated by
TM in different parts of the body depending on the local TM concentration in the vasculature.
Introduction
The fibrinolytic system plays an important role in the dissolution and removal of fibrin
deposition from the circulation, thereby restoring the haemostatic equilibrium after activaton of
coagulation (132, 134, 135). However, excessive fibrinolysis may result in a bleeding tendency
whereas impairment of fibrinolysis represents a haemostatic abnormality associated with
thrombosis. A careful regulation of coagulation and fibrinolysis is therefore required. Recently,
a new mechanism for the down regulation of fibrinolysis upon activation of the coagulation
cascade was described and involves the thrombin catalyzed activation of thrombin activatable
fibrinolysis inhibitor (TAFI; EC 3.4.17.20) (18).
TAFI is a carboxypeptidase B-like proenzyme synthesized in the liver (16, 154) and circulates
in plasma at a concentration of about 275 nM (26). After activation by thrombin or plasmin
activated TAFI (TAFIa) attenuates fibrinolysis. TAFIa is alternatively referred to as plasma
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carboxypeptidase B (pCPB) (16), carboxypeptidase U (CPU) (17) or carboxypeptidase R (15).
Down regulation of fibrinolysis by TAFIa involves the removal of carboxy-terminal lysine (and
arginine) residues from fibrin that augment the cofactor activity of fibrin in the tPA mediated
activation of plasminogen (17, 50, 56).
Activation of TAFI is mediated by thrombin generated by the coagulation cascade. Thrombin
mediated factor XI activation was shown to generate large amounts of additional thrombin via the
intrinsic pathway that result in a TAFI dependent down regulation of fibrinolysis (64, 65, 82).
The endothelial cell receptor thrombomodulin (TM) stimulates the thrombin mediated activation
of TAFI more than 1,000 fold and consequently thrombomodulin has a drastic effect on the down
regulation of fibrinolysis (29).
Regulation of TAFI activity occurs most likely by a rapid spontaneous decay of TAFIa
activity, a process that involves temperature-dependent conformational instability and results in
a half-life of TAFIa at 37°C of about 10 minutes (30). To date there have been no reports on
human endogenous TAFIa inhibitors.
Since TAFI is activated by thrombin, TAFI activation can be controlled by enzymes that
regulate the formation of thrombin, such as activated protein C (APC). APC attenuates the
formation of thrombin by inactivating the factors Va and VIIIa in the presence of the non-
enzymatic cofactor protein S and a phospholipid surface (155, 156). This phenomenon has been
previously described as the profibrinolytic effect of APC and could be attributed to reduced TAFI
activation (22-25).
Activation of both protein C and TAFI is enhanced when thrombin is bound to TM (29, 157).
This suggests a paradoxical role for TM in the regulation of fibrinolysis. On one hand
thrombomodulin stimulates the activation of TAFI which results in a down regulation of
fibrinolysis. On the other hand TM enhances the activation of protein C which attenuates
thrombin formation and this inhibits the activation of TAFI, resulting in an up regulation of
fibrinolysis. Both effects of TM on fibrinolysis have been previously described. TM corrected the
premature lysis of clots prepared from factor X, IX, VIII and XI deficient plasmas in vitro (48)
and TAFI dependent down regulation of fibrinolysis was shown to be augmented by both soluble
(29, 59, 109) and cellular (142) TM. Modulation of fibrinolysis by APC has been described both
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in vitro (22, 23, 25, 158) and in vivo (152, 159, 160) whereas factor VLeiden, in which the
inactivation of factor Va by APC is severely compromised due to a mutation in factor V
(Arg506Gln), was shown to enhance the down regulation of fibrinolysis (89, 161)
However, the question remains how the opposite effects of TM on fibrinolysis are modulated
and what the overall outcome is in plasma. Therefore, our goal for this study was to clarify these
effects of TM on fibrinolysis, by studying the role of TAFI and protein C in this mechanism.
Materials and Methods
Materials
Recombinant human tissue factor (Innovin) was obtained from Baxter (Unterschleissheim,
Germany). Carboxy peptidase inhibitor (CPI) was purchased from Calbiochem (La Jolla, CA),
cyanuric chloride and gelatin were from Merck (Amsterdam, The Netherlands) and tissue type
plasminogen activator (583,000 IU/mg) was from Chromogenix (Mölndal, Sweden).
Hippuryl-Arg, H-D-Phe-Pro-Arg-chloromethylketone (PPACK) and H-Gly-Pro-Arg-Pro-NH2
were obtained from Bachem (Bubendorf, Switzerland). Rabbit lung thrombomodulin and a
monoclonal antibody against TM were purchased from American Diagnostica (Greenwich, CT),
recombinant thrombomodulin fragment 4-6 was from Alexis (San Diego, CA) and hippuric acid
was from Sigma (St. Louis, MO). Polyclonal antibodies against protein C and protein S were
purchased from Dako (Glostrup, Denmark). All other chemicals obtained were the best grade
available.
Proteins and antibodies
A monoclonal antibody against factor XI (XI-1) capable of blocking factor XI activity had
been prepared as described previously (144). Purified human thrombin was a kind gift from
Dr. W. Kisiel (University of New Mexico, Albuquerque, NM, USA). Protein C was isolated and
activated as described (162). All purified proteins appeared homogeneous on SDS-PAGE.
Plasmas
Normal plasma was derived from a donor pool of 40 healthy volunteers. Blood was taken
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from the antecubital vein, collected in 3.8% trisodium citrate (0.129 M) as the anticoagulant
(9:1 v/v). To obtain platelet poor plasma the samples were centrifuged twice for 15 min at
2500 g, after which the plasma was stored at -70°C until use. For the preparation of protein C
depleted plasma, a plasma pool of 4 healthy donors was prepared as above, and subsequently
passed over a Sepharose column to which a monoclonal antibody against protein C (RU-PC4D1)
was immobilized. The undiluted flow through was collected and was found to contain less than
1% protein C as determined by ELISA. Factor VLeiden plasma was obtained from an individual that
was genotyped to be homozygous for the factor VLeiden mutation (Arg506Gln). All plasmas used
contained normal amounts of TAFI as determined by ELISA (26).
Clot lysis assay
Clot lysis was studied in a plasma system in which tPA-mediated fibrinolysis (30 U/ml) of a
thrombin-induced (20 nM) clot is measured using turbidity as described earlier (26). Clot lysis
times were determined as the time between the maximum turbidity and the midpoint of the
maximum turbid-to-clear transition that characterizes the lysis of fibrin.
Tissue factor induced activation of TAFI in plasma
To determine the activation of TAFI in plasma, coagulation was initiated by tissue factor in
the presence of TM. Normal plasma (30 µl) was incubated with different concentrations of tissue
factor (dilutions of Innovin, 1*102-1*106) in the presence of TM (2.5 nM), phospholipid vesicles
40% PC/20% PS/40% PE (10 µM) (26) and calcium chloride (17 mM, resulting in a free calcium
concentration of 2.3 mM) after which the volume was adjusted to 60 µl with Hepes buffer (20 mM
Hepes, pH 7.4, 137 mM NaCl, 4 mM KCl, 0.1% BSA and 3 mM CaCl2) and coagulation was
allowed to proceed for different time intervals at 37°C. The reaction was stopped with PPACK
(20 µl, 150 µM), and the carboxypeptidase activity was determined as described before (26).
Hippuryl-Arg (20 µl, 20 mM) was added, and the reaction mixture was incubated at room
temperature. After 10 min, the substrate conversion was stopped by the addition of 20 µl 1 M HCl
and the amount of hippurate that had been formed was determined (26). Briefly, the pH of the
samples was neutralized by addition of 20 µl 1 M NaOH after which 25 µl 1 M sodium phosphate
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(pH 7.4) and 30 µl 6% cyanuric chloride in 1,4-dioxane were added and the color was allowed to
develop, during which the samples were extensively vortexed. Denaturated protein and excess
cyanuric chloride were removed by centrifugation (10 min, 4000 rpm) and 100 µl of the
supernatant was transferred to a 96-wells microtiterplate. Absorbance was measured at 405 nm
in a microplate reader. Another carboxypeptidase present in plasma, carboxypeptidase N (CPN),
is constitutively active and, like TAFI, has specificity for carboxy-terminal lysines and arginines
(17). In contrast to TAFIa, however, it cannot down regulate fibrinolysis (50) and it is not
inhibited by CPI, a carboxypeptidase inhibitor from potato tubers (17, 50). To distinguish
between the constitutive carboxypeptidase activity (CPN) and the inducible carboxypeptidase
activity (TAFIa) in plasma, the TAFIa activity was determined as the carboxypeptidase activity
sensitive to inhibition by CPI (25 µg/ml). The activated TAFI concentrations were calculated
from the kinetic parameters for the hydrolysis of hippuryl-arginine by TAFIa in plasma
(K
m
 = 0.75 mM, k
cat
 = 13 s-1). In some experiments the total amount of TAFIa generated was
evaluated by integrating the area under the TAFIa versus time curve and expressed in arbitrary
units (AU). The effect of the factor XI (intrinsic) feedback loop was determined by preincubating
the plasma samples for 30 min at room temperature with a monoclonal antibody (XI-1), capable
of blocking factor XIa activity (13,35).
The effect of protein C on the activation of TAFI
The effect of TM on the activation of TAFI in normal- and protein C depleted plasma was
determined essentially as described above, using a 1*104 fold dilution of Innovin and different
concentrations of TM (0.05-10 nM). The effect of the absence of protein C on the activation of
TAFI was determined in protein C depleted plasma essentially as described above. Coagulation
was initiated by a 1*104 fold dilution of Innovin and 10 nM TM. Protein C depleted plasma was
also reconstituted with purified protein C (0-40 nM). In addition, protein C depleted plasma was
incubated with different concentrations of purified APC (0-5 nM), using a 1*104 fold dilution of
Innovin and 2.5 nM TM. The role of factor VLeiden on the activation of TAFI was studied in factor
VLeiden plasma using a 1*104 dilution of Innovin and 5 or 10 nM TM after which the TAFI
activation was determined as described above.
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Activation of TAFI in plasma on endothelial cells
Human microvascular endothelial cells (HMEC-1) (163) were seeded at 3 different densities
(10,000; 30,000 and 90,000 cells per well) on gelatin coated 24-wells dishes at 37°C in 5% CO 2
in RPMI (Gibco) with 10% heat-inactivated fetal calf serum (FCS) supplemented with 5 U/ml
heparin, 100 U/ml penicillin and 100 mg/ml streptomycin. After two days cells were washed
4 times with phosphate buffered saline (PBS) and 220 µl normal plasma was added that was
preincubated for 30 min with either Hepes buffer, a polyclonal antibody against protein C or a
monoclonal antibody against human thrombomodulin that inhibits the binding of thrombin to
TM. Coagulation was initiated by the addition of tissue factor (1*104 dilution of Innovin), CaCl2
(17 mM), PC/PS/PE vesicles (10 µM) and H-Gly-Pro-Arg-Pro-NH2 (5 mM) to prevent fibrin
polymerization. The volume was adjusted to 400 µl and 30 µl aliquots were taken in time for the
determination of TAFIa activity as described.
Results
The pro- and antifibrinolytic properties of TM
Up- and down regulation of fibrinolysis by TM was determined in a clot lysis assay in the
presence of TM or recombinant TM consisting of EGF domains 4 to 6 (TM4-6). This TM4-6
lacks the EGF domain 3 that is essential for the stimulation of TAFI activation but has retained
its capacity to stimulate the activation of protein C (31, 68). In figure 1 it is shown that increasing
concentrations of TM4-6 result in an increased rate of clot lysis due to the activation of protein C.
In contrast to TM4-6, TM (1 nM) induces a down regulation of fibrinolysis caused by the
activation of TAFI. The effect of TM on fibrinolysis was determined in the presence of different
concentrations of TM (figure 2). Low concentrations of TM (0-1 nM) induced a prolongation of
the clot lysis times whereas at higher concentrations of TM (5 nM and up) the clot lysis times
decreased, approximating the clot lysis times in the presence of CPI. The decrease in clot lysis
times at high TM was less pronounced in the presence of antibodies that inhibit the activation of
protein C or the function of protein S. This suggests that at high (>5 nM) concentrations of TM
the activation of TAFI declines by APC mediated inhibition of thrombin generation.
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Figure 2. TM dependent up- and down regulation of fibrinolysis
Normal plasma was incubated with either buffer () or antibodies inhibiting the activation of
protein C () or inhibiting the function of protein S (). Clot lysis times were determined in the
presence of different concentrations of TM. The arrow denotes the clot lysis time in the presence
of CPI (25 µg/ml)(). Each point represents the mean ± SEM of 3 independent experiments.
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Figure 1. Pro- and antifibrinolytic properties of TM
Clot lysis was determined in plasma by measuring the turbidity of a thrombin induced fibrin clot
and tPA mediated fibrinolysis. Normal plasma was incubated with different concentrations of
TM4-6 (1 nM (), 5 nM (), 10 nM (), 50 nM ()), CPI 25 µg/ml (), 1 nM TM () or buffer ().
Each point represents the mean of two independent experiments.
0 15 30 45 60 75 90 105 120
0.2
0.3
0.4
0.5
0.6
0.7
Time (min)
Tu
rb
id
ity
 (4
05
 
n
m
)
65
C
H
A
P
T
E
R
3
Tissue factor dependent activation of TAFI in plasma in the presence of TM
The role of the extrinsic pathway in the activation of TAFI was studied by incubating normal
plasma with different concentrations of tissue factor in the presence of TM after which the TAFI
activity was determined in time. A tissue factor concentration dependent activation of TAFI was
observed (figure 3a). A decrease in tissue factor concentration (from 1*102 to 1*106 dilution of
Innovin) resulted in a decrease in the maximum TAFIa concentration obtained and in an increase
in lag-time before the activation of TAFI started. Preincubation of the plasma with an antibody
that inhibits factor XIa had no effect on TAFI activation at relatively high tissue factor
concentrations (less than 1*104 dilution of Innovin) whereas at the lowest tissue factor
concentration used a minor contribution of the intrinsic pathway of coagulation on the activation
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Figure 3. Tissue factor dependent activation of TAFI in normal plasma
Coagulation was initiated by different concentrations of tissue factor in the presence of 2.5 nM
TM (Panel A).  After different time intervals coagulation was stopped by PPACK and the amount
of TAFIa was determined. To determine the influence of thrombin generation via the factor XI
(intrinsic) feedback loop on the activation of TAFI, plasma was preincubated with an antibody
(XI-1) that blocks this feedback loop. Panel B: The total amount of TAFIa generated, calculated
from the area under the curve and expressed in arbitrary units (AU), in the absence () and
presence () of a factor XIa inhibiting antibody. Tissue factor (dilutions of Innovin): 1*102 ();
1*104 (); 1*105 () and 1*106 (). Each point represents the mean ± SEM of 3 independent
experiments.
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of TAFI was observed (figure 3b). This indicated that in the presence of TM sufficient thrombin
was generated by the extrinsic pathway for the activation of TAFI, whereas in the absence of TM
additional thrombin formation via the intrinsic pathway is required for the activation of TAFI (64,
65, 82).
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Figure 4.  TM dependent activation of TAFI in plasma
TAFI activation was determined in normal plasma (Panel A) and protein C depleted plasma
(Panel B) in the presence of different concentrations of TM (0.05 nM (); 0.25 nM  (); 2.5 nM ();
5 nM () and 10 nM ()). Coagulation was initiated by tissue factor (1*104 dilution of Innovin).
Panel C: TM dependent TAFI activation in normal () and protein C depleted plasma ()
expressed as the total amount of TAFIa generated, calculated from the area under the curve
and expressed in arbitrary units (AU). Each point represents the mean ± SEM of 3 independent
experiments.
0 5 10 15 20 25 30
0
25
50
75
100
125
A
Time (min)
TA
FI
a 
(nM
)
0 5 10 15 20 25 30
0
50
100
150
200
Time (min)
TA
FI
a 
(nM
)
B
67
C
H
A
P
T
E
R
3
The effect of the TM concentration on the activation of TAFI in plasma
Increasing the TM concentration from 0.05 to 5 nM resulted in an increase in the rate of TAFI
activation (figure 4a). A further increase of the TM concentration to 10 nM resulted in a down
regulation of TAFI activation. This might be due to the inhibitory effect of APC on thrombin
generation, in agreement with its previously demonstrated profibrinolytic role (25).
The effect of protein C on the activation of TAFI in plasma
To determine if the decrease in TAFI activation at high TM concentrations in normal plasma
was indeed caused by the activation of protein C, coagulation was initiated by tissue factor in
protein C depleted plasma in the presence of different concentrations of TM (figure 4b).  As in
normal plasma the activation of TAFI increased at increasing TM concentrations (0.25-5 nM).
However in contrast to normal plasma no decrease in TAFI activation was observed at 10 nM of
TM in protein C depleted plasma (figure 4c).  Also the maximum level of activated TAFI
generated in protein C depleted plasma was higher than in normal plasma. Reconstitution of
protein C depleted plasma with purified protein C restored the inhibition of TAFI activation in a
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Figure 5. Reconstitution of protein C depleted plasma
TAFI activation (Panel A) was determined in normal plasma () and protein C depleted plasma
(open symbols) reconstituted with purified protein C (0 nM (); 10 nM (); 20 nM () and 40 nM
()). Coagulation was initiated with tissue factor (1*104 dilution of Innovin) in the presence of
10 nM TM. Panel B: The total amount of TAFIa generated, calculated from the area under the
curve and expressed in arbitrary units (AU), in protein C depleted plasma () and normal
plasma (). Each point represents the mean ± SEM of 3 independent experiments.
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dose dependent manner (figure 5a). At a concentration of 40 nM protein C, the TAFI activation
was decreased to the same extent as in normal plasma (figure 5b). To determine how much APC
was needed for the inhibition of TAFI activation, different concentrations of purified APC were
added to protein C depleted plasma (figure 6a). A dose dependent inhibition of TAFI activation
by APC was observed, resulting in an almost complete inhibition of TAFIa generation at 5 nM
APC (figure 6b). These experiments demonstrated that in normal plasma the activation of TAFI
was inhibited by the generation of activated protein C at high TM concentrations.
Activation of TAFI in factor VLeiden  plasma upon tissue factor induced coagulation
The decrease in the rate of TAFI activation at high concentrations of TM in normal plasma
was attributed to the generation of increasing amounts of APC and subsequent down regulation
of thrombin formation resulting in a decrease in TAFI activation. To determine the effect of the
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Figure 6.  APC mediated inhibition of TAFI activation
TAFI activation (Panel A) was determined in normal plasma () and protein C depleted plasma
(open symbols) in the presence of APC (0 nM (); 1 nM (); 1.75 nM (); 2.5 nM () and 5 nM
()). Coagulation was initiated with tissue factor (1*104 dilution of Innovin) in the presence of 2.5
nM TM. Panel B: The total amount of TAFIa generated, calculated from the area under the curve
and expressed in arbitrary units (AU), in protein C depleted plasma () and normal plasma ().
Each point represents the mean ± SEM of 3 independent experiments.
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APC mediated inactivation of factor Va and factor VIIIa, TAFI activation was studied in plasma
of an individual homozygous for factor VLeiden. Stimulation of TAFI activation was similar in
normal plasma and factor VLeiden plasma in the presence of 5 nM TM (figure 7). However, no inhibition
of TAFI activation in factor VLeiden plasma was observed in the presence of 10 nM TM, whereas
the TAFI activation in normal plasma was severely inhibited (figure 7). This indicated that the
inhibition of TAFI activation in normal plasma at 10 nM TM was caused by the generation of
APC and subsequent APC mediated inactivation of factor Va.
Activation of TAFI in plasma on endothelial cells
The TM dependent stimulation of TAFI activation and inhibition by APC was
determined on endothelial cells using membrane bound TM expressed by endothelial cells.
Human microvascular endothelial cells (HMEC-1) were seeded at different densities.
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Figure 7. The effect of factor VLeiden on the activation of TAFI in plasma
TAFI activation was determined in normal plasma (Panel A: open symbols, Panel B: dark gray
bars) and in the plasma of an individual homozygous for the factor VLeiden mutation (Panel A:
closed symbols, Panel B: light gray bars). Coagulation was initiated with tissue factor (1*104
dilution of Innovin) in the presence of 5 nM (,) and 10 nM (,) TM. Panel B: The total amount
of TAFIa generated, calculated from the area under the curve and expressed in arbitrary units
(AU). Each point represents the mean ± SEM of 3 independent experiments.
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Control experiments confirmed that the total amount of TM present in the wells increased with
the number of cells seeded (data not shown) and in the presence of an antibody to TM that inhibits
the binding of thrombin to TM or in the absence of endothelial cells no activation of TAFI was
observed which indicates that the TAFI activation in this system was dependent on TM
(figure 8b). Increasing the cell density from 1*104 cells/well to 3*104 cells/well resulted in an
increase of the activation of TAFI in plasma (figure 8a). A further increase of the cell density to
9*104 cells/well reduced the activation of TAFI. In contrast, when the activation of protein C was
blocked by antibodies, the activation of TAFI increased with the cell density and did not show a
reduction of TAFI activation at the highest cell density as observed in the absence of protein C
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A Figure 8. TAFI activation on
endothelial cells in plasma
TAFI activation was determined in
plasma on endothelial cells (HMEC-1)
seeded at different densities
without the addition of exogeneous
TM. Coagulation was initiated by
tissue factor (1*104 dilution of
Innovin) in normal plasma (Panel A),
in the presence of an antibody
inhibiting the activation of protein C
(Panel B, left), in the presence of an
antibody inhibiting the binding of
thrombin to TM and in the absence
of HMEC-1 (Panel B, right). The total
amount of TAFIa generated is
calculated from the area under
the TAFIa versus time (0-30 min)
curve and expressed in arbitrary
units (AU). Each point represents
the mean ± SEM of 4 independent
experiments.
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inhibiting antibodies. This demonstrates that also on endothelial cells low concentrations of TM
promote TAFI activation whereas high concentration of TM diminish TAFI activation by the
activation of the protein C pathway.
Discussion
TM is considered to induce a change in the substrate specificity of thrombin from a
procoagulant into a potent activator of protein C. Recent developments however have indicated
that the function of TM is more complex. The identification of TAFI as a novel link between
coagulation and fibrinolysis not only introduced a new mechanism for the down regulation of
fibrinolysis and provided an explanation for the profibrinolytic effect of APC, it also suggested
an additional function of TM in the regulation of fibrinolysis. On one hand TM can down regulate
fibrinolysis by stimulating the activation of TAFI whereas on the other hand TM can up regulate
fibrinolysis by stimulating the activation of protein C, which results in a decreased rate of
thrombin formation and consequently a reduced activation of TAFI. Both effects of TM on
fibrinolysis were demonstrated in clot lysis assays using TM or TM4-6. TM4-6 does not
stimulate the thrombin mediated activation of TAFI since it lacks the EGF domain 3 that is
essential for the stimulation of TAFI activation but has retained its capacity to stimulate the
activation of protein C (31, 68). TM4-6 up regulated fibrinolysis in a dose dependent manner
indicating the profibrinolytic effect of APC whereas TM down regulated fibrinolysis (figure 1).
The down regulation of fibrinolysis by TM is presumably the net effect of stimulation of TAFI
activation and inhibition of TAFI activation by APC. This balance between the anti- and
profibrinolytic properties of TM changes from antifibrinolytic to profibrinolytic upon increasing
TM concentrations (figure 2). In addition the profibrinolytic effect of TM was dependent on a
functional anticoagulant pathway.
To identify the mechanisms that regulate the activation of TAFI an assay was developed for
the determination of the activation of TAFI in plasma. A tissue factor dependent activation of
TAFI was observed, which in the presence of TM was only marginally dependent on the
formation of thrombin via the factor XI (intrinsic) feedback loop (figure 3b). In the presence of
TM only small amounts of thrombin were needed for the activation of TAFI, which were
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generated in sufficient amounts by the extrinsic pathway. In contrast, the relative high
concentrations of thrombin required for the activation of TAFI in  the absence of TM are
generated by thrombin mediated factor XI activation and subsequent thrombin formation via the
intrinsic pathway (64, 65).
The effect of TM on the activation of TAFI in normal plasma was found to be optimal at 5 nM
(figure 4) in our system. At low concentrations of TM (<5 nM) a dose dependent increase of TAFI
activation was observed. In contrast,  at higher concentrations of TM (10 nM and 25 nM (data not
shown)) a dose dependent decrease of the activation of TAFI was observed. The decrease in TAFI
activation at these TM concentrations was not observed in protein C depleted plasma (figure 4),
whereas reconstitution with purified protein C restored the inhibition of TAFI activation in a dose
dependent fashion (figure 5). This indicated that the decrease in TAFI activation was due to
inhibition of thrombin generation by APC. Indeed addition of APC to protein C depleted plasma
resulted in a dose dependent inhibition of TAFI activation, with a complete inhibition of the TAFI
activation at about 5 nM APC (figure 6). In agreement with this, the decrease in TAFI activation
at relative high TM concentrations was not observed in plasma of an individual homozygous for
the factor VLeiden mutation (figure 7).  Interestingly, Braat et al. (77) reported that similar
concentrations of TM (± 10 nM) were required to inhibit the thrombin mediated inactivation of
single-chain urokinase type plasminogen activator by endogenous formed APC in plasma.
Although activation of both protein C and TAFI occur simultaneous, the TM concentration
was found to be the determining factor in the outcome of the overall effect. This is unexpected
because the kinetic parameters for activation of TAFI (15, 16, 37) and protein C (164, 165) in the
presence of TM are similar, suggesting an equal rate of activation of TAFI and protein C.
An alternative explanation is that TAFI and protein C bind competitively to the thrombin-TM
complex thereby compromising the activation of the other (Ki2 and 3 µM for competitive
inhibition by TAFI and protein C, respectively (31)). This effect however is expected to be
minimal under physiological conditions such as in plasma because the plasma concentration of
protein C (65 nM) and TAFI (70-275 nM) (25, 26) are 5-50 fold below their respective K
m
 values
for activation.
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Therefore we hypothesize that inhibition of  TAFI activation by APC which proceeds
indirectly via the inactivation of factors Va and VIIIa requires more time compared to the direct
stimulation of TAFI activation by TM.  High concentrations of thrombin-TM are needed to
generate adequate amounts of APC to inhibit thrombin formation before TAFI activation can
occur.
In vivo, TM is predominantly located on the surface of endothelial cells. In plasma soluble
TM circulates in a concentration of ± 10 ng/ml (108). When cultured microvascular endothelial
cells were used as the source of TM, similar results were obtained compared to TM in solution.
TAFI activation first increased and then decreased at increasing cell density (read TM
concentration) in normal plasma but upon inhibition of the activation of protein C no decrease of
TAFI activation was observed at higher cell density (figure 8).  This indicates that TM on the
endothelial cell is also capable of modulating TAFI activation similar to TM in solution and
suggests that endothelial cells in vivo are likely to do the same.
Endothelial cells of different organs and tissues display considerable diversity and
heterogeneity (166).  Expression of TM on endothelial cells varies substantially throughout the
vasculature (167, 168). Tissues such as lung and heart are known to express adequate amounts of
TM, whereas the brain is practically void of TM (167, 168). This suggests that, based on our
results, fibrinolysis might be either up- or down regulated in different parts of the body.
Also, the vessel size may be an important factor determining the effective TM concentration
in the vasculature.  Esmon (169) and Busch et al. (170) calculated that the effective TM
concentration rises from less than 5 nM to more than 100 nM as the blood moves from the aorta
to the capillaries, suggesting that differential regulation of fibrinolysis by TM may occur in vivo.
In analogy with the thrombin paradox (90) in which thrombin is an anticoagulant at low
concentrations but a procoagulant at high concentrations, we postulate the TM paradox in which
TM is antifibrinolytic at low concentrations but profibrinolytic at higher concentrations.
This implies that a procoagulant state due to a high thrombin concentration becomes more
thrombotic when it is accompanied by a down regulation of fibrinolysis caused by a low TM
concentration and vice versa an anticoagulant state due to a low thrombin concentration is more
antithrombotic in the presence of high concentrations of TM which up regulates fibrinolysis.
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However when thrombin and TM are both present at low concentration, fibrin formation is
hampered by the anticoagulant state induced by thrombin, but if fibrin is formed it is protected
against lysis due to the down regulation of fibrinolysis by TM. This mechanism ensures stable
clot formation at sites where it is needed such as in the haemostatic plug.
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Summary
Thrombin Activatable Fibrinolysis Inhibitor (TAFI) is a carboxypeptidase B-like proenzyme
that after activation by thrombin down regulates fibrinolysis. Thrombomodulin (TM) stimulates
the activation of both TAFI and protein C whereas activated protein C (APC) inhibits the
activation of TAFI by down regulating thrombin generation. Recently, protein C inhibitor (PCI)
was identified as a potent inhibitor of thrombin bound to TM and it can thereby regulate the
balance between TAFI activation, and inhibition of TAFI activation by APC.  Both in a purified
system and in plasma, activation of TAFI and protein C by thrombin-TM could be inhibited by PCI.
Previously we found in plasma that at low concentrations (~1 nM), TM predominantly stimulated
the activation of TAFI whereas at higher concentrations of TM (~10 nM) the activation of protein C
resulted in inhibition of the activation of TAFI.  In agreement with this, PCI inhibited the
activation of TAFI at 1 nM TM whereas at 10 nM TM PCI inhibited the activation of protein C
resulting in an increase in the activation of TAFI. This suggests that PCI can up regulate TAFI
activation by inhibiting the protein C activation. PCI may therefore be an important regulator in
the balance between coagulation and fibrinolysis by differentially inhibiting the activation of
TAFI and of protein C. The local TM concentration plays an important role in the outcome of this
process.
Introduction
Protein C inhibitor (PCI) is a plasma glycoprotein which belongs to the SERPIN superfamily
of serine protease inhibitors, of which α1-protease inhibitor (α1-PI) is the prototype (171, 172).
PCI was originally identified as an inhibitor of the anticoagulant protease activated protein C
(APC) (173, 174), but was later shown to have a broad target specificity. PCI is capable of
inhibiting various blood coagulation enzymes such as thrombin, factor Xa and factor XIa
(175-178). A role for PCI in fibrinolysis was implicated after its discovery in urine, where it
inhibited urokinase and was named PAI-3, subsequently (179, 180). Due to the broad target
specificity of PCI and the contradictory pro- and anticoagulant effects of PCI, the physiological
role of PCI in blood remains unclear. Recently it was found that PCI plays a regulatory role in the
protein C pathway by inhibiting the thrombin-thrombomodulin complex thereby decreasing the
activation of protein C (181, 182).
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Thrombomodulin (TM) is an integral membrane glycoprotein that is predominantly
expressed on vascular endothelial cells (183). By binding to thrombin in a 1:1 stoichiometric
complex, TM inhibits the procoagulant functions of thrombin and acts as a cofactor for thrombin
catalyzed activation of protein C. APC in the presence of cofactor protein S degrades the factors
Va and VIIIa resulting in a down regulation of thrombin formation (155, 156). The importance of
this anticoagulant pathway is evident from the increased thrombotic risk associated with a
deficiency in either protein C or protein S (184-186). TM also stimulates the activation of
thrombin activatable fibrinolysis inhibitor (TAFI; EC 3.4.17.20) (29), but it is unknown if PCI
can regulate this function as well.
TAFI (18) is a recently identified fibrinolysis inhibitor in plasma and is considered to be an
important link between coagulation and fibrinolysis. Amino-terminal sequence analysis revealed
that activated TAFI (TAFIa) is identical to plasma carboxypeptidase B (pCPB) (16) and
carboxypeptidase U (CPU) (17). After activation, TAFIa potently down regulates fibrinolysis by
removing the carboxy-terminal lysines and arginines from partially degraded fibrin that are
involved in the binding of tPA and plasminogen and the formation of plasmin (17, 50, 56).
Although relatively high concentrations of thrombin are required for the activation of TAFI,
evidence from both in vitro (64, 65) and in vivo (87, 99) experiments suggest that in plasma an
intact factor XI (intrinsic) feedback loop generates sufficient thrombin for the activation of TAFI.
However, in the presence of the cofactor TM, much lower concentrations of thrombin are
required for TAFI activation due to an increase of the catalytic efficiency of about 1250 fold (29).
Since TAFI is activated by thrombin, TAFI activation can be controlled by factors that
regulate the thrombin formation, such as APC, or that affect the thrombin-TM complex, such as PCI.
The effect of APC on the activation of TAFI was previously described as the profibrinolytic effect
of APC (22, 23, 159) and could be attributed to inhibition of TAFI activation due to the APC
mediated down regulation of thrombin formation (25). This suggests a duplicitous role for TM in
the regulation of fibrinolysis. On one hand TM down regulates fibrinolysis by stimulation of
TAFI activation but on the other hand TM up regulates fibrinolysis by stimulation of protein C
activation resulting in the inhibition of TAFI activation. Inhibition of thrombin bound to TM by
PCI might therefore result in either an up- or down regulation of fibrinolysis depending on the
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balance between TAFI activation and protein C activation, respectively. Recently we found that
the activation of TAFI is predominantly stimulated at low TM concentrations resulting in a down
regulation of fibrinolysis whereas at high TM concentrations the activation of protein C becomes
more important resulting in a decrease of TAFI activation and consequently an up regulation of
fibrinolysis (72). Based on these observations the TM paradox was postulated in which TM is
antifibrinolytic at low concentrations but profibrinolytic at higher concentrations. Here the
effects of PCI on the fibrinolytic properties of TM were determined.
Materials and Methods
Materials
Recombinant human tissue factor (Innovin) was obtained from Baxter (Unterschleissheim,
Germany). Carboxypeptidase inhibitor (CPI) was purchased from Calbiochem (La Jolla, CA)
and cyanuric chloride was from Merck (Amsterdam, The Netherlands). Hippuryl-Arg and H-D-
Phe-Pro-Arg-chloromethylketone (PPACK) were obtained from Bachem (Bubendorf,
Switzerland). Rabbit lung thrombomodulin was purchased from American Diagnostica
(Greenwich, CT), hippuric acid was from Sigma (St. Louis, MO) and the chromogenic substrate
S-2366 was obtained from Chromogenix (Mölndal, Sweden). All other chemicals obtained were
the best grade available.
Proteins
Protein C was isolated and activated as described by Hackeng et al. (162) and appeared
homogeneous on SDS-PAGE. The concentration was based on A280 nm readings using ε1%,280 = 14.5
as the absorption coefficient and Mr = 62 kDa. Human plasma PCI was purified from fresh frozen
plasma as described (187) and recombinant human wild type PCI was purified as before (187).
The concentration of plasma and recombinant PCI was determined by active-site titration and
immunoassay as described (187). A monoclonal antibody against factor XI (XI-1) capable of
blocking factor XI activity had been prepared as described previously (144). The monoclonal
antibody against PCI (API-79) capable of abolishing the inhibitory function of PCI was prepared
according to standard procedures.  Purified human thrombin was a generous gift from Dr. Walter
Kisiel (University of New Mexico, Albuquerque, NM, USA).
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Purification of TAFI
Human TAFI was isolated from fresh frozen citrated plasma, containing 10 mM
benzamidine, 10 mM EDTA, 15 KIE/ml Trasylol (aprotinin), 0.01% polybrene and 40 mM
ε-aminocaproic acid (εACA) by affinity chromatography on an anti-TAFI monoclonal antibody
column (1.5 x 2 cm, 5 mg MoAb-9H10 coupled to 5 ml CNBr activated Sepharose) equilibrated
in buffer A (50 mM Tris, 150 mM NaCl, 10 mM benzamidine, 10 mM EDTA, 15 KIE/ml
Trasylol, 0.01% polybrene and 40 mM εACA, pH 7.4).  After loading, the column was
extensively washed with buffer A followed by buffer B (25 mM Tris, pH 7.4) after which the
bound protein was eluted with 0.1 M glycine (pH 2.7).  Fractions containing TAFI were
neutralized, pooled, diluted five times in water and passed through a protein G Sepharose column
(1.5 x 3 cm) and a Fast Flow Q Sepharose column (1.5 x 0.5 cm), equilibrated in buffer B.
After washing with 100 ml buffer B, TAFI was eluted with a 0-0.25 M NaCl salt gradient (2x4
ml) in buffer B.  Fractions containing TAFI were pooled and stored at -70°C.  TAFI appeared
homogeneous on SDS-PAGE and the concentration was determined with a BCA assay (Pierce,
Rockfort, IL) using bovine serum albumin as a standard.
Plasmas
Normal plasma was derived from a  pool of 40 healthy volunteers. Blood was taken from the
antecubital vein, collected in 3.2% trisodium citrate (0.109 M) as the anticoagulant (9:1 v/v).
To obtain platelet poor plasma the samples were centrifuged twice for 15 min at 2500 g, after
which the plasma was stored at -70°C until use. For the preparation of PCI depleted plasma
and protein C/PCI double depleted plasma, a plasma pool of 4 healthy donors was prepared
as above, and passed over a Sepharose column to which a monoclonal antibody against PCI
(API-39) and/or protein C (RU-PC4D1) was coupled. The undiluted flow through was
collected and was found to contain less than 1% of the depleted factors as determined by
ELISA. Control plasma was obtained by passing plasma over a Sepharose column to which
bovine serum albumin had been coupled. All plasmas used contained normal levels of TAFI
as determined by ELISA (26).
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Phospholipid vesicles
Phospholipid vesicles consisting of 40% phosphatidylcholine (PC), 20% phosphatidylserine
(PS) and 40% phosphatidylethanolamine (PE) were prepared according to Brunner
(146), with some modifications (139). The total phospholipid content of the vesicles containing
fractions was determined by phosphate analysis (147).
Inhibition of the activation of TAFI and protein C by PCI
TAFI (150 nM) or protein C (0.5 µM) were activated with thrombin (0.5 nM) and TM (50 nM)
in the presence of different concentrations of plasma PCI (0-50 nM) in Hepes buffer (20 mM
Hepes, pH 7.4, 137 mM NaCl, 4 mM KCl, 0.1% BSA and 3 mM CaCl2). Also thrombin (50 nM)
mediated activation of TAFI (300 nM) and protein C (50 nM) was determined in the presence of
different concentration of TM (0-20 nM) in the presence of PCI (0, 80 or 160 nM). In time the
activation of TAFI was stopped by PPACK (30 µM, f.c.) and the activity was determined using
the substrate hippuryl-Arg (4 mM, f.c.) and colorimetric detection of hippurate based on cyanuric
chloride as described before (26, 72). The activated TAFI concentrations were calculated from
the kinetic parameters for the hydrolysis of hippuryl-arginine by TAFIa (KM = 0.750 mM,
k
cat
 = 13 s-1) (72). Activation of protein C was stopped in time by the addition of hirudin
(25 U/ml, f.c.) and EDTA (15 mM, f.c.) and the activity was determined using the chromogenic
substrate S-2366. The APC activity was quantified using purified APC as a reference.
The effect of PCI on the activation of TAFI in plasma
Activation of TAFI was determined in time in normal-, PCI depleted and PCI depleted plasma
to which purified recombinant PCI (160 nM) was added in the presence of 1 and 10 nM TM. TAFI
activation was also determined in normal plasma in the absence and presence of an antibody
inhibiting the function of PCI (API-79) and in protein C/PCI double depleted plasma
reconstituted with either buffer, protein C (50 nM), PCI (160 nM) or both, in the presence of 1 and
10 nM TM. Plasma (30 µl) was incubated with tissue factor (1*105 dilution of Innovin) in the
presence of TM (1 or 10 nM), PC/PS/PE vesicles (10 µM) and calcium chloride (8.5 mM) after
which the volume was adjusted to 60 µl with Hepes buffer and coagulation was allowed to
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proceed for different time intervals. The reaction was stopped with PPACK (20 µl, 150 µM),
and the carboxypeptidase activity was determined with hippuryl-Arg (20 µl, 20 mM).
After 10 min, the substrate conversion was stopped by the addition of 20 µl 1 M HCl and the
amount of hippurate that had been formed was determined using cyanuric chloride as described
before (26, 72). The TAFI activity was determined as the carboxypeptidase activity sensitive to
inhibition by carboxypeptidase  inhibitor (CPI) (25 µg/ml). The activated TAFI concentrations
were calculated from the kinetic parameters for the hydrolysis of hippuryl-arginine by TAFIa
(KM = 0.75 mM, kcat = 13 s-1) (72). In some experiments the total amount of TAFIa generated was
evaluated by integrating the area under the TAFIa versus time curve and expressed in arbitrary units (AU).
The effect of PCI on clot lysis
Clot lysis was studied in a plasma system in which tPA mediated fibrinolysis of a tissue
factor-induced plasma clot is measured using turbidity as described earlier (26, 64). The plasma
was preincubated for 30 min at room temperature with a monoclonal antibody (XI-1) that inhibits
factor XI activity and clot lysis was determined in PCI depleted plasma in the absence and
presence of recombinant PCI (80 or 160 nM) using different concentrations of TM (0-0.5 nM).
Tissue factor (1*105 dilution of Innovin), PC/PS/PE vesicles (10 µM), calcium chloride
necessary for recalcification (8.5 mM) and tPA (30 U/ml) were added to 62.5 µl of citrated plasma
after which the volume was adjusted to 125 µl with Hepes buffer. After mixing, 100 µl of the
reaction mixture was pipetted into a microtiter plate and then incubated at 37°C during which the
turbidity was measured in time at 405 nm in a Spectramax 340 kinetic microtiter plate reader
(Molecular Devices Corporation, Menlo Park, CA, USA). The clot lysis time was determined as
the time from the half-maximum turbidity that characterizes the formation of fibrin to the half-
maximal turbidity that characterizes the lysis of fibrin.
Results
Effect of PCI on the activation of TAFI and protein C
The effect of PCI on the activation of TAFI and protein C by the thrombin-TM complex was
tested in a system consisting of purified components. The activation of both TAFI (figure 1a) and
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protein C (figure 1b) was inhibited by PCI in a dose dependent fashion. The effect of PCI on the
activation of TAFI was not caused by a direct inhibition of TAFIa by PCI, whereas direct
inhibition of APC by PCI accounted for only 2.5% of the total inhibition (data not shown).
The effect of PCI on the activation of TAFI in plasma
The effect of PCI on the activation of TAFI was also measured in plasma, using a previously
described assay (26, 72). In this assay tissue factor is used to initiate the coagulation system and
TM (1 nM, figure 2a/c or 10 nM, figure 2b/c) is added to the plasma to enhance the activation of
TAFI by thrombin. At a TM concentration of 1 nM the activation of TAFI was increased in PCI
depleted plasma compared to normal plasma (figure 2a/c). Addition of purified PCI (160 nM)  to
PCI depleted plasma restored the inhibition of TAFI activation to the same level as observed in
normal plasma. Also addition of an antibody that inhibits the function of PCI (API-79) to normal
plasma resulted in an increased activation of TAFI (data not shown). In the presence of 10 nM TM
the activation of TAFI was previously shown to be inhibited as a result of the activation of protein
Figure 1. PCI mediated inhibition of TAFI and protein C activation
In a system with purified components, TAFI (150 nM) (A, closed symbols) or protein C (0.5 µM)
(B, open symbols) were activated by thrombin (0.5 nM) and TM (50 nM) in the presence of
different concentrations of plasma PCI {0 nM (,); 10 nM (,); 25 nM (,) and 50 nM
(,)}. TAFI activity was determined using the substrate hippuryl-Arg and APC activity was
determined using the chromogenic substrate S-2366.
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C (72). At 10 nM TM the activation of TAFI was decreased in PCI depleted plasma compared to
normal plasma (figure 2b/c). Addition of an excess of purified PCI (160 nM) to PCI depleted
plasma in the presence of 10 nM TM resulted in a large increase in the activation of TAFI. This
suggests that PCI inhibited the thrombin-TM mediated activation of protein C. These data
indicate that in plasma PCI can inhibit the activation of both TAFI and protein C. TAFI activation
Figure 2. Regulation of TAFI activation by PCI in plasma
TAFI activation was determined in normal plasma (), PCI depleted plasma () and in PCI
depleted plasma reconstituted with 160 nM  PCI (	). Coagulation was initiated with tissue factor
(1*105 dilution of Innovin), calcium chloride necessary for recalcification and phospholipid
vesicles (10 µM) in the presence of 1 nM (panel A) or 10 nM TM (panel B) after which TAFI
activation was determined in time. The total amount of TAFIa generated was calculated from
the area under the TAFIa versus time (0-30 min) curve and expressed in arbitrary units (AU), (panel
C). Normal plasma (solid bars), PCI depleted plasma (dark gray bars) and in PCI depleted
plasma reconstituted with 160 nM  PCI (light gray bars). Each point represents the mean ± SEM
of 3 independent experiments.
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was inhibited by PCI in the presence of 1 nM TM whereas protein C activation was inhibited by
PCI in the presence of 10 nM TM resulting in an increase in the activation of TAFI.
Effect of PCI on the activation of TAFI and protein C in plasma
APC inhibits the activation of TAFI by down regulation of thrombin generation which is
required for the activation of TAFI. Because PCI was found to inhibit the activation of both
Figure 3. PCI mediated inhibition and stimulation of TAFI activation
TAFI activation was determined in protein C and PCI double depleted plasma () reconstituted
with 50 nM protein C (	), 160 nM PCI () or both ().  Coagulation was initiated by tissue factor
(1*105 dilution of Innovin), calcium chloride necessary for recalcification and phospholipid
vesicles (10 µM) in the presence of 1 nM (panel A) or 10 nM TM (panel B) after which TAFI
activation was determined in time. The total amount of TAFIa generated was calculated from
the area under the TAFIa versus time (0-30 min) curve and expressed in arbitrary units (AU),
(panel C). Protein C and PCI double depleted plasma (solid bars) reconstituted with 160 nM PCI
(dark gray bars), 50 nM protein C (light gray bars) or both (open bars). The results of a typical
experiment are shown.
1 nM TM 10 nM TM
0
1000
2000
3000
C
To
ta
l T
A
FI
a 
(A
U
)
0 5 10 15 20 25 30
0
25
50
75
100
 1 nM TM
A
Time (min)
TA
FI
a 
(nM
)
0 5 10 15 20 25 30
0
50
100
150
200
 10 nM TM
Time (min)
TA
FI
a 
(nM
)
B
85
C
H
A
P
T
E
R
4
protein C and TAFI we studied the individual effects of protein C and PCI on the activation of
TAFI in protein C/PCI double depleted plasma at low (1 nM) and high (10 nM) TM
concentrations. Reconstitution of the double depleted plasma with PCI decreased the rate of
activation of TAFI at 1 nM of TM (figure 3a/c), indicating that PCI inhibited the activation of
TAFI  independent of protein C.  Reconstitution of the double depleted plasma with protein C also
resulted in a decrease of the activation of TAFI (figure 3a/c), indicating that in the absence of PCI
even at low TM concentration some APC is generated that inhibits the activation of TAFI.
Reconstitution with both PCI and protein C resulted in a further inhibition of the TAFI
generation. At high TM concentrations (10 nM)  reconstitution with PCI had no effect on the
activation of TAFI, whereas reconstitution with protein C almost abolished the activation of
TAFI (figure 3b/c). Addition of both protein C and PCI resulted in an increase of TAFI activation
compared to the result in the presence of protein C alone (figure 3b/c). This result is in contrast
to reconstitution with both protein C and PCI at low TM concentration which had only a marginal
inhibitory effect on TAFI activation compared to reconstitution with protein C alone.
Figure 4. Activation of TAFI and protein C at different TM concentrations
In a system with purified components, TAFI (300 nM) (closed symbols) or protein C (50 nM) (open
symbols) were activated by thrombin (50 nM) and TM (0-20 nM) in the presence of different
concentrations of plasma PCI {0 nM (,), 80 nM (
,	) and 160 nM (,)}. TAFI activity was
determined using the substrate hippuryl-Arg and APC activity was determined using the
chromogenic substrate S-2366. Each point represents the mean ± SEM of 3 independent
experiments.
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This suggests that at high TM concentration PCI stimulates the activation of TAFI by inhibition
of the activation of protein C and has no direct effect on the activation of TAFI, whereas at low
TM concentrations PCI inhibits the activation of TAFI directly.
The effect of PCI on the activation of TAFI and protein C at different TM
concentrations
In order to understand the different effects of PCI at low and high TM concentrations, purified
TAFI or protein C was activated by thrombin in the presence of different concentrations of TM.
In figure 4 it is show that the activation of TAFI is maximally stimulated at much lower TM
concentrations than those required for protein C activation. Accordingly, PCI inhibits TAFI
activation at low TM concentration but not at higher TM concentrations, whereas activation of
protein C is inhibited by PCI at high TM concentrations.
Effect of PCI on clot lysis
Clot lysis was determined by measuring the turbidity of tPA mediated fibrinolysis of a tissue
factor induced plasma clot.  The plasma was preincubated for 30 min at room temperature with
a monoclonal antibody that inhibits factor XI activity. In this way the activation of TAFI was
dependent on the concentration of TM present in the plasma, because thrombin formation via the
intrinsic pathway could no longer contribute to the activation of TAFI and the amount of
thrombin generated by the extrinsic pathway at the tissue factor concentration used is not
sufficient to down regulate fibrinolysis (64). The effect of PCI on clot lysis was determined in PCI
depleted plasma in the presence and absence of PCI. In the absence of TM there was no effect of
PCI on fibrinolysis (figure 5a). Addition of 0.05 or 0.5 nM TM to PCI depleted plasma resulted
in a prolongation of the clot lysis time (clot lysis times increased from 26.3 to 45.6 and 64.5 min,
respectively). Reconstitution of the PCI depleted plasma with PCI shortened the TM mediated
prolongation of the clot lysis time (clot lysis times decreased from 45.6 to 39.0 and from 64.5 to
52.7 min in the presence of 0.05 or 0.5 nM TM respectively) indicating that PCI inhibited the
activation of TAFI. TM dependent prolongation of the clot lysis time was expressed as
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percentage of the clot lysis time in the absence of TM (figure 5b) and demonstrated that the
inhibition of the TM mediated prolongation of the clot lysis time by PCI was dependent on the
concentration of PCI.
Discussion
Protein C inhibitor (PCI) was recently identified as a potent inhibitor of the thrombin-TM
complex (181, 182). Here we demonstrate that PCI may play a role in the regulation of
fibrinolysis by thrombin-TM. Regulation of fibrinolysis by TM involves both stimulation of
Figure 5. PCI mediated inhibition of TAFI activation by the thrombin-
thrombomodulin complex in plasma.
Clot lysis times were determined in PCI depleted plasma reconstituted with buffer, 80 nM or
160 nM PCI in the presence of different concentrations of TM. Coagulation was initiated by tissue
factor (1*105 dilution of Innovin), calcium chloride necessary for recalcification, phospholipid
vesicles (10 µM)  and tPA (30 U/ml) in the presence of an antibody that inhibits factor XIa.  Fibrin
formation and lysis were measured in time as the change in turbidity at 405 nm. Panel A: clot lysis
in PCI depleted plasma in the absence (open symbols) or presence (closed symbols) of 160 nM
PCI at 0 nM (	,
), 0.05 nM (,) and 0.5 nM TM  (, ). Panel B: the TM dependent increase
of the clot lysis time in PCI depleted plasma reconstituted with different concentrations of PCI
(0 nM (), 80 nM (	) and 160 nM PCI ()). The TM dependent prolongation of the clot lysis time
was expressed as a percentage of the clot lysis time in the absence of TM. Each point represent
the mean of two independent measurements.
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TAFI activation and inhibition of TAFI activation via stimulation of APC formation leading to
down regulation of thrombin formation.  In a previous study we demonstrated that the activation
of TAFI is predominantly stimulated at low TM concentrations whereas at high TM
concentrations activation of TAFI is inhibited by the activation of protein C (72). Our results
described here indicate that at low TM concentrations PCI predominantly inhibits the activation
of TAFI whereas at higher TM concentrations PCI inhibits the generation of APC by the
thrombin-TM complex resulting in a stimulation of the activation of TAFI. This resulted in the
postulation of a model for the regulation of fibrinolysis by PCI and TM (figure 6). The inhibition
of  TAFI activation by PCI at low TM concentrations but not at high TM concentrations
demonstrated that relatively low TM concentrations were sufficient to maximally stimulate TAFI
activation. This indicates that at high TM concentrations even in the presence of PCI sufficient
thrombin-TM complexes remained available to stimulate TAFI activation (figure 5).  In contrast,
protein C activation was only affected by PCI at high TM concentrations suggesting that for the
activation of protein C higher TM concentrations were required for maximal stimulation than for
TAFI (figure 5) and is in agreement with our previous study (72).
The differences in the required TM concentration for TAFI and protein C are unexpected
since analysis of the kinetic parameters suggest that the concentration of both TAFI and protein
C are 10-50 fold below their respective K
m
 values for activation by the thrombin-TM complex
(25, 26). However competition between TAFI and protein C for binding to TM has been
demonstrated at concentrations far above their physiological concentrations in blood (31). TAFI
specifically binds to the epidermal growth factor like (EGF) domain 3 in TM while protein C
binds to EGF-4 (31, 67). Also critical residues in both thrombin and TM for selective stimulation
of either TAFI or protein C activation have now been identified (68, 69). The exact implications
for the regulation of TAFI and protein C activation will have to be addressed in future studies.
In vivo, TM is predominantly located on the surface of endothelial cells. Recently we found
that when cultured microvascular endothelial cells were used as the source of TM, a similar TM
dependent regulation of TAFI and protein C activation was observed compared to TM in solution
(72), suggesting that endothelial cells in vivo are likely to do the same. Endothelial cells of
different organs and tissues display considerable diversity and heterogeneity (166) and the
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Figure 6. Effect of PCI on the regulation of fibrinolysis by thrombomodulin
At low TM concentrations (panel A) the activation of TAFI is stimulated by TM whereas the
activation of protein C has only a minor (negative) effect on the activation of TAFI. Inhibition of
the thrombin-TM complex by PCI decreases the activation of TAFI which results in an up
regulation of fibrinolysis. At high TM concentrations (panel B) the activation of TAFI is inhibited
indirectly via the activation of protein C by the thrombin-TM complex. Inhibition of the thrombin-
TM complex by PCI has no direct effect on the activation of TAFI but increases the activation of
TAFI by inhibiting the activation of protein C which results in a down regulation of fibrinolysis.
Abbreviations used: IIa, thrombin; IIa-TM, thrombin-thrombomodulin complex; APC, activated
protein C; TAFIa, activated thrombin activatable fibrinolysis inhibitor; PCI, protein C inhibitor. An
uninterrupted line indicates activation, while an interrupted line indicates inhibition.
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expression of TM on endothelial cells varies substantially throughout the vasculature (167, 168).
This suggests that, based on our results, fibrinolysis might be either up- or down regulated in
different parts of the body depending on the local TM and PCI concentration. A model of
vascular-bed-specific haemostasis, as was recently postulated by Rosenberg et al. (188) indicates
that the haemostatic balance of each vascular bed is the net result of the local balance between
pro- and anticoagulant and pro- and antifibrinolytic mechanisms. The fact that congenital or
acquired hypercoagulable states are characterized by thrombotic phenotypes in different parts of
the vasculature imply that coagulation and fibrinolysis are differentially regulated in different
segments of the vascular bed. Tissues such as lung and heart are known to express adequate
amounts of TM (167, 168), whereas the brain is practically void of TM (167, 168).
The combination of high tissue factor (189) expression in the brain and low expression of TM
suggests that the brain may have preferentially adapted to guard against hemorrhage as bleeding
inside a closed and rigid cavity such as the skull could be life-threatening (167), a hypothesis
which is in agreement with our results.
Also, the vessel size may be an important factor determining the effective TM concentration
in the vasculature. Assuming a constant TM density per endothelial cell, the effective TM
concentration rises from less than 5 nM to more than 100 nM as blood moves from the aorta to
the capillaries (169, 170),  suggesting that differential regulation of fibrinolysis by TM and PCI
is possible in vivo.
Furthermore circulating levels of soluble TM which represent the products of limited
proteolytic cleavage of cell surface and/or intracellular TM have been implicated in the activation
of TAFI (109). These soluble TM fragments circulate at about 5-20 ng/ml (100-400 pM) in
normal adults and are elevated to more than 50 ng/ml in plasma from patients with diseases
accompanied by endothelial cell damage such as disseminated intravascular coagulation (DIC),
diabetes mellitus with angiopathy and systemic lupus erythematosus (109). The physiological
relevance of these TM fragments is not yet clear but the results of this study suggest that the potent
PCI mediated inhibition of thrombin in the presence of low levels of TM may explain the absence
of a significant effect of soluble TM (figure 6).
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Until now the physiological role of PCI is unclear. In vivo studies indicated that PCI is
responsible for the inactivation of 10-50% of APC (190, 191), but in vitro studies indicated that
the inhibition of APC by PCI occurs at a low rate (175, 176, 182). Although PCI has been
implicated in the regulation of fibrinolysis as an inhibitor of both tPA and uPA (176), our results
imply a function for PCI in fibrinolysis by regulating the thrombin-TM complex in the activation
of TAFI and inhibition of TAFI activation by the activation of protein C.
Modulation of TAFI activity can have profound implication for the stability of fibrin clots.
Stimulation of TAFI activation by TM was found to correct the premature clot lysis in factor VIII,
IX, X and XI deficient plasma (48). In dogs a correlation was found between the reperfusion time
and the levels of  inducible carboxypeptidase activity (117), while addition of carboxypeptidase
inhibitor (CPI), a specific inhibitor of TAFIa, in a rabbit thrombolysis model enhanced both
endogenous thrombolysis (99) and tPA induced thrombolysis (98). Furthermore, in a clot lysis
assay the TAFI concentration in healthy individuals correlated with the clot lysis time in the
presence of an intact intrinsic pathway of coagulation and a linear relation was observed between
TAFI concentration and inducible TAFI activity in these individuals (26).
The mechanism described  here for the regulation of TAFI activation by PCI may have
profound implications for fibrinolysis, especially because up- or down regulation of TAFI
activation by PCI is dependent on the TM concentration.
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Summary
Thrombin Activatable Fibrinolysis Inhibitor (TAFI) is a carboxypeptidase B-like proenzyme
that after activation by thrombin down regulates fibrinolysis. Thrombomodulin stimulates the
activation of both TAFI and protein C whereas activated protein C inhibits the activation of TAFI
by down regulation of thrombin formation, a process in which protein S acts as a cofactor.
Here we determined the role of protein S in the activation of TAFI and regulation of fibrinolysis.
Depletion of protein S from plasma or inhibition of protein S by specific antibodies resulted in an
increased rate of TAFI activation and in an increased maximum of TAFIa activity generated.
The effect on the rate of TAFI activation could be attributed to the APC-independent
anticoagulant function of protein S whereas the effect on the maximum activity could be
attributed to the APC cofactor function of protein S. Therefore it is concluded that protein S
inhibits TAFI activation in two ways. On one hand, protein S functions as a cofactor for APC
which results in a reduction of the maximum induced TAFI activity and on the other hand protein S
inhibits the initial thrombin formation independently of APC which results in a decreased rate of
TAFI activation. The effect of the APC-independent anticoagulant activity of protein S on the
activation of TAFI provides a new mechanism for the regulation of fibrinolysis in the early stages
of clot formation.
Introduction
Protein S is a vitamin K-dependent glycoprotein that serves as a non-enzymatic cofactor to
the anticoagulant serine protease activated protein C and belongs to the anticoagulant pathway of
coagulation (192). During normal haemostasis a delicate balance between coagulant,
anticoagulant and fibrinolytic pathways maintains the patency of the vasculature and preserves
the circulation. The physiological importance of the anticoagulant pathway is most clearly
demonstrated by the increased risk for venous thromboembolism associated with heterozygous
protein C deficiency and by the massive thrombotic complications occurring in infants with
homozygous protein C- or protein S deficiency (185, 186, 193, 194).
Activated protein C (APC) inhibits thrombin formation by proteolytically inactivating factors
Va and VIIIa, a process that is stimulated by protein S. APC cleaves factor Va at Arg306 and Arg506.
The importance of cleavage at Arg506 is evident from the increased risk for thromboembolism
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associated with factor VLeiden, in which the inactivation of factor Va by activated protein C is
severely compromised due to a mutation in factor V (Arg506Gln). Protein S specifically
stimulates the APC mediated inactivation cleavage of factor Va at Arg306 , whereas in factor VIIIa
protein S abolishes the factor IXa mediated protection of factor VIIIa against APC via specific
acceleration of the APC-mediated cleavage at Arg562 (195, 196). Also factor V was recently
shown to function, apart from being a precursor to the procoagulant factor Va, as a synergistic
cofactor with protein S to APC in the degradation of factor VIIIa (197).
Besides the APC cofactor activity, protein S exhibits also an APC-independent anticoagulant
function, which involves direct inhibition of the tenase- and prothrombinase complex (198-202).
The binding of protein S to the phospholipid surface (203, 204) and direct interactions of protein S with
factor Va (199, 201), factor VIIIa (200) and factor Xa (198, 201) appear to be important in the
regulation of tenase and prothrombinase activity on negatively charged phospholipids (198-200),
endothelial cells (200-202) and platelets (200, 201).
In plasma the function of protein S is regulated by a component of the complement system,
C4b-binding protein (C4BP). About 60% of protein S in plasma circulates in a reversible
complex with C4BP. Protein S complexed to C4BP is unable to function as cofactor for APC in
the inactivation of factor Va whereas in the inactivation of factor VIIIa the synergistic effect of
factor V is no longer supported. In contrast to the inactivation of factor Va, the cofactor function
of protein S for the APC mediated inactivation of factor VIIIa is retained (205, 206). Comparable
to the protein S-C4BP complex, thrombin-cleaved protein S is deprived of APC cofactor function
for both the APC mediated inactivation of factor Va and factor VIIIa (207). However the APC-
independent anticoagulant activity of protein S is preserved in both protein S in complex with
C4BP and thrombin-cleaved protein S (200, 201).
Activated protein C can also stimulate fibrinolysis. The profibrinolytic effect of APC was
attributed to inhibition of thrombin formation and subsequent reduced activation of thrombin
activatable fibrinolysis inhibitor (TAFI; EC3.4.20.17) (24, 25). TAFI is a carboxypeptidase B-
like proenzyme that after activation down regulates fibrinolysis and is also referred to as plasma
procarboxypeptidase B (16), procarboxypeptidase U (17) or procarboxypeptidase R (15).
The mechanism by which activated TAFI (TAFIa) inhibits fibrinolysis involves the removal of
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carboxy-terminal lysines (and arginines) from partially degraded fibrin that are involved in the
binding and activation of plasminogen (17, 50, 56).
Activation of TAFI is mediated by thrombin, generated by the coagulation cascade. Both in
vitro and in vivo experiments suggest that in plasma an intact factor XI (intrinsic) feedback loop
is necessary to generate sufficient thrombin for TAFI activation (64, 65, 99). Activation of factor
XI by thrombin was shown to play a role in the protection of the fibrin clot against lysis and could
be attributed to activation of TAFI (65, 82). Thrombomodulin (TM) stimulates the activation of
both TAFI and protein C by thrombin and can therefore stimulate both the up regulation and
down regulation of fibrinolysis (29). Recently we found that up- or down regulation of
fibrinolysis by TM is dependent on the concentration of TM (72). At relatively low
concentrations, TM predominantly stimulates the activation of TAFI resulting in a down
regulation of fibrinolysis, whereas at higher concentrations of TM the activation of TAFI is
inhibited by the activation of protein C, resulting in an up regulation of fibrinolysis.
Because of the pronounced role of the anticoagulant pathway in the activation of TAFI and
the regulation of fibrinolysis we studied the effect of protein S on the activation of TAFI in plasma
and determined its role in the regulation of fibrinolysis.
Materials and Methods
Materials
Recombinant human tissue factor (Innovin) was obtained from Baxter (Unterschleissheim,
Germany). Carboxy peptidase inhibitor (CPI) was purchased from Calbiochem (La Jolla, CA)
and cyanuric chloride was from Merck (Amsterdam, The Netherlands). Hippuryl-Arg and
H-D-Phe-Pro-Arg-chloromethylketone (PPACK) were obtained from Bachem (Bubendorf,
Switzerland) and hippuric acid was from Sigma (St. Louis, MO). Rabbit lung thrombomodulin
was purchased from American Diagnostica (Greenwich, CT) and recombinant human
thrombomodulin EGF 4-6 was from Alexis (San Diego, CA). Rabbit polyclonal antibodies
against protein S and protein C were obtained from Dako (Glostrup, Denmark). All other
chemicals obtained were the best grade available.
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Proteins
Protein C was isolated as described by Hackeng et al. (162). Protein S and C4BP were purified
from fresh frozen citrated plasma as described previously (204). Thrombin-cleaved protein S was
prepared according to Hackeng et al. (201) and did not contain any detectable amount of
uncleaved protein S. Purified human thrombin was a generous gift from Dr. Walter Kisiel
(University of New Mexico, Albuquerque, NM, USA). All proteins appeared homogeneous on
SDS-PAGE
Plasmas
Normal plasma was obtained from a donor pool of 40 healthy volunteers. Blood was taken
from the antecubital vein, collected in 3.2% trisodium citrate (0.109 M) as the anticoagulant. To
obtain platelet poor plasma the samples were centrifuged twice for 15 min at 2500 g, after which
the plasma was stored at -70°C until use. For the preparation of plasma depleted of both protein
S and C4BP and of plasma depleted of protein C, protein S and C4BP, a plasma pool of 4 healthy
donors was prepared as above, and subsequently passed over a Sepharose column to which
monoclonal antibodies against either protein C (RU-PC4D1), protein S (RU-PS7E9) or C4BP
(RU-C4BP9H10) were immobilized. The undiluted flow through of these columns was collected
and used as protein S/C4BP double depleted plasma (PS/C4BPdP) and protein C/protein S/C4BP
triple depleted plasma (PC/PS/C4BPdP) respectively. The depleted plasmas were tested with the
corresponding ELISA’s and the plasmas were found to contain less than 1% of the depleted
factors. Factor VLeiden plasma was obtained from an individual that was genotyped to be
homozygous for the factor VLeiden mutation (Arg506Gln). All plasmas used contained normal
amounts of TAFI as determined by ELISA (26).
Phospholipid vesicles
Phospholipid vesicles consisting of 40% phosphatidylcholine (PC), 20% phosphatidylserine
(PS) and 40% phosphatidylethanolamine (PE) were prepared according to Brunner (146),
with some modifications (139). The total phospholipid content of the versicles was determined
by phosphate analysis (147).
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Clot lysis assay
Clot lysis was studied in a plasma system in which tPA mediated fibrinolysis of a thrombin-
induced plasma clot is measured using turbidity as described earlier (26, 64). Clot lysis was
determined in PC/PS/C4BPdP in the presence of recombinant TM containing EGF domains 4 to 6
(TM4-6) (50 nM). PC/PS/C4BPdP was reconstituted with either buffer, purified protein C
(60 nM), protein S (350 nM) or both. Thrombin (20 nM), PC/PS/PE vesicles (10 µM), calcium
chloride necessary for recalcification (10 mM) and tPA (30 U/ml) were added to 62.5 µl of
citrated plasma after which the volume was adjusted to 125 µl with Hepes buffer. Clot lysis was
also determined in PS/C4BPdP in the presence of different concentrations of protein S (0-1400 nM)
or thrombin-cleaved protein S (0-350 nM) in the absence of TM4-6. In some experiments the clot
lysis in the presence of CPI (25 µg/ml), a carboxypeptidase inhibitor from potato tubers that
inhibits the activity of TAFIa was included. After mixing, 100 µl of the reaction mixture was
pipetted in a microtiter plate and then incubated at 37°C during which the turbidity was measured
in time at 405 nm in a Spectramax 340 kinetic microtiter plate reader (Molecular Devices
Corporation, Menlo Park, CA, USA). Clot lysis time was defined as the time between the
maximum turbidity and the midpoint of the maximum turbid-to-clear transition that characterizes
the lysis of fibrin.
Tissue factor induced activation of TAFI in plasma
To determine the activation of TAFI in plasma, coagulation was initiated by tissue factor in
the presence of TM as described before (51, 72). Briefly, plasma (30 µl) was incubated with tissue
factor (1*105 dilution of Innovin) in the presence of TM (1 or 10 nM), phospholipid vesicles
(10  µM) and calcium necessary for recalcification (10 mM) after which the volume was adjusted
to 60 µl with Hepes buffer (20 mM Hepes, pH 7.4, 137 mM NaCl, 4 mM KCl, 0.1% BSA) and
coagulation was allowed proceed for different time intervals. The reaction was stopped with
PPACK (20 µl, 150 µM) and hippuryl-Arg (20 µl, 20 mM) was added. After 10 min substrate
conversion was stopped by the addition of 1 M HCl (20 µl). The amount of hippurate that was
formed was determined using cyanuric chloride as described (72). TAFI activity was determined
as the carboxypeptidase activity sensitive to inhibition by CPI (25 µg/ml). The activated TAFI
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concentrations were calculated from the kinetic parameters for the hydrolysis of hippuryl-
arginine by TAFIa (KM = 0.75 mM, kcat = 13 s-1) (72). In some experiments the total amount of
TAFIa generated was evaluated by integrating the area under the TAFIa versus time curve and
expressed in arbitrary units (AU).
The influence of the anticoagulant protein C pathway on the activation of TAFI
The role of the anticoagulant mechanism on the activation of TAFI was determined in
PC/PS/C4BPdP in the presence and absence of protein C (60 nM) and/or protein S (350 nM) and
in normal and factor VLeiden plasma in the presence and absence of inhibitory antibodies against
protein C and/or protein S. In addition PS/C4BPdP was reconstituted with different
concentrations of purified protein S (0-700 nM), protein S (350 nM) in complex with a twofold
molar excess of C4BP or thrombin-cleaved protein S (350 nM).
Results
The effect of protein C and protein S on fibrinolysis
The effect of protein C and protein S on fibrinolysis was determined in a clot lysis assay using
thrombin induced coagulation and tPA mediated fibrinolysis in the presence of recombinant TM
consisting of EGF domains 4 to 6 (TM4-6). This TM4-6 lacks the EGF domain 3 that is essential
for the stimulation of TAFI activation but has retained its capacity to stimulate the activation of
protein C (31, 68). This way the effect of protein C activation on the rate of fibrinolysis can be
studied without the concomitant stimulation of TAFI activation by TM. The activation of TAFI
in this system is mediated by thrombin generation via the intrinsic pathway. In figure 1 it is shown
that the clot lysis time is significantly prolonged in PC/PS/C4BPdP compared to that of normal
plasma. Reconstitution of the PC/PS/C4BPdP with protein C resulted in a minor up regulation of
fibrinolysis whereas reconstitution of the depleted plasma with both protein C and protein S
resulted in a decrease of the clot lysis time similar to that observed in the presence of CPI,
indicating that activation of TAFI was severely compromised by the presence of both protein C
and protein S. This is in accordance with the profibrinolytic effect of protein C and the cofactor
function of protein S. Interestingly reconstitution of the PC/PS/C4BPdP with protein S alone also
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showed a marked decrease of the clot lysis time, suggesting a role for protein S in the regulation
of fibrinolysis independently of protein C.
TAFI activation in PC/PS/C4BP triple depleted plasma
Based on the role of protein S in the up regulation of fibrinolysis in the clot lysis assay (figure 1),
the effect of protein S on the activation of TAFI was determined in plasma using a previously
developed assay for the activation of TAFI in plasma (51, 72). In this assay coagulation is
initiated by tissue factor in the presence of TM and TAFI activation is measured using the
substrate hippuryl-Arg and a colorimetric detection method for hippuric acid. Previously,
we reported a TM dependent activation of TAFI in plasma (72). At TM concentrations up to 5 nM
there was a dose dependent increase in the activation of TAFI whereas at higher TM
concentrations (>= 10 nM) the activation of TAFI was inhibited by the activation of protein C.
Therefore the effect of protein C and protein S on the activation of TAFI was determined in
PC/PS/C4BPdP in the presence of 10 nM TM (figure 2). A large increase in the amount of
Figure 1. The effect of the anticoagulant pathway on fibrinolysis
Clot lysis was determined in protein C/protein S and C4BP triple depleted plasma by measuring
the turbidity of a thrombin (20 nM) induced plasma clot and tPA (30 U/ml) mediated fibrinolysis
in the presence of 50 nM TM4-6. The PC/PS/C4BPdP was reconstituted with either buffer (),
60 nM protein C (), 350 nM protein S (), both 60 nM protein C and 350 nM protein S ()
or 25 µg/ml CPI (). Clot lysis was also determined in normal plasma in the absence of TM4-6 ( ).
Each point represents the mean of two independent experiments.
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activated TAFI was observed in PC/PS/C4BPdP compared to normal plasma. Upon
reconstitution of PC/PS/C4BPdP with both protein C and protein S, the activation of TAFI was
inhibited similar to that observed in normal plasma. The importance of the anticoagulant protein C
pathway on the down regulation of TAFI activation was evident from the increased TAFI
activation in the absence of protein C alone (= PC/PS/C4BPdP reconstituted with protein S). An
increased rate of TAFI activation was observed in the absence of protein S alone (= PC/PS/
C4BPdP reconstituted with protein C). The increased rate of TAFI activation was observed in
PC/PS/C4BPdP and in PC/PS/C4BPdP reconstituted with protein C but not in PC/PS/C4BPdP
reconstituted with protein S. This suggests that protein S decreases the rate of TAFI activation
independent of protein C.
Figure 2. The effect of the anticoagulant pathway on TAFI activation
Coagulation was initiated in protein C/protein S and C4BP triple depleted plasma by tissue
factor (1*105 dilution of Innovin) in the presence of 10 nM TM. After different time intervals
coagulation was stopped by PPACK and the amount of TAFIa was determined. PC/PS/C4BPdP
was reconstituted with either buffer (), 60 nM protein C (), 350 nM protein S (), or both 60 nM
protein C and 350 nM protein S (). TAFI activation in normal plasma is given as reference ().
Each point represents the mean ± SEM of 3 independent experiments.
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The role of protein S on TAFI activation in normal and factor VLeiden plasma
The role of protein S in the activation of TAFI independent of protein C was further
substantiated by incubation of normal plasma with antibodies that inhibit either the activation of
protein C or the function of protein S (figure 3). In the presence of anti-protein C antibodies, the
activation of TAFI was increased. However, in the presence of anti-protein S antibodies, either
in the presence or absence of anti-protein C antibodies the activation of TAFI was increased with
a concomitant shift in the time to reach maximum TAFIa activity, indicating an increased rate of
TAFI activation. The shift in the time to reach maximum TAFIa activity was not observed in the
presence of anti-protein C antibodies and indicates that this effect was specific for protein S
independently of protein C. Factor VLeiden, in which the inactivation of factor Va by APC is
severely compromised, was previously shown to have an antifibrinolytic effect due to an
increased activation of TAFI caused by the incapability of ACP to down regulate thrombin
formation (89). Therefore the effect of protein S on TAFI activation in factor VLeiden plasma was
Figure 3. TAFI activation upon inhibition of the anticoagulant pathway in normal
plasma
TAFI activation was determined in normal plasma after initiation of coagulation by tissue factor
(1*105 dilution of Innovin) and in the presence of 10 nM TM. Normal plasma was incubated with
either buffer () or a polyclonal antibody inhibiting the activation of protein C (), a polyclonal
antibody inhibiting the function of protein S ( ) or both (). Each point represents the mean ± SEM
of 3 independent experiments.
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determined (figure 4a). As anticipated, TAFI activation was increased in factor VLeiden plasma
compared to normal plasma (figure 4b, open bars) and addition of an antibody inhibiting the
activation of protein C did not increase TAFI activation in factor VLeiden plasma as it did in normal
plasma (figure 4a and b). In contrast, addition of antibodies inhibiting the function of protein S
to factor VLeiden plasma did show a similar increase in the rate of TAFI activation as was observed
in normal plasma. These results suggest that protein S plays a role in the down regulation of TAFI
activation in two way: protein S acts as a cofactor for activated protein C but has also a function
independently of protein C.
Figure 4. TAFI activation upon inhibition of the anticoagulant pathway in factor
VLeiden plasma
TAFI activation was determined in factor VLeiden plasma after initiation of coagulation by tissue
factor (1*105 dilution of Innovin) and in the presence of 10 nM TM. (Panel A) Factor VLeiden plasma was
incubated with either buffer () or a polyclonal antibody inhibiting the activation of protein C (),
a polyclonal antibody inhibiting the function of protein S () or both (). (Panel B) The total
amount of TAFIa generated, calculated from the area under the TAFIa versus time curve and
expressed in arbitrary units (AU) was determined in normal plasma (see figure 3) and factor VLeiden
plasma in the absence of antibodies (open bars) and in the presence of anti-protein C (light gray
bars), anti-protein S (dark gray bars) or both (solid bars).  Each point represents the mean ± SEM
of 3 independent experiments.
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The effect of protein S on the activation of TAFI independent of protein C
Since the role of the protein C pathway is less pronounced at low TM concentrations when the
activation of TAFI is preferentially stimulated by TM (72) we further investigated the role of
protein S on the activation of TAFI in PS/C4BPdP in the presence on 1 nM TM. In figure 5a it
is shown that also in the presence of 1 nM TM depletion of protein S or addition of an antibody
inhibiting the function of protein S to normal plasma resulted in an increased rate of TAFI
activation as was observed in the presence of 10 nM. Furthermore reconstitution of the
PS/C4BPdP with increasing amounts of protein S showed a protein S concentration dependent
decrease in the rate of TAFI activation. This  suggests that the inhibitory potential of protein S on
the activation of TAFI in plasma is mediated by the APC cofactor function of protein S and by
the APC-independent anticoagulant activity of protein S.
Figure 5. The effect of protein S on the activation of TAFI
TAFI activation was determined in normal and protein S/C4BP double depleted plasma.
Coagulation was initiated by tissue factor (1*105 dilution of Innovin) in the presence of 1 nM TM.
(Panel A) Normal plasma in the presence () and absence () of a polyclonal antibody
inhibiting the function of protein S. PS/C4BPdP reconstituted with either buffer () or 700 nM
protein S (). (Panel B) PS/C4BPdP was reconstituted with different concentrations of protein S:
0 nM (), 35 nM (), 175 nM (), 350 nM () and 700 nM () protein S.  Each point represents
the mean ± SEM of 3 independent experiments.
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The influence of the APC-independent activity of protein S on the activation of
TAFI
The effect of the APC-independent activity of protein S on the activation of TAFI was
determined by addition of thrombin-cleaved protein S and protein S in complex with C4BP to
PS/C4BPdP. Both thrombin-cleaved protein S and protein S in complex with C4BP decreased
the rate of TAFI activation in PS/C4BPdP (figure 6). Addition of C4BP alone to PS/C4BPdP had
no effect on the activation of TAFI or the rate of TAFI activation (data not shown). The additional
decrease in the rate of TAFI activation caused by thrombin-cleaved protein S compared to protein
S in complex with C4BP might originate from the differences in APC cofactor activity for the
inactivation of factor VIIIa (206), since thrombin-cleaved protein S is deprived of both the APC
cofactor function and its supporting role in the factor V synergism whereas protein S in complex
with C4BP has retained the capacity to act as a cofactor to APC in the inactivation of factor VIIIa.
Figure 6. The effect of the APC-independent anticoagulant activity of protein S
on TAFI activation
TAFI activation was determined in protein S/C4BP double depleted plasma reconstituted with
either buffer (), 350 nM protein S (), 350 nM thrombin-cleaved protein S () or 350 nM protein
S preincubated with 700 nM C4BP (). Coagulation was initiated by tissue factor (1*105 dilution
of Innovin) in the presence of 1 nM TM. Each point represents the mean ± SEM of 3 independent
experiments.
0 5 10 15 20 25 30
0
25
50
75
100
125
150
Time (min)
TA
FI
a 
(nM
)
106
P
R
O
T
E
I
N
S
Effect of the APC-independent anticoagulant activity of protein S on fibrinolysis
The role of the APC-independent anticoagulant activity of protein S in the regulation of
fibrinolysis, clot lysis times was determined in PC/PS/C4BPdP reconstituted with different
concentrations of either protein S or thrombin-cleaved protein S in the absence of TM or TM4-6.
Protein S up regulated fibrinolysis in a concentration dependent manner, ultimately resulting in
a complete inhibition of TAFI activation as is demonstrated by the decrease in the clot lysis time
similar to that in the presence of CPI. Also thrombin-cleaved protein S showed a concentration
dependent decrease of the clot lysis time. Since thrombin-cleaved protein S is devoid of APC
cofactor function, protein C was depleted from the plasma and no TM was added which could
induce activation of possible trace amounts of protein C left in the plasma, these results strongly
suggest that protein S was responsible for the inhibition of TAFI activation and up regulation of
fibrinolysis independently of APC.
Figure 7. The effect of the APC-independent anticoagulant activity of protein S
on fibrinolysis
Protein C/protein S and C4BP triple depleted plasma was incubated with different
concentrations of protein S () or thrombin-cleaved protein S (). Clot lysis times were
determined by measuring the turbidity of a thrombin (20 nM) induced plasma clot and tPA
(30 U/ml) mediated fibrinolysis in the absence of TM. The maximum concentration of thrombin-
cleaved protein S that could be achieved in the clot lysis assay was 350 nM. The clot lysis time in
the presence of 25 µg/ml CPI is given for reference (). Each point represents the mean of two
independent experiments.
0 500 1000 1500
0
10
20
30
40
50
60
70
Protein S (nM)
Cl
o
t l
ys
is 
tim
e 
(m
in)
107
C
H
A
P
T
E
R
5
Discussion
Modulation of fibrinolytic activity by the protein C pathway has been extensively described
(22) and an effect of protein S on fibrinolytic activity was first described by de Fouw and
colleagues who found that protein S was an obligatory cofactor of APC in the acceleration of in
vitro fibrinolysis (208). Since APC was not intrinsically profibrinolytic, Bajzar and coworkers
pursued this issue and identified in 1995 a new fibrinolysis inhibitor in plasma which was
activated by thrombin and named it TAFI (18). The profibrinolytic effect of APC could be
attributed to TAFI and was caused by the inhibition of thrombin formation by APC leading to a
decreased activation of TAFI and subsequent up regulation of fibrinolysis (25). Previously we
determined the role of TM in the activation of TAFI and the regulation of fibrinolysis, since
activation of both TAFI and protein C is stimulated by TM. This resulted in the formulation of the
TM paradox, in which TM is antifibrinolytic at low concentrations due to the preferential
stimulation of TAFI activation whereas at higher concentrations TM is profibrinolytic caused by
the increased activation of protein C and subsequent inhibition of TAFI activation (72). Here we
describe the role of protein S in the activation of TAFI and the regulation of fibrinolysis.
Protein S functions as a cofactor to APC in the inactivation of factor Va and factor VIIIa and
accordingly the presence of protein S was found to be essential for the down regulation of
thrombin formation by APC and the inhibition of TAFI activation. Interestingly, we also found
a role for protein S in the activation of TAFI which was independent of the presence of protein
C. Whereas activated protein C predominantly affected the maximum of TAFIa generation, the
effect of protein S on the activation of TAFI was twofold. On one hand protein S acted as a
cofactor to APC in the inactivation of factor Va and factor VIIIa thereby affecting the total
amount of TAFIa generated. On the other hand protein S caused a decrease in the rate of TAFI
activation which was independent of the presence of protein C or the activity of APC.
We postulate that this APC-independent effect of protein S on the activation of TAFI is caused
by the previously described APC-independent anticoagulant function of protein S since
thrombin-cleaved protein S and protein S in complex with C4BP were both capable of inducing
a decrease in the rate of TAFI activation. The significance of the APC-independent anticoagulant
function of protein S for the regulation of fibrinolysis was demonstrated by the fact that both
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protein S and thrombin-cleaved protein S were capable of decreasing the clot lysis time in the
absence of TM and protein C.
The APC-independent anticoagulant function of protein S involves the inhibition of initial
thrombin formation by the coagulation cascade, which explains the protein S induced shift in the
time to reach maximum TAFIa activity. The mechanism by which this is accomplished is not
completely clear yet. The high affinity of protein S for negatively charged phospholipids is
presumed to interfere with the assembly of fully functional tenase- and prothrombinase
complexes on these negatively charged phospholipids (203, 204) but also a direct inhibition of the
tenase- and prothrombinase complex might be involved (198-201). The relevance of the APC-
independent anticoagulant activity of protein S in plasma was also demonstrated in a flow model
using the matrix of stimulated endothelial cells as a procoagulant surface (202). In this system
depletion of protein S from the plasma resulted in a 5 to 25 fold increase in thrombin generation
suggesting an important role for protein S as an APC-independent regulator of coagulation.
The regulation of fibrinolysis by TAFI is becoming more and more complex. In the absence
of TM, TAFI is activated by relatively high concentrations of thrombin that are generated by the
thrombin mediated activation of factor XI and the subsequent amplification power of both the
tenase and prothrombinase complex and defects in the clotting cascade result in a decreased TAFI
activation and an up regulation of fibrinolysis (64, 65). In haemophilia patients the bleeding
complications were suggested to be exacerbated by the incapability of the coagulation cascade to
protect the fibrin clot against premature degradation by the fibrinolytic system (48, 82, 209)
whereas the localization of bleeding complications in haemophilia C (factor XI deficiency)
patients in tissues with a high fibrinolytic activity was attributed to their incapability to generate
sufficient thrombin for TAFI activation (82). In contrast the increased risk for venous thrombosis
in individuals with high factor XI levels was contributed to increased TAFI activation and
subsequent impaired fibrinolytic capacity to remove fibrin clots from the circulation (95).
In the presence of TM much lower concentrations of thrombin are required for TAFI
activation and the influence of thrombin formation by the intrinsic pathway seems to be less
important. However in the presence of TM the concentration of TM was found to be an essential
factor for the activation of TAFI and the regulation of fibrinolysis (72). The activation of TAFI
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is predominantly stimulated at low TM concentration whereas at high TM concentrations the
activation of TAFI is inhibited by the activation of protein C. The fact that the expression of TM
is very heterogenous in different parts of the body and the profound implications of the vessel size
for the effective TM concentration suggest differential regulation of TAFI activation and
fibrinolysis in different parts of the vascular system. Recently different structural elements in TM
have been identified that are responsible for the specific stimulation of TAFI or protein C
activation (31, 68). Especially the observation that oxidation of methionine 388 in TM greatly
abolished the stimulatory effect of TM in the activation of protein C (113) but had no significant
effect on the stimulation of TAFI activation (68) might be important since activated neutrophils
can cause oxidation of Met-388 and thereby create a procoagulant and antifibrinolytic state (113).
Also the concentration of TAFI itself is an important factor in the regulation of fibrinolysis by
TAFI since the TAFI concentration in plasma is below its KM for activation by thrombin and
subsequently an increase in the TAFI concentration will result in an increased amount of
activated TAFI (26, 29). In agreement with this, TAFI levels in healthy individuals correlated
with the clot lysis time (26) and elevated TAFI levels were found to be a risk factor for venous
thrombosis (49). Furthermore the impaired clot lysis times in haemophilia A patients were
corrected by a twofold increase of the plasma TAFI concentration (209). Recently TAFI was
found to be an acute phase reactant in the mouse (38) and correlation between TAFI levels and
acute phase reactants such as C-reactive protein and haptoglobin in healthy individuals suggest
that this may be similar in man (42). These observations suggest a shift towards inhibition of
fibrinolysis in processes that are accompanied by increased levels of acute-phase reactants, such
as inflammation.
In this study we report an additional mechanism for the regulation of TAFI activation that
involves the APC-independent anticoagulant function of protein S. Upon initiation of
coagulation, protein S inhibits the initial formation of thrombin and thereby delays the activation
of TAFI. This way protein S provides a threshold for TAFI activation and prevents clot protection
when coagulation does not persevere and fibrin must be rapidly removed but enables clot
protection upon adequate stimulation of the coagulation cascade.
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Summary
Thrombin Activatable Fibrinolysis Inhibitor (TAFI) is a carboxypeptidase B-like proenzyme
that after activation by thrombin down regulates fibrinolysis. Plasma TAFI levels varied
considerably between healthy individuals and were positively correlated with the clot lysis time.
Variation of the TAFI concentration might therefore have profound implications for the
regulation of fibrinolysis. Platelets are known to contain various clotting- and fibrinolytic factors
that are secreted during platelet activation. Therefore, the occurrence of TAFI in human platelets
was analyzed. TAFI was identified in platelets in a concentration of 48 ± 5 ng/1*109 platelets and
is presumably localized in the α-granules. TAFI was secreted upon platelet activation and
migrated with a slightly lower molecular mass compared to plasma TAFI on SDS-PAGE.
In addition, platelet activation by thrombin also resulted in the secretion, and activation of TAFI.
The presence of TAFI mRNA in the megakaryocytic cell lines DAMI and CHRF, representing
the intermediate and late stages of megakaryocyte development, in combination with the lower
molecular mass of platelet-derived TAFI suggested that TAFI was synthesized in the
megakaryocyte during the process of megakaryocytopoiesis. These results imply a possible new
mechanism for clot protection in the early stages of clot formation by increased local TAFI levels
during platelet plug formation.
Introduction
Upon initiation of the coagulation cascade, when tissue factor is exposed to blood, a series of
linked enzymatic reactions in which coagulation factor zymogens are converted to their active
serine proteases, ultimately result in the formation of thrombin (210). Thrombin, the key enzyme
of coagulation, is not only responsible for the formation of a fibrin clot but also for the protection
of a fibrin clot against fibrinolysis. Although thrombin has been implicated before in the
inhibition of clot lysis by activation of factor XIII (73) and by the inactivation of single-chain
urokinase (75, 211), a new mechanism for the down regulation of fibrinolysis was recently
described. This mechanism involved the thrombin mediated activation of a carboxypeptidase
B-like proenzyme, thrombin  activatable fibrinolysis inhibitor (TAFI; EC3.4.20.17) (18).
Activated TAFI (TAFIa), also known as plasma carboxypeptidase B (16), carboxypeptidase U
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(17) or carboxypeptidase R (15), potently attenuates fibrinolysis by removing carboxy-terminal
lysines (and arginines) from partially degraded fibrin that are involved in plasminogen binding
and activation (50, 56).
Activation of TAFI is mediated by relatively high concentrations of thrombin generated by the
coagulation cascade. Previously it was shown that thrombin mediated activation of factor XI and
subsequent amplification by both the tenase- and prothrombinase complex generated sufficient
thrombin for TAFI activation and down regulation of fibrinolysis (64, 65). Activated platelets
play an important role in the formation of thrombin by providing a negatively charged surface for
the assembly of functional tenase- and prothrombinase complexes. (Meizo)thrombin mediated
factor XI activation was enhanced in the presence of PC/PS/PE phospholipid vesicles or activated
platelets (139, 212). Both in vitro and in vivo experiments have demonstrated that obstruction of
the intrinsic pathway, either by a deficiency in one of the coagulation factors (such as the case in
haemophilia or by an antibody against factor XI), results in a decreased activation of TAFI and
an up regulation of fibrinolysis (48, 65, 87, 99). However, in the presence of the endothelial cell
receptor thrombomodulin, much lower concentrations of thrombin are required for the activation
of TAFI due to an increase of the catalytic efficiency of about 1250 fold (29). Consequently,
the contribution of the intrinsic pathway to the activation of TAFI is less pronounced in the
presence of thrombomodulin.
The observation that the concentration of TAFI in plasma (70-250 nM) is 10-30 fold below its
KM for activation by thrombin suggests that the amount of TAFIa that is formed during activation
is greatly influenced by the TAFI concentration (25, 26). TAFI levels were found to vary
considerably between individuals and the differences in clot lysis times could be attributed to the
variations in TAFI levels (26). TAFI levels were found to increase with age whereas women
using oral contraceptives also showed elevated TAFI levels (81, 96, 97). TAFI levels were found
to be increased in men with symptomatic coronary artery disease and high TAFI levels were
established as an independent risk factor for venous thrombosis (42, 49). These observations
indicated an important role for the TAFI levels in the regulation of fibrinolysis and the occurrence
of thromboembolic disease.
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Since platelets are known to contain coagulation factors in their α-granules which are secreted
upon activation, this study was initiated to evaluate if TAFI was also present in platelets and could
possibly contribute to the down regulation of fibrinolysis.
Materials and Methods
Materials
RPMI 1640 medium, Fisher’s medium, Iscove’s Modified Dulbecco’s Medium (IMDM),
fetal bovine serum, horse serum and glutamin/penicillin/streptomycin were from GIBCO
(Paisley, Scotland). Carboxy peptidase inhibitor (CPI) was purchased from Calbiochem
(La Jolla, CA) and cyanuric chloride was purchased from Merck (Amsterdam, The Netherlands).
Hippuryl-Arg was obtained from Bachem (Bubendorf, Switzerland). Rabbit lung
thrombomodulin was purchased from American Diagnostica (Greenwich, CT) and affinity-
purified sheep anti-TAFI was from Affinity Biologicals (Hamilton, Canada). All other chemicals
obtained were the best grade available.
Proteins
Purified human thrombin was a kind gift from Dr. W. Kisiel (University of New Mexico,
Albuquerque, NM, USA). TAFI was purified as described before (51).
Platelet isolation
Freshly drawn blood from healthy volunteers, who claimed not to have taken any medication
in the previous 10 days, was collected in 3.8% trisodium citrate (0.129 M) as the anticoagulant
(9:1 v/v). Platelet rich plasma (PRP) was prepared by centrifugation (200g, 10 min, 22°C) and
acidified to pH 6.5 with ACD (2.5 g trisodium citrate, 1.5 g citric acid and 2.0 g D-glucose
in 100 ml distilled water). Platelets were isolated by gel-filtration of PRP on a Sepharose 2B
column equilibrated in Tyrode buffer (137 mM NaCl, 2.68 mM KCl, 0.42 mM NaH2PO4, 1.7 mM
MgCl2, 11.9 mM NaHCO3, pH 7.3).
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Megakaryocytic cell line culture
MEG-01 cells (213) were provided by Dr. H. Saito, Nagoya University School of Medicine
(Nagoya, Japan) and cultured in RPMI 1640 medium supplemented with 20% fetal bovine
serum. DAMI cells (214), a gift from Dr. R.I. Handin, Brigham and Women’s Hospital (Boston,
MA, USA) were grown in IMDM supplemented with 10% horse serum. CHRF-288-11 cells
(215) were a gift of Dr. M. Lieberman, Dept of Molecular Genetics, Biochemistry and
Microbiology, University of Cincinnati (Cincinnati, OH, USA) and were cultured in Fisher’s
medium supplemented with 20% horse serum. All cells were cultured in the presence of 2 mM
L-glutamine, 100 U/ml penicillin and 100 U/ml streptomycin at 37°C in a humified atmosphere
with 5% CO2.
Immunofluorescence microscopy
Cytospins of gel-filtered platelets, fixed with 2% para-formaldehyde were permeabilized with
1% saponine and subsequently incubated with a monoclonal antibody against TAFI (9H10) and
a FITC labeled secondary goat anti-mouse antibody.
TAFI secretion from platelets
Gel-filtered platelets (100 µl, 280*103/µl) were incubated for 15 min at 37°C with different
agonists (thrombin, thrombin receptor activating peptide (TRAP), collagen, ADP and
epinephrine). After centrifugation (14,000 rpm, 5 min) the secretion of TAFI was measured in the
supernatant using a previously described ELISA specific for the proenzyme, TAFI (26).
Isolation of mRNA and RT-PCR
Total RNA was isolated from cells using the RNAzolTM B method (216) as described by the
manufacturer (TEL-TEST). First strand cDNA was synthesized by addition of 1 µl of oligo dT
(0.5 µg/µl) to the RNA in a final volume of 25 µl. The mixture was incubated at 70°C for 10 min
and immediately put on ice. Then 8 µl of 5x first strand buffer, 4 µl 0.1 M DTT, 0.8 µl 25 mM
dNTPs and 2 µl of Superscript II-Reverse Transcriptase (GIBCO) was added. Reactions were
allowed to proceed for 90 min at 37°C. Finally the mixtures were put at 68°C for 15 min and
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stored at -20°C. The generated cDNA was amplified by PCR using the following TAFI specific
primer combinations:
1. CTCGAGTTTCAGAGTGGCCAAGTTC and CTCGAGTTATCGGGG GCTGACTGTG
2. TGCAGCCTTGCAGTCCT and TTCCACGTCTGCCAGCA
3. TTTCTCGAGTCTAGAGCCACCATGAAGCTTTGCAGCCTTG and
 GGGGTACCTTAAACATTCCTAATGAC
 4. GTTTCTTGAGAAGAAATATC and CATGCCATGGCATTAAACATTCCTAATGAC
and the actin primers:
 5. GCTCACCATGGATGATGATATCGC and GGAGGAGCAATGATCTTGATCTTC
PCR reactions (100 µl) contained approximately 10 pmol of each primer, 500 µM of dNTPs, 2
µl of template DNA from the reverse transcription reaction and 5 units of Pwo polymerase
(Roche, Almere, The Netherlands). PCR cycling conditions were as follows: 1 min 95°C, 1 min
at 50°C (primer set 2, 4 and 5), 55°C (primer set 3) or 60°C (primer set 1).  PCR products were
separated on 1 to 1.2% agarose gels.
Determination of TAFIa activity in platelets
Activation of TAFI derived from platelets was measured using a previously developed assay
for the determination of small amounts of TAFIa activity in plasma (79). Gel-filtered platelets
(3*108) were incubated with thrombin (50 nM), thrombomodulin (10 nM), CaCl2 (5 mM) and the
substrate for TAFIa, Hippuryl-Arg (5 mM), in Hepes-Tyrode (145 mM NaCl, 5 mM KCl, 0.5 mM
NaHPO4, 1.7 mM MgCl2, 10 mM Hepes, 5 mM glucose, pH 7.4). After 60 min, platelet debris
was pelleted by centrifugation (5 min, 14,000 rpm) and the amount of hippuric acid was
determined in the supernatant as described (79). In control experiments, TAFI activation was
determined in the supernatant of resting platelets or in the absence of thrombin.
Results
Identification of TAFI in platelets
To evaluate if TAFI was present in platelets, lysates of gel-filtered platelets were prepared
either by freeze-thawing or by incubation with 0.5% Triton. Using an ELISA specific for the
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zymogen form of TAFI, the concentration in platelets (mean ± SD) obtained from 3 different
donors was estimated to be 48 ± 5 ng/1*109 platelets. TAFI was also detected in the supernatant
of activated but not in the supernatant of resting platelets. Upon activation of the platelets with
different agonists secretion of TAFI was dependent on the activator used (figure 1). Thrombin
was found to be the strongest agonist of TAFI release from platelets and induced the secretion of
approximately 50% of the total amount of TAFI in platelets. Activation of the platelets by TRAP
or collagen resulted in the secretion of approximately 40% and 30% of the total amount of TAFI
present in platelets, respectively. Weak agonists of platelet activation such as ADP and
epinephrine resulted only in the secretion of a minor amount of TAFI from platelets (<10%).
Remarkably, a concentration dependent secretion of TAFI was observed with TRAP and
collagen but not with thrombin. The reduced secretion of TAFI at a high thrombin concentration
compared to the secretion at a low thrombin concentration suggests that activation of TAFI might
have occurred during the activation of the platelets and/or secretion of TAFI. TAFIa is not
recognized by the antibody that is used in the ELISA, which is specific for the proenzyme.
Figure 1. TAFI secretion by stimulated platelets
Gel-filtered platelets were incubated with a high (dark bars) or a low (light bars) concentration
of platelet agonist for 15 min at 37°C. After centrifugation the secretion of TAFI was determined
in the supernatant by ELISA. The agonist used were: thrombin ((IIa) 5 or 0.5 U/ml), TRAP (100 or 10
µM), ADP (20 or 2 µM), collagen ((COL) 10 or 1 µg/ml) and epinephrine ((EPI) 10 or 1 µM). Each bar
represents the mean ± SEM of 5 independent experiments using platelets from different donors.
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Figure 2. Analysis of platelet-derived TAFI
Platelet-derived TAFI and TAFI purified from plasma (lane 1, 300 pg) were analysed on Western
blot. Gel-filtered platelets (3*107 cells) were incubated with either 0.5% triton (lane 2), buffer (lane
3) or 0.5 U/ml thrombin (lane 4) at 37°C. After 15 min and centrifugation (5 min, 14,000 rpm),
samples were subjected to 12% SDS-PAGE under reducing conditions and transferred to
nitrocellulose membrane. TAFI was visualized by incubation with a monoclonal antibody against
TAFI (9H10), rabbit anti-mouse IgG, biotin labeled goat anti-rabbit IgG, peroxidase labeled
streptavidin and enhanced chemiluminescence. The positions of molecular mass markers are
shown to the left of the blot.
Analysis of platelet-derived TAFI by immunoblotting
Secretion of TAFI from platelets after stimulation with thrombin was analyzed on Western
blot (figure 2). TAFI was detected in a 0.5% Triton platelet extract (lane 2) and in the supernatant
of thrombin activated platelets (lane 4), whereas the presence of TAFI in the supernatant of
resting platelets (lane 3) was much less pronounced.  The multiple bands observed in the platelet
lysate is most likely due to proteolysis of TAFI by lysosomal enzymes from the platelets. TAFI
secreted by platelets migrated on SDS-PAGE with an estimated molecular mass of 50 kD which
is slightly lower than TAFI purified from plasma (lane 1). In order to evaluate if platelet derived
TAFI could be activated by thrombin during platelet activation, 1*108 platelets were incubated
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Figure 3. Activation of platelet-derived TAFI by thromin
Activation of platelet-derived TAFI by different concentrations of thrombin was analyzed on
Western blot. Gel-filtered platelets (8*107 cells) were incubated with thrombin (0.25 U/ml, lane 2;
0.5 U/ml, lane 3; 2.5 U/ml, lane 4; 5 U/ml, lane 5; 25 U/ml, lane 6 or 50 U/ml, lane 7) for 15 min at 37°C.
After centrifugation, samples were subjected to 12% SDS-PAGE under reducing conditions,
followed by Western blot analysis using a polyclonal sheep anti-TAFI antibody that reacts with
both the zymogen and the activated form of TAFI. Following incubation of the blot with a
secondary rabbit anti-sheep antibody, biotin labeled goat anti-rabbit IgG and peroxidase
labeled streptavidin, immunoreactive bands were visualized by chemiluminescence. For
comparison TAFI purified from plasma and activated by the thrombin-thrombomodulin complex
is shown in lane 1. The positions of the molecular weight markers are shown on the left and the
approximate location of TAFI and TAFIa are indicated on the right.
with different concentrations of thrombin after which the samples were analyzed on Western blot
using an affinity purified sheep polyclonal antibody that reacts with both the proenzyme and
activated TAFI (43). In figure 3 it is shown that a band of about 35 kD becomes apparent at
increasing thrombin concentration, indicating the formation of TAFIa.
Enzymatic activity of  platelet-derived TAFI
Generation of TAFIa activity in thrombin activated platelets was determined using a
previously described assay developed for the detection of small amounts of activated TAFI in
TAFI
TAFIa
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Figure 4. Induction of carboxypeptidase activity in stimulated platelets
Activation of platelet-derived TAFI was measured using the substrate hippuryl-Arg and a
colorimetric detection method for hippuric acid based on cyanuric chloride. Gel-filtered
platelets (3*108 cells) were either incubated with thrombin (50 nM), thrombomodulin (10 nM), CPI
(10 µg/ml) or a combination as indicated. The control, in which the platelets were removed by
centrifugation before addition of thrombin-thrombomodulin to the supernatant (SUP) is shown
on the left. The inactivation of platelet-derived TAFIa was analyzed by incubation of the
activated platelet mixture for 30 min at 37°C before addition of the substrate and is shown on the
right. Each bar represents the mean ± SEM of 3 independent experiments.
plasma (79). In figure 4 it is shown that TAFIa activity was generated upon activation of platelets
by thrombin and that the activation of platelet derived TAFI was enhanced by thrombomodulin.
The carboxypeptidase activity was specific for TAFIa since it was inhibited by the
carboxypeptidase inhibitor CPI, which in plasma is specific for TAFIa. Incubation of the
thrombin-thrombomodulin activated platelet suspension for 30 min at 37° C before addition of
the substrate for TAFIa resulted in a decreased activity, indicating that platelet derived TAFIa
was also sensitive to temperature-dependent inactivation similar to TAFIa from plasma (19, 35).
No TAFIa activity was detected in the supernatant of resting platelets or in the absence of
thrombin. These results indicate that despite the somewhat lower molecular mass of platelet-
derived TAFI compared to TAFI purified from plasma, the enzymatic characteristics are similar.
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Immunofluorescent localization of TAFI in platelets
Immunofluorescence was used to evaluate the localization of TAFI in platelets. For this
purpose, cytospins of fixed resting platelets were incubated with a monoclonal antibody to TAFI
(9H10). In the absence of permeabilization of the platelets with saponin, no fluorescence could
be observed (data not shown), indicating that TAFI was localized intracellular and that no plasma
derived TAFI was bound to the surface of the platelets. After permeabilization, the staining
pattern of TAFI exhibited a homogenous fluorescence pattern as well as a spotted staining pattern
(figure 5), which suggests intracellular localization of the protein in granules.
Figure 5. Immunofluorescent analysis of TAFI in platelets
Cytospins of gel-filtered platelets were incubated with a monoclonal antibody against TAFI
(9H10) and a FITC labeled secondary goat anti-mouse IgG. Platelets stained positive with the
anti-TAFI antibody (A and B), whereas no fluorescence was observed when the monoclonal anti-
TAFI antibody is omitted (C), and light microscopy confirmed the presence of platelets (D). The
bars in the lower right corner of each figure represents 5 µm.
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Synthesis of TAFI in megakaryocytes
The possible synthesis of TAFI by megakaryocytes was studied using RT-PCR on mRNA of
megakaryocytic cell lines. The megakaryocytic cell lines MEG01, DAMI and CHRF represent
the early, intermediate and late stages of megakaryocyte development, respectively (213-215).
Controls included samples in the absence of cells, which in all cases were negative, HepG2 and
endothelial (HUVEC) cells. A primer set for actin was used as a positive control for the presence
of mRNA and was positive in all samples tested. TAFI mRNA could not be detected in MEG01
cells and endothelial cells but was present in DAMI, CHRF and HepG2 cells (table 1).
In addition, RT-PCR of mRNA with various primer sets covering the coding region of TAFI gave
identical fragments as those obtained from mRNA of HepG2 cells, suggesting that there were no
gross deletions or rearrangements in the mRNA that could account for the differences of lower
molecular mass of platelet-derived TAFI compared to plasma TAFI.
Discussion
Exposure of the perivascular connective tissue upon rupture of the endothelium leads to
platelet adhesion to extracellular matrix proteins such as collagens and von Willebrand factor
thereby forming a provisional platelet plug (217). This unstable platelet plug is strengthened by
the formation of a fibrin network. During the process of stable plug formation, activated platelets
Table 1. Detection of TAFI mRNA in HepG2, HUVEC and megakaryocytic cell lines
localisation primerset
(see Methods)
spanning bases (bp)
corresponding aa
MEG01 DAMI CHRF HepG2 HUVEC
activation peptide 1 86-361(275 bp)
Phe1-Arg92
-    -
signal + activation
peptide
2 29-316 (287 bp)
Cys-19-Glu77
-    -
prepro-enzyme 3 1-1291 (1291 bp)
Glu-28-STOP402
n.d. n.d.  n.d. n.d.
carboxy-terminal
end enzyme
4 900-1292 (392 bp)
Ser272-STOP402
-    -
actin 5 n.a.     
n.d.: not determined
n.a.: not applicable
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release the contents of α-granules and dense granules (217). This includes substances that
potentiate the activation of the platelets such as ADP, serotonin and thromboxane A2, coagulation
factors such as fibrinogen and factor V to facilitate the formation of a fibrin network and PAI to
inhibit fibrinolysis.
Given the presence of so many coagulation and fibrinolytic factors in platelets, the presence
of TAFI in platelets was evaluated. Previously, other members of the exopeptidase family were
identified in platelets (218), such as carboxypeptidase N and aminopeptidase P. In addition
platelets were found to contain small amounts of basic carboxypeptidase activity (13). Here we
report on the presence of TAFI in platelets. TAFI was secreted from platelets upon stimulation
of the platelets by various agonists and a fragment of approximately 35 kD corresponding to that
of TAFIa from plasma was observed on Western blot after incubation of platelets with thrombin-
thrombomodulin. Thrombin-induced TAFIa activity was observed both in the presence and
absence of thrombomodulin and the enzymatic characteristics, with respect to inhibition by CPI
and temperature-dependent inactivation, were similar in platelet-derived TAFIa and TAFIa from
plasma. Based on the secretion profile of TAFI from platelets upon activation with various
stimuli and the immunohistochemical staining pattern of TAFI in platelets, localization of TAFI
in the α-granules, at least in part, is suggested. The presence of mRNA in megakaryocytic cell
lines representing the more mature stages of megakaryocytopoiesis and the slightly lower
molecular mass of platelet-derived TAFI suggest synthesis of TAFI in the megakaryocyte.
However, no mRNA encoding for TAFI could be observed in the megakaryocytic cell lines on
Northern blot and uptake of TAFI from plasma by platelets and/or megakaryocytes can therefore
not be excluded. Megakaryocytes and platelets are known to endocytose proteins from the
surrounding media (219) as was recently shown for factor V (220).  The fact that no TAFI activity
was observed and only a minor amount of TAFI was detected on Western blot in the supernatant
of resting platelets indicates that platelet-TAFI was not derived from trace amounts of plasma
TAFI whereas the absence of a fluorescent signal in unpermeabilized platelets indicates that no
TAFI from plasma is bound to the surface of the platelet.  Furthermore platelet-derived TAFI
seemed to migrate on SDS-PAGE with a slightly lower molecular mass compared to TAFI from
plasma, which argues against a significant contamination of TAFI from plasma in the platelet
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suspension. Whether the difference in the molecular weight between platelet-derived TAFI and
plasma TAFI is derived from alternative glycosylation, limited proteolysis or some other process
is unknown. However, it seems unlikely that the difference in molecular mass originates from
alternative processing or splicing of the mRNA in the megakaryocyte since PCR products of
megakaryocytic cell lines and HepG2 cells using various primer combinations comprising the
coding region of TAFI revealed identical fragments.
Secretion of coagulation factors during platelet activation increases the local concentration of
specific coagulation factors at the site of injury. Some factors are present in relative high
concentrations in the platelet compared to plasma (e.g. fibrinogen (221), plasminogen activator
inhibitor 1 (PAI-1) (222) and factor V (223)) and some are not (e.g. factor IX (224), protein S
(225), α2-antiplasmin (226) and protein C inhibitor (227, 228)). The concentration of TAFI in
platelets (48 ng/1*109 platelets) is only 0.1% of the total amount of TAFI found in plasma (platelet
rich plasma (3*108 platelets/ml) contains 14.4 ng/ml platelet-derived TAFI vs 15.6 µg/ml TAFI in
plasma (26)) whereas based on volume the concentration of TAFI in platelets is only 3 fold lower
than in plasma (based on a platelet volume of 7*10-15 l, approximately 1*1011 platelets comprise
a ml and contain 4.8 µg/ml of platelet derived TAFI). The level of TAFI in platelets, however,
does not necessarily preclude its physiological importance. Since platelets are concentrated
within the fibrin clot, local concentrations could approach significant levels and relatively small
variations in the TAFI concentration were found to influence the clot lysis time (26). Our results
suggest that a considerable amount of TAFIa is formed in thrombin-activated platelets and the
amount of substrate (hippuryl-Arg) that is cleaved by thrombin-thrombomodulin activated
platelets is in the same order of magnitude as previously observed for TAFI in plasma activated
by endogenously formed thrombin (79). Also thrombomodulin present in platelets (229, 230)
might contribute to the formation of these relatively high amounts of TAFIa in platelets by
thrombin.
Platelets possess both pro- and antifibrinolytic activities (231, 232), and the proximal
relationship between platelets and fibrin within thrombi suggests that these activities may
contribute to the regulation of fibrinolysis. Platelets secrete a variety of proteins that inhibit
fibrinolysis such as PAI-1 (222), α2-antiplasmin (226) and factor XIII (233) and secretion of
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TAFI by platelets is a new addition to this list. On the other hand platelets stimulate plasmin
formation and binding of plasminogen to the platelet surface was increased 5 fold by thrombin
stimulation compared to unstimulated platelets (234). Similarly, binding of plasminogen to cells
was found to increase plasmin formation since surface-bound plasminogen is a better substrate
for plasminogen activators and bound plasmin is protected from rapid inactivation by
α2-antiplasmin (235, 236). Plasminogen binding to cells was found to be mediated by carboxy-
terminal lysines on the cell surface, either occurring as natural carboxy-termini of proteins or as
a result of limited proteolysis and removal of these lysines by carboxypeptidase B-like enzymes,
such as TAFIa abrogated the binding of plasminogen to cells (50). This suggests that TAFIa from
activated platelets might abrogate the stimulating effect of platelets on plasmin formation in a
similar way. In addition fibrinogen is an important factor for the aggregation of platelets via
integrin αIIbß3 and excessive plasmin formation during the early stages of platelet plug formation
might interfere with the formation of a stable platelet plug. The observation that fibrin adherent
to the surface of thrombin-stimulated platelets lysed 20-50% more slowly than bulk fibrin (237),
indicating that fibrin bound to the platelet surface is protected from fibrinolysis by tPA, suggests
a possible role for TAFIa from platelets.
The results of the present study show the presence of fully functional TAFI in platelets that is
presumable synthesized in the megakaryocyte during the process of megakaryocytopoiesis.
TAFI is secreted upon stimulation of the platelets and the formation of TAFIa upon stimulation
of platelets by thrombin suggests a possible new mechanism for  clot protection in the early stages
of clot formation during platelet plug formation.
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Summary
Inhibition of angiogenesis, the formation of new blood vessels, offers an exiting new
opportunity to treat cancer and other angiogenesis dependent diseases. Endostatin is one of the
most promising anti-angiogenic molecules, but its mode of action is not known. Here we report
that endostatin binds plasminogen and tissue-type plasminogen activator (tPA) and potently
stimulates the formation of the serine protease plasmin. Carboxy-terminal lysines in endostatin
were essential for plasmin formation, since treatment with B-type carboxypeptidases inhibited
the effect. The antitumoral effect of endostatin was similarly dependent on these carboxy-
terminal lysines. These results indicate that endostatin inhibits angiogenesis by enhancing
extracellular matrix degradation by plasmin and thereby interferes with endothelial cell adhesion.
Furthermore, these results imply that carboxypeptidases such as thrombin activatable
fibrinolysis inhibitor (TAFI) can affect angiogenesis. Our demonstration that enhanced
fibrinolysis inhibits angiogenesis provides the rationale to develop new inhibitors of
angiogenesis.
Introduction
The formation of a provisional extracellular matrix is a hallmark of angiogenesis. This occurs
after initiation of the coagulation cascade upon vascular injury, during inflammation, and in
tumors (238, 239). Fibrin is a major constituent of the provisional matrix. Fibrin formation is
triggered by tissue factor, which is present on stimulated endothelial cells, in the subendothelial
matrix and on many tumor cells (240). Tissue factor exposure leads to thrombin activation, and
as a result fibrin is formed by polymerization of thrombin cleaved fibrinogen (238). Together
with other adhesive proteins, such as vitronectin and fibronectin, fibrin forms the provisional
matrix. The provisional matrix supports tissue remodeling, wound healing, angiogenesis and
tumor growth (241). Fibrin and the other components of the extracellular matrix regulate cell
proliferation, migration and survival or apoptosis through interactions with adhesion molecules
on the cell surface. Important adhesion molecules include the receptors for fibrin and vitronectin,
the integrins α
v
β3 and αvβ5. Plasmin has been implicated as modulator of the interactions between
cells and the extracellular matrix. Plasmin mediates proteolysis of the extracellular matrix
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directly by degrading fibrin, called fibrinolysis, and other extracellular matrix molecules,
including vitronectin. In addition plasmin mediates proteolysis indirectly by the activation of
metalloproteinases, which in turn degrade other components of the extracellular matrix,
including collagen.
The formation of plasmin through cleavage of its zymogen plasminogen is mediated by tPA
and greatly stimulated by fibrin. Carboxy-terminal lysine residues that are generated in fibrin
during initial plasmin digestion are essential (53). The binding of plasminogen and tPA to fibrin
is mediated by the lysine-binding sites in the kringle domains of plasminogen and tPA and by the
carboxy-terminal lysine residues that are generated in fibrin during plasmin digestion. TAFI is a
carboxypeptidase-B type proenzyme in blood involved in the regulation of fibrinolysis (67).
TAFI can bind plasminogen and after activation by thrombin or plasmin potently attenuates
fibrinolysis by removing carboxy-terminal lysine residues from partially degraded fibrin.
Activation of TAFI by thrombin, that is generated by the coagulation system, is stimulated 1250-
fold by thrombomodulin, a protein specifically expressed on endothelial cells.
Endostatin, a proteolytic fragment of collagen XVIII, is one of the most potent inhibitors of
angiogenesis and tumor growth (242, 243), but its molecular action(s) are unknown. Because
endostatin is a fragment of the extracellular matrix, exerts its effects via the tumor vasculature and
has a carboxy-terminal lysine, we examined whether endostatin regulates plasmin formation.
Material and Methods
Proteins and reagents
The cDNA for murine endostatin (kindly provided by dr. Fukai, Boston) was amplified by
PCR and cloned into the prokaryotic expression vector pET15b (Invitrogen, The Netherlands).
Recombinant murine endostatin was produced by Escherichia coli as described (242). TAFI was
purified from fresh frozen plasma by affinity chromatography using monoclonal antibody 9H10
as described (51). Plasminogen was from Sigma Chemical Co (St. Louis, MO), tPA and plasmin
substrate S-2251 were from Chromogenix AB (Mölndal, Sweden), DESAFIB-X was from
Biopool AB (Umeå, Sweden), porcine pancreas carboxypeptidase B was from Boehringer
Mannheim (Mannheim, Germany), carboxypeptidase inhibitor was from Calbiochem (La Jolla,
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CA). Thrombomodulin, anti-plasminogen monoclonal antibody and anti-tPA polyclonal
antibodies were from American Diagnostica (Greenwich, CT).
Binding experiments
Binding of plasminogen and tPA was carried out in 96-well microtiter plates coated overnight
at room temperature with 50 µl endostatin (20 µg/ml) or DESAFIB-X (20 µg/ml) in coat buffer
(15 mM Na2CO3, 35 mM NaHCO3, 0.02 % NaN3, pH 9.6). The wells were blocked with 3%
bovine serum albumin (BSA) in PBS for one hour and washed three times with PBS containing
0.3% BSA. Where indicated the wells were treated with porcine pancreas carboxypeptidase B
(50 µg/ml) for one hour at 37°C in PBS containing 3% BSA and washed 3 times with PBS/BSA.
Plasminogen and tPA, at various concentrations, were allowed to bind for one hour. After
3 washes, bound plasminogen or tPA were detected with specific anti-plasminogen and anti-tPA
antibodies followed by peroxidase conjugated secondary antibodies. Peroxidase activity was
measured using ortho-phenylenediamine as substrate. The reaction was stopped by the addition
of 1 M H2SO4 and absorbance was measured at 490 nm.
Measurement of plasmin activity
The reactions were performed at 37°C in HBS buffer (20 mM Hepes, 4 mM KCl, 137 mM
NaCl, 3 mM CaCl2, 0.1 % BSA, pH 7.4) containing 50 µg/ml plasminogen with various
concentrations of endostatin, DESAFIB-X or with a control sample. The reactions were started
by the addition tPA at a final concentration of 30 U/ml. At several time points, 20 µl samples were
taken and stopped with 20 µl HBS containing 150 mM εACA and 150 mM EDTA. Plasmin
activity was determined in 96-well plates after the addition of 20 µl chromogenic substrate
S-2251 at a final concentration of 1.6 mM. Increase in absorbance was measured at 405 nm for
10 min. When applicable test samples were preincubated for 30 minutes with 25 µg/ml
carboxypeptidase B, 50 µg/ml carboxypeptidase inhibitor, 10 nM thrombin, 2 nM
thrombomodulin or 4 µg/ml TAFI. Plasmin measurements in plasma were performed in a similar
manner, using 50% plasma with 50% HBS buffer. Hirudin (1000 U/ml) was added to prevent clot
formation.
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Tumor experiments
Male 6 to 8 week old BALB/c mice (General Animal Laboratory, University Medical Center
Utrecht, Utrecht, The Netherlands) were used. All mice were fed a diet of animal chow and water
ad libitum. Experiments were performed according to the guidelines of the Utrecht Animal
Experimental Committee, University Medical Center (Utrecht, The Netherlands). Mice were
inoculated subcutaneously with 1x106 C26 colon carcinoma cells in 200 µl PBS. Endostatin or
control solvent was given by subcutaneous daily injection at a dose of 20 mg/kg/day, which
results in this model in approximately 50% inhibition of tumor growth.  Carboxypeptidase B was
given continuously using a mini-osmotic pump (Alzet pump, Alza, Palo Alto, California, USA,
type 2002 (14 days)) containing 200 µl carboxypeptidase B at a concentration of 5 mg/ml. The
pump was implanted subcutaneous in the dorsal skin fold. In mice bearing subcutaneous tumors,
absence of contact between tumor deposit and pump was assured by implanting the pump in the
contralateral side. Animals received an initial subcutaneous bolus injection of 40 µg
carboxypeptidase B in 100 µl PBS. Tumor diameters were determined by caliper and tumor
volume was calculated with the formula: width2 x length x 0.52.
Results and Discussion
Endostatin binds both plasminogen and tPA in a dose-dependent and saturable manner
(figure 1a, b). Binding of tPA to endostatin (apparent dissociation constant (Kd) = 0.5  ± 0.1 µM)
was about 2 to 3-fold higher than the binding of tPA to standard fibrin degradation products
(DESAFIB-X , Kd = 1.3 ± 0.2 µM). The affinity of plasminogen for endostatin (Kd = 2.7 ± 0.6 µM)
was also higher than the affinity of plasminogen for DESAFIB-X (Kd = 28.4  ± 5.8 µM). We next
measured the generation of plasmin from plasminogen by tPA in the absence and presence of
endostatin, using a chromogenic substrate for the determination of plasmin activity. Endostatin
stimulated tPA-mediated plasminogen activation in a dose-dependent manner (figure 1c).
Stimulation of tPA-mediated activation of plasminogen by endostatin was equally potent as
DESAFIB-X, the commonly used stimulator of tPA-mediated plasminogen activation (figure
1d). These results show that endostatin serves as a cofactor for tPA-mediated activation of
plasminogen.
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Figure 1. Endostatin binds to plasminogen and tPA and stimulates tPA-mediated
plasminogen activation
Binding of plasminogen (A) or tPA (B) to endostatin (, ) or fibrin degradation products
(DESAFIB-X) (, ) immobilized in microtiter wells was measured. The effect of endostatin (C) on
plasmin formation by tPA was determined by adding various concentrations of endostatin to
plasminogen and tPA and measure the formation of plasmin at various time points using the
chromogenic substrate S-2251. Endostatin: 0 µM (); 0.5 µM (); 1 µM (); 2 µM (); 4 µM ().
(D), Effect of fibrin degradation products (DESAFIB-X) 0 µM (); 0.5 µM (); 1 µM (); 2 µM ();
4 µM () on plasmin formation by tPA. No activation of plasminogen was observed in the
absence of tPA and endostatin alone did not convert the chromogenic substrate (not shown).
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To determine the effect of carboxy-terminal lysine residues on endostatin stimulated plasmin
formation, we analyzed the effect of endostatin in the presence of porcine pancreas
carboxypeptidase B (CPB) or TAFI, enzymes capable of removing carboxy-terminal lysine
residues. Addition of CPB or TAFI completely abolished endostatin stimulated plasmin
formation indicating that carboxy-terminal lysine residues are critically involved (figure 2a, b).
The inhibitory effect of  CPB and TAFI on endostatin was greatly reduced by the addition of a
specific carboxypeptidase inhibitor (CPI), indicating that the effect of these carboxypeptidases is
due to carboxypeptidase activity. Our findings are supported by a recent finding that endostatin
isolated from patients does not inhibit endothelial cell proliferation and lacks the carboxy-
terminal lysine residue (244). Subsequent binding studies revealed that removal of the carboxy-
terminal lysine of endostatin by  CPB abrogated plasminogen binding for more than 90%, but had
little or no effect on tPA binding (figure 2c). Binding of plasminogen was also blocked in the
presence of the lysine analogue epsilon-amino caproic acid (εACA, not shown), indicating that
indeed the lysine binding-sites in plasminogen are responsible for binding to endostatin. In
contrast, binding of tPA to endostatin seems not to depend on the carboxy-terminal lysine and the
lysine binding site of tPA, suggesting that other domains in tPA and endostatin are important.
This is in agreement with the described importance of the finger domain of tPA in the binding of
fibrin (245). Recently, Boehm et al. (246) described that endostatin expressed in Pichia pastoris,
which is commonly used for large scale production of proteins, was truncated at its carboxy-
terminus due to the activity of KEX1, a yeast B-type carboxypeptidase. This finding, together
with our data suggest that the activity of endostatin may be altered depending on the expression
system used. However, a mutant form of endostatin, lacking the carboxy-terminal lysine was also
able to stimulate tPA mediated plasmin formation in a carboxypeptidase B sensitive manner (not
shown). Internal lysine residues that become carboxy-terminal after proteolysis mediated this
effect. Taken together, our results demonstrate that carboxy-terminal lysine residues in
endostatin are essential for plasminogen binding and critical for its stimulatory activity on the
formation of plasmin by tPA. Moreover these results imply a role for TAFI in endostatin function
and angiogenesis. The coagulation system may provide a regulatory role in this process by
generating activated TAFI and abrogating the effect of endostatin on fibrinolysis.
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To determine the possible role for carboxy-terminal lysine residues in the antitumoral effect of
endostatin in vivo we treated mice with endostatin in the absence or presence of  CPB. Endostatin
treated mice showed reduced growth of a subcutaneous colon carcinoma, while the presence of
carboxypeptidase completely abolished this reduction (figure 2d). The anti-tumor effect of  CPB
alone, although not significant, may be caused by removal of endogenously generated carboxy-
terminal lysines residues in fibrin that stimulate plasmin formation and angiogenesis.
Figure 2. Effect of carboxypeptidases on endostatin activity
(A), Carboxypeptidase B inhibits endostatin mediated plasmin formation by tPA. The formation
of plasmin was measured in the presence of 4 µM endostatin. Prior to the start of the reactions
with tPA the samples were incubated for 30 minutes at 37°C with carboxypeptidase B. The
carboxypeptidase inhibitor (CPI) was included to demonstrate that the effect of
carboxypeptidase B was the result of specific carboxpeptidase activity. Symbols used: control
(); endostatin (); endostatin with CPB () and endostatin with CPB and CPI (). (B), TAFIa
abolishes the stimulatory effect of endostatin on plasmin formation by tPA. TAFI was activated
with thrombin in the presence of thrombomodulin. Incubations with thrombin, thrombomodulin,
and CPI alone had no effect on endostatin activity (not shown). The carboxypeptidase inhibitor
(CPI) was included to demonstrate that the effect of TAFI was the result of specific
carboxpeptidase activity. Symbols used: control (); endostatin (); endostatin with TAFIa ()
and endostatin with TAFIa and CPI (). (C), Treatment of endostatin with pancreas
carboxypeptidase B abolished plasminogen binding, but not tPA binding. Plasminogen and tPA
(500 ng/ml) were allowed to bind immobilized endostatin, which was pre-incubated with (gray
bars) or without (solid bars) carboxypeptidase B for one hour. (D), inhibition of tumor growth by
endostatin is ablolished by carboxypeptidase treatment. Mice (n=4/group) were inoculated
subcutaneously with 1x106 C26 colon carcinoma cells and treated daily with endostatin or
control solvent in the presence or absence of carboxypeptidase B as indicated. The inhibitory
effect of endostatin on tumor growth (p=0.046 vs. control solvent) was completely abolished by
continuous administration of carboxypeptidase B (p=0.03 vs. endostatin). Treatment with
carboxypeptidase B alone resulted in a slight inhibitory effect, which was not significant (p=0.23
vs. control solvent). The experiment shown is a representative of three independent experiments.
Values represent mean number ± SEM.
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Uncontrolled activation of tPA by endostatin may result in substantial systemic toxicity. We
therefore determined whether activation of tPA occured in the circulation. We found that addition
of endostatin to plasma had no effect on the activation of plasminogen by the low concentration
of tPA present in plasma (figure  3). However, increasing the concentration of  tPA to levels that
are expected to be released by activated endothelial cells under physiological conditions, such as
in response to vascular endothelial growth factor, lead to rapid formation of plasmin. These
results strongly support the hypothesis that circulating endostatin only exerts its effect on
stimulated endothelial cells that are present in the tumor vasculature or in other angiogenesis-
dependent diseases. These findings are in agreement with the lack of systemeic toxicity and
explain why endostatin is specific for activated endothelial cells (242).
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The fibrinolytic system plays an important role in angiogenesis and tumor growth (239, 247).
In cancer patients levels of fibrinogen degradation products as well as complexes between
plasmin and α2-antiplasmin are elevated. This indicates an increased turn-over of fibrinogen and
plasminogen. Furthermore, fibrin depositions are found in many tumors and plasminogen
activators and plasminogen activator inhibitor (PAI) are often highly expressed. Plasmin
formation and action is under stringent control of activators, including tPA, and inhibitors, such
as PAI-1 and α2-antiplasmin. The balance between the levels and activity of these components is
tightly controlled by extracellular matrix proteins and their cell surface receptors (248). Precisely
regulated pericellular proteolysis dictates coordinated cell proliferation, migration and invasion.
A shift in this balance has been shown to have profound effects on either endothelial cell
adhesion, migration, angiogenesis, metastasis or tumor growth. Our results suggest that
overstimulation of the plasminogen system may be a novel mechanism by which endostatin
inhibits angiogenesis and tumor growth (figure  4). The concept of tPA induced plasmin mediated
Figure 3. Endostatin does not stimulate plasminogen activation in plasma
The formation of plasmin was measured in the presence or absence of 4 µM endostatin. Only
after the addition of both tPA and endostatin plasmin is rapidly formed. The subsequent decline
in plasmin activity is explained by the presence of α2-antiplasmin, present in plasma, which
inhibits plasmin in solution. The symbols used are: control (); tPA (), endostatin (); endostatin
and  tPA ().
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inhibition of tumor growth is further supported by our recent finding that continous systemic
treatment of mice with tPA, which efficiently generates plasmin in vivo and is used clinically in
patients with myocardial infarction, also inhibits tumor growth (unpublished observations).
Moreover, others have demonstrated in vitro that induction of plasminogen activation leads to
endothelial cell detachment (249), inhibition of cell adhesion (250) or endothelial cell destruction
(251). Our findings may explain the observation that vascularization and tumor invasion is
prevented in the absence of PAI (252) when increased levels of plasmin are likely being formed.
Finally, high concentrations of tPA are generated (253, 254) and PAP levels are elevated (254) in
patients with peripheral tumors that are treated with tumor necrosis factor alpha (TNFα), which
results in tumor reduction. At present, research is primarily focussed at the identification and
analysis of inhibitors of proteases. We propose that molecules that lead to excessive proteolysis
in the tumor may be powerful anti-angiogenic and anti-tumorigenic agents (255).
Figure 4. Schematic representation of inhibition of angiogenesis by induction of
hyperfibrinolysis
In quiescent endothelial cells, the extracellular matrix supports cell survival (top). Stimulated
endothelial cells synthesize and secrete tPA, which mediates migration, invasion and
proliferation (bottom left). Overstimulation of tissue-type plasminogen activator by endostatin
leads to excess plasmin formation and causes degradation of the matrix. Ultimately, endothelial
cells detach and undergo apotosis (bottom right).
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Summary
TAFI (thrombin activatable fibrinolysis inhibitor) down regulates fibrinolysis after activation
by relatively high concentrations of thrombin generated during coagulation via thrombin
mediated factor XI activation and subsequent activation of the intrinsic pathway. It is this
secondary burst of thrombin that is severely diminished in haemophilia A, a deficiency of
coagulation factor VIII. We therefore investigated the role of TAFI in haemophilia A by
measuring the clot lysis times of tissue factor induced fibrin formation and tPA mediated
fibrinolysis. In haemophilia A plasma clot lysis times were normal at relatively high tissue factor
concentrations but severely decreased at moderate to low tissue factor concentrations, indicating
that the thrombin generation via the extrinsic pathway was insufficient to activate TAFI.
Addition of factor VIII, TAFI or thrombomodulin restored the clot lysis times at low tissue factor
concentrations. This confirms the hypothesis that the bleeding disorder in haemophilia A is not
merely a defect in the initial clot formation but is in fact a triple defect: reduced thrombin
formation via the extrinsic pathway at low tissue factor concentrations, a reduced secondary burst
of thrombin generation via the intrinsic pathway and a defective down regulation of the
fibrinolytic system by the intrinsic pathway.
Introduction
Haemophilia A is an X-linked hereditary bleeding disorder characterized by a deficiency or
a functional defect in coagulation factor VIII that affects approximately 1-2 in 10,000 males
(256). The severity of the bleeding symptoms is dependent on the residual factor VIII clotting
activity. Patients with a severe form of haemophilia (factor VIII:C<1%) suffer from spontaneous
joint and muscle bleedings whereas bleedings in moderate haemophilia (factor VIII:C 2-5%) are
generally preceded by minor trauma (257).
Factor VIII participates in the intrinsic pathway of coagulation and is an essential cofactor in
the tenase complex which catalyzes the activation of factor X by factor IXa. Coagulation is
initiated by exposure of tissue factor to the blood. At high tissue factor concentrations, factor X
is mainly activated by the factor VIIa-tissue factor complex, whereas at low tissue factor
concentrations the activation of factor IX and the contribution of the tenase complex in the
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activation of factor X becomes more pronounced (258). This predicts that haemophilia A patients
bleed predominantly from areas of the body which contain low tissue factor concentrations and
indeed deep skeletal muscles and joints were found to have undetectable to low tissue factor
expression (189). Interestingly, haemostatic plug abnormalities in haemophiliacs could not be
detected directly after plug formation, but only after 2 hours (259). Although this has previously
been explained by the impaired fibrin formation this is unlikely in view of the small amounts of
thrombin that are necessary for fibrin formation and the presence of an unaffected extrinsic
pathway of coagulation in these patients. Recently a revised model of blood coagulation was
proposed which provides an alternative explanation for the delay in haemostatic plug
abnormalities (82). In this model initiation of coagulation and fibrinolysis are closely regulated
via the activation of thrombin activatable fibrinolysis inhibitor (TAFI; EC 3.4.17.20) (18).  TAFI,
also referred to as procarboxypeptidase U (17) or plasma procarboxypeptidase B (16), is a
carboxypeptidase B like proenzyme that after activation inhibits fibrinolysis by removing
carboxy-terminal lysine residues from fibrin that play a role in plasminogen binding and
activation (50). Activation of TAFI is mediated by relatively high concentrations of thrombin that
are formed via the intrinsic pathway in a factor XI dependent way (64). This secondary burst of
thrombin was found to protect the clot against premature lysis and was dependent on an intact
intrinsic pathway of coagulation and on TAFI (65).
The defect in the intrinsic pathway in haemophilia A would predict a diminished TAFI
activation resulting in a rapid lysis of the clot. Indeed Broze et al. have shown that the clot lysis
time is decreased in factor VIII, IX, X and XI deficient plasma and could be restored by addition
of the deficient factor (48). Also addition of thrombomodulin (TM), an endothelial cell receptor
that stimulates the thrombin mediated TAFI activation more than 1000 fold, was shown to correct
the clot lysis times in haemophilia plasma (29, 48). This suggests that the clot lysis times could
be restored in haemophilia A by restoring the activation of TAFI. However, TM also stimulates
the activation of the anticoagulant protein C pathway, thereby inhibiting thrombin formation, an
undesired side effect in haemophilia A (25, 72). Recently we have shown that at low
concentrations, TM predominantly stimulates the activation of TAFI whereas at 5 nM or higher
the activation of protein C becomes more pronounced and subsequently TAFI activation is
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downregulated by activated protein C (72). Another way of increasing the activation of TAFI
would be by increasing the TAFI plasma concentration, since the plasma concentration of TAFI
(4-15 µg/ml) is well below the Km for thrombin mediated TAFI activation (25, 26, 29). Addition
of purified TAFI to normal plasma resulted in an increased activation of TAFI and a dose
dependent down regulation of fibrinolysis (26).
In this study we characterize the activation of TAFI in severe haemophilia A and compare the
effects of TAFI and TM administration on the clot lysis in individual patients with severe
haemophilia A and patients with high anti-factor VIII antibody titres.
Materials and Methods
Materials
Recombinant human tissue factor (Innovin) was obtained from Baxter (Unterschleissheim,
Germany). Carboxy peptidase inhibitor (CPI) was purchased from Calbiochem (La Jolla, CA)
and tissue type plasminogen activator (583,000 IU/mg) was from Chromogenix (Mölndal,
Sweden). Rabbit lung thrombomodulin was purchased from American Diagnostica (Greenwich,
CT) and Enzygnost F1+2 kits were obtained from Behring (Marburg, Germany). The factor VIII
source was Monoclate-P (Armour, Collegeville, PA) All other chemicals obtained were the best
grade available.
Proteins and antibodies
A monoclonal antibody against factor XI (XI-1) capable of blocking factor XI activity had
been prepared as described previously (64). TAFI was purified by immunochromatography from
human plasma as described elsewhere (26) and appeared homogeneous on SDS-PAGE.
Plasmas
Normal plasma was derived from a donor pool of 40 healthy volunteers. Blood was taken
from the antecubital vein, collected in 3.2% trisodium citrate (0.109 M) as the anticoagulant
(9:1 v/v). To obtain platelet poor plasma the samples were centrifuged twice for 15 min at
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2500 g, after which the plasma was stored at -70°C until use. Plasma samples from 56 patients
with severe haemophilia A (factor VIII:C < 1%) without an inhibitor and from 4 patients with a
high anti-factor VIII antibody titre were collected by the Van Creveld Kliniek (Utrecht, the
Netherlands) and the clinical data were extracted from the individual medical records. The pooled
haemophilia A plasma consisted of the plasmas of 10 patients with severe haemophilia A (factor
VIII:C < 1%). TAFI antigen levels were determined by ELISA as described (26).
Clot lysis assay
Clot lysis was studied in a plasma system in which tPA-mediated fibrinolysis (30 U/ml) of a
tissue factor-induced (dilution of Innovin) clot is measured using turbidity as described earlier
(26). Clotting- and clot lysis times were determined in normal and pooled haemophilia A plasma
using different dilutions of Innovin (1*103-1*107) in the absence and presence of factor VIII
(1 U/ml), CPI (50 µg/ml) or an inhibiting antibody against factor XIa. Also, clot lysis times were
Table 1. Patients characteristics
reference value hae
number of patients (male/female)
age (years)
factor VIII:C (%NP) 60-130
APTT (sec) 36.4 (± 5.0)
vWF (µg/ml) 6-13
TAFI antigen (% NP) 97.9 (± 19.0) (26)
fVIII inhibitor (BU/ml)
age first bleeding (years)
frequency of bleeding 1st year
age start profylaxis (years)
profylaxise per year (x103 units)
mean (± SD)
n.d.: not determined
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determined in pooled haemophilia A plasma using a 1*105 dilution of Innovin in the presence of
different concentrations of factor VIII (0-5 U/ml) or TAFI (0-150 µg/ml). Clot lysis times in the
individual haemophilia A patients were determined in the absence and presence of factor
VIII (1 U/ml), TAFI (15 µg/ml), TM (1 nM) or CPI (50 µg/ml) in the presence of a 1*105 dilution
of Innovin. Clotting times were defined as the time to the midpoint of the clear-to-maximum
turbid transition that characterizes the formation of fibrin. Clot lysis times were determined as the
time between clotting time and the midpoint of the maximum turbid-to-clear transition that
characterizes the lysis of fibrin.
F1+2 assay
Fibrin formation was induced by 1*105 dilution of Innovin in normal- and pooled
haemophilia A plasma as described above in the absence or presence of factor VIII (1 U/ml). At
different time intervals, 100 µl of Hepes buffer containing 10 mM EDTA and 50 U/ml hirudin
was added to the fibrin clot. After thorough mixing for 1 min and centrifugation (2 min, 15,000 g), the
amount of prothrombin activation was determined in the supernatant by measuring the
concentration of fragment F1+2 by ELISA.
Statistical analysis
 Since the clot lysis times showed a non-gaussian distribution, the Kruskal-Wallis test
followed by Dunn’s multiple comparison test was performed using GraphPad Prism version 3.02
for Windows (GraphPad Software, San Diego CA) unless noted otherwise.
Results
Tissue factor dependent clot lysis in normal- and haemophilia A plasma
Activation of TAFI in normal- and pooled haemophilia A plasma was determined in a clot
lysis assay by measuring the turbidity of a tissue factor induced plasma clot and tissue-type
plasminogen activator (tPA) mediated fibrinolysis. Clot lysis times in normal plasma were
independent of the tissue factor concentration used (range 1*103 to 1*107 dilution of Innovin) to
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initiate coagulation (figure 1a). In the presence of an inhibitory antibody against factor XI (XI-1) the
clot lysis times were decreased at low tissue factor to the same level as obtained in the presence
of the TAFIa inhibitor carboxypeptidase inhibitor (CPI). At high tissue factor concentrations the
clot lysis time remained unchanged in the presence of the factor XI inhibiting antibody. This
indicates that sufficient amounts of thrombin required for TAFI activation are generated by the
extrinsic pathway in the presence of high tissue factor concentrations (<10,000 dilution of
Innovin) but not in the presence of low tissue factor concentrations (>100,000 dilution of
Innovin), where feedback via the intrinsic pathway is essential. Accordingly the clot lysis times
in pooled haemophilia A plasma were normal at high tissue factor concentrations but decreased
to those in the presence of CPI at low tissue factor concentration (figure 1b). Reconstitution of the
haemophilia A plasma with plasma concentrations of factor VIII (1 U/ml) restored the clot lysis
time at low tissue factor concentrations.
Figure 1. Tissue factor dependent clot lysis in normal- and haemophilia A plasma
Clot lysis times were determined in normal plasma (panel A) and pooled haemophilia A plasma
(panel B). Coagulation was initiated by different tissue factor concentrationS (1*103 - 1*107
dilution of Innovin) and tPA (30 U/ml) was used to initiate fibrinolysis. Clot lysis times were
determined in the absence () and presence of an antibody against factor XI (), 50 µg/ml CPI
() or 1 U/ml factor VIII (). Each point represents the mean of two independent experiments.
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Previously we found that the clot lysis time was dependent on the amount of thrombin
generated after clot formation in the presence of an intact intrinsic system. In agreement with the
results obtained with the clot lysis test we found that at low tissue factor concentrations the
activation of prothrombin as measured by the release of fragment 1+2 after clot formation was
decreased in haemophilia A plasma compared to normal plasma. Addition of factor VIII to
haemophilia A plasma restored the activation of prothrombin and normalized the clot lysis time
(figure 2a).
Figure 2. The effect of factor VIII on the activation of prothrombin and fibrinolysis
in haemophilia A plasma
The effect of factor VIII on the activation of prothrombin, as measured by the release of
fragment 1+2 was determined in time (panel A). Coagulation was initiated (1*105 dilution of
Innovin) in normal- () and pooled haemophilia A plasma in the absence () and presence of
1 U/ml factor VIII (). Clot lysis times were determined in pooled haemophilia A plasma (panel
B) in the presence of different concentrations of factor VIII (0-5 U/ml) () and a 1*105 dilution of
Innovin. The clot lysis times in normal plasma are also depicted in the absence () and presence
() of 50 µg/ml CPI. Each point represents the  mean of two experiments.
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Normalization of clot lysis times in haemophilia A plasma
The effect of different concentrations of factor VIII on the clot lysis time in haemophilia A
plasma was tested. Addition of 0.5 U/ml factor VIII to pooled haemophilia A plasma was already
sufficient to restore the clot lysis time to the same level as observed in normal plasma (figure 2b).
Increasing the factor VIII level to 5 U/ml did not result in a further prolongation of the clot lysis
times.
Previously we found a correlation between the clot lysis time and the TAFI concentration in
normal plasmas (26). Addition of purified TAFI to pooled haemophilia A plasma resulted also in
a dose dependent increase of the clot lysis times (figure 3). Increasing the plasma TAFI
concentration from 15 to 30 µg/ml resulted in a 3 fold increase of the clot lysis time in haemophilia A
plasma whereas a 10 fold increase of the TAFI plasma concentration resulted in a 7 fold increase
of the clot lysis time which could be completely inhibited by the TAFIa inhibitor CPI.
Figure 3. TAFI dependent increase of the clot lysis time in haemophilia A plasma
Clot lysis times were determined in pooled haemophilia A plasma in the presence of different
concentrations of TAFI (0-150 µg/ml) and a 1*105 dilution of Innovin in the absence () and
presence of 50 µg/ml CPI (). The clot lysis times in normal plasma are also depicted in the
absence () and presence () of CPI.  Each point represents the mean of two independent
experiments.
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Figure 4. Clotting- and clot lysis times in individual haemophilia A plasmas
Tissue factor clotting times (1*105 dilution of Innovin) were determined in the plasma of 56
individual haemophilia A patients (panel A). Also the clot lysis times were determined in these
patients using a 1*105 dilution of Innovin to induce clot formation and 30 U/ml of tPA to induce
fibrinolysis (panel B). The effect of the absence or presence of 1 U/ml factor VIII, 15 µg/ml TAFI,
1 nM TM and 50 µg/ml CPI were determined and are summarized in table 2.
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Table 2. Clotting- and clot lysis times in haemophilia A patients
none fVIII TAFI TM
number of patients (n) 56 56 53* 5
median clotting time (min) 12.4 6.3† 11.9 1
25th-75th percentile (min) 10.0-16.9 5.2-8.1 9.5-15.1 10.9
median clot lysis time (min) 21.2 39.9† 43.5† 83
25th-75th percentile (min) 18.7-24.7 35.7-44.4 30.1-63.6 73.5
average fold increase 1 1.8 2.1 3
*
 not sufficient plasma available.
†
 p<0.001 compared to no addition; Kruskal-Wallis test
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The clot lysis times in individual haemophilia A patients
The clot lysis times were determined in the plasma of 56 individual patients with severe
haemophilia A (table 1). Clot lysis times in the haemophilia A patients (median, 21.2 min) were
similar to the clot lysis times in the presence of CPI (18.8 min), indicating that only limited TAFI
activation has occurred (figure 4 and table 2). Addition of factor VIII (1 U/ml) induced a
prolongation of the clot lysis times (39.9 min). Doubling the TAFI concentration resulted in an
2 fold increase of the clot lysis times (43.5 min), whereas addition of TM (1 nM) resulted in a 3.7
fold increase of the clot lysis time (83.9 min). The tissue factor (1*105 dilution of Innovin)
induced clotting times were determined. A median value of 12.4 min was obtained and addition
of 1 U/ml factor VIII resulted in a shortening of the mean clotting time to 6.3 min in the
haemophilia A patients. The clotting times were not significantly different after addition of TAFI,
TM or CPI.
Figure 5. Relationship between clot lysis times and TAFI levels in haemophilia A
In 56 haemophilia A patients, TAFI antigen levels were measured and the clot lysis times were
determined in the absence (panel A) and presence of 1 U/ml factor VIII (panel B). TAFI antigen
levels were expressed as a percentage of normal plasma.
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Figure 6. Clot lysis times in congenital- or acquired haemophilia A with a factor
VIII inhibitor
Clot lysis times were determined in the plasmas of three patients with congenital haemophilia A
with high anti-factor VIII titres (114 BU/ml (dark grey circles), 133 BU/ml (light grey circles) and 188
BU/ml (open circles)) and one acquired haemophilia A patient with a high inhibitor titre (181 BU/
ml (solid circles)). Coagulation was initiated by tissue factor (1*105 dilution of Innovin) and
30 U/ml of tPA was used to induce fibrinolysis. The effect of the absence or presence of 1 U/ml
factor VIII, 15 µg/ml TAFI, 1 nM TM and 50 µg/ml CPI were determined.
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TAFI levels in individual haemophilia A patients
In haemophilia A patients the mean TAFI level was decreased compared to the 40 normal
individuals that comprise the normal plasma pool (82.0% vs.  97.7% (26); p<0.0004 (t-test)) or
(82.0% vs 98.8%; p<0.0029) when women were omitted from the control group. Because TAFI
levels were found to increase with age (97) and the haemophilia A patients were on average
younger than the control group (13.6 vs 36.1 years), TAFI levels were determined in a group of
young children (n=11; mean age 7.5 years).  In this group of children TAFI levels were also
decreased compared to the control group and were not significantly different from the
haemophilia A patients (81.9% vs 82.0%).
Since TAFI levels were found to determine the clot lysis times in normal healthy individuals
(26), the clot lysis time or the TAFI level might give an insight in the severity of the bleeding
complications of the haemophilia A patients. TAFI levels correlated with the clot lysis times in
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haemophilia A patients in the presence of factor VIII (spearman r = 0.33; p= 0.015) but not in the
absence of factor VIII (figure 5). However no correlation between the TAFI levels and the
severity of the bleeding complications in haemophilia A patients (as characterized by age of first
bleeding, frequency of bleeding in first year or the total amount of profylaxis per year) could be
observed.
Addition of TM or TAFI to patients with factor VIII inhibitors
In approximately 25% of the patients with severe haemophilia A inhibitory antibodies
directed against factor VIII develop after multiple transfusions with factor VIII concentrate (260).
To determine if addition of TAFI or TM also increased the clot lysis times in patients who have
developed inhibitory antibodies against factor VIII, clot lysis times were determined in four
patients with high factor VIII antibody titres (three congenital inherited haemophilia A patients:
188, 133 and 114 BU/ml and one acquired haemophilia A patient: 181 BU/ml). As anticipated,
addition of factor VIII had no effect on the clot lysis times. In contrast, addition of both TAFI or
TM increased the clot lysis times, similarly to that observed in the haemophilia A patients without
an inhibitor (figure 6).
Discussion
Here we report that the down regulation of fibrinolysis is severely impaired in haemophilia A
patients due to the absence of TAFI activation at low tissue factor concentrations. The bleeding
complications in haemophilia A patients have always been attributed to defective clot formation
despite the fact that bleeding occurs hours or days after injury (after the clot had been formed).
This can not be explained by a defective clot formation alone and suggests that additional
mechanisms are involved in the manifestation of bleeding in haemophilia A patients. Recently,
a revised model of blood coagulation provided a plausible explanation for the defect in
haemophilia A (82). In this model coagulation is initiated via the extrinsic system by the exposure
of tissue factor resulting in the generation of sufficient amounts of thrombin to induce fibrin
formation. Thrombin formation continues inside the fibrin clot via the intrinsic pathway by the
activation of factor XI by thrombin (64). Although only small amounts of activated factor XI are
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formed, a secondary burst of thrombin formation is provided by the intrinsic pathway due to the
continued activation of factor XI by thrombin and the amplification power of both the tenase and
the prothrombinase complex. These high concentrations of thrombin are needed for the
activation of TAFI and the inactivation of scu-PA that results in a down regulation of fibrinolysis
(65, 75). Thrombin thus not only forms the fibrin clot but also protects the fibrin clot against lysis.
This model implies that haemophilia A patients have a defective thrombin formation via the
extrinsic pathway at low tissue factor concentrations, a reduced secondary burst of thrombin
formation via the intrinsic pathway and a defective TAFI and scu-PA mediated down regulation
of the fibrinolytic system. We studied the regulation of tissue factor induced coagulation and
fibrinolysis in haemophilia A patients using a clot lysis assay that measures the efficiency of the
coagulation system to generate thrombin to down regulate fibrinolysis. We found a defective
TAFI dependent downregulation of fibrinolysis when low tissue factor concentrations were used
to initiate coagulation, whereas at high tissue factor concentrations a normal TAFI dependent clot
lysis time was obtained. This indicates that in haemophilia A plasma at low tissue factor
concentrations not enough thrombin is generated  via both the extrinsic and intrinsic pathway to
activate TAFI whereas at high tissue factor concentrations the extrinsic pathway generates
sufficient thrombin to activate TAFI independent of the intrinsic system. In previous studies we
found in normal individuals a correlation between the TAFI levels and the clot lysis time in the
presence of an intact coagulation system (26). An abnormal clot lysis time could therefore also
be explained by a decreased TAFI level. The TAFI levels in the haemophilia A patients were
found to be lower compared to a control group of normal individuals, but the TAFI level was not
significantly different from an age matched group of young children. TAFI levels are known to
increase with age (96, 97). In agreement with our previous study where correlation between the
TAFI level and clot lysis was lost upon disruption of the intrinsic pathway (26), the TAFI level
and the clot lysis time did not show a significant correlation in the haemophilia A patients. No
correlation was found between TAFI levels and bleeding complications (age of first bleeding,
frequency of bleeding in the first year or the total amount of factor VIII used for prophylactic
treatment per year).
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Reconstitution of haemophilia A  plasma with factor VIII resulted in a significant correlation
between the clot lysis time and TAFI level as was also observed in the plasmas of normal
individuals. This indicates that the activation of TAFI and the down regulation of fibrinolysis
proceeds normally in haemophilia A plasma provided factor VIII is present.
The defective clot lysis time in haemophilia A was also corrected by increasing the TAFI
level. Previous studies had shown that the TAFI concentration in plasma is well below the Km
of the activation reaction of TAFI by thrombin. Increasing the TAFI level two fold resulted
indeed in a normalization of the clot lysis time and the clot lysis times continued to prolong at
increasing TAFI concentrations. This indicates that some thrombin is generated via the extrinsic
pathway at low tissue factor concentrations that is capable of activating TAFI which becomes
more pronounced when the TAFI level is increased. This is in contrast to the effect of increasing
the factor VIII level. At >1% factor VIII a normal clot lysis time is observed and higher levels of
factor VIII do not result in a further prolongation of the lysis time suggesting that the thrombin
formation already proceeds at its maximal rate at about 0.01 U/ ml of factor VIII.
Thrombomodulin was shown before to correct the impaired clot lysis in plasma of patients
with haemophilia A (48). Thrombomodulin increases the efficiency of thrombin to activate TAFI
many fold making trace amounts of thrombin more effective in the activation of TAFI (29).
Thrombomodulin also stimulates the activation of protein C which acts not only as an
anticoagulant by the inactivation of factors Va and VIIIa but also as an profibrinolytic effect
because it reduces the generation of thrombin (25). Recently we showed that at low
concentrations thrombomodulin predominantly stimulates the activation of TAFI by thrombin
and thus has an antifibrinolytic effect whereas at high concentrations of thrombomodulin protein C is
activated and  the profibrinolytic effect becomes more pronounced (72). The shift from
antifibrinolytic to profibrinolytic depending on the concentration of thrombomodulin hampers an
eventual clinical use of thrombomodulin. Recently, critical residues have been identified in both
thrombin and thrombomodulin that selectively stimulate TAFI or protein C activation (68, 69).
Such variants might become useful tools for selectively increasing the rate of TAFI activation in
haemophiliacs.
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TAFI dependent down regulation of fibrinolysis is severely impaired in haemophilia A
patients with an inhibitor against factor VIII. In these patients the clot lysis could not be corrected
by reconstitution with factor VIII. However addition of TAFI or thrombomodulin normalized the
clot lysis test indicating that trace amounts of thrombin generated by the extrinsic pathway could
be used effectively in these patients in the down regulation of fibrinolysis.
These data suggest that antifibrinolytic therapy would contribute to reduce the bleeding
complications in haemophilia A. The concept of an antifibrinolytic therapy in haemophilia A is
not new and has been advocated for 30 years. Systemic fibrinolysis inhibitors, such as tranexamic
acid, a lysine analog that competes with the binding of tPA and plasminogen to fibrin were
successfully used during tooth extraction and are still frequently used for the treatment of
haemophilia A patients with inhibitors (261). Our data suggest that other agents might be
developed that improve the efficiency of TAFI to down regulate fibrinolysis such as agents that
increase the rate of activation of TAFI by thrombin or that increase the stability of activated
TAFI. Such agents could be useful in the treatment of patients with haemophilia A.
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The Regulation of Coagulation and Fibrinolysis:
It’s All About Balance
Chapter 9
Laurent O. Mosnier
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Introduction
The coagulation cascade is a prominent mechanism to prevent excessive blood loss upon
injury to the vascular system. Upon initiation of the coagulation cascade, when the endothelial
cell lineage is ruptured and tissue factor is exposed to the blood,  a series of linked enzymatic
reactions in which coagulation factor zymogens are converted to their active serine protease
ultimately result in the formation of thrombin (210, 262). Thrombin is the key enzyme of the
coagulation system and has multiple substrates. The preference for these substrates is dependent
on the thrombin concentration (263). At the subnanomolar range thrombin acts as an agonist for
platelet activation thereby sustaining the primary haemostatic response, the formation of a
platelet plug. Thrombin also activates factors V and VIII thereby accelerating its own formation
by the coagulation cascade. At the low nanomolar concentrations, thrombin converts fibrinogen
into insoluble fibrin polymers which stabilizes the platelet plug and forms the clot. After the
formation of the fibrin clot, thrombin formation continues inside the clot (64) and at the high
nanomolar range (>100 nM) thrombin predominantly inhibits fibrinolysis by the activation of
factor XIII (264), the inactivation of single-chain urokinase (77, 211) and the activation of TAFI
(18, 65).
The fibrinolytic system
By inhibition of fibrinolysis, thrombin prevents undesired and premature degradation of the
fibrin clot which could otherwise result in episodes of rebleeding. The fibrinolytic system also
plays an important role in the dissolution and removal of fibrin clots from the circulation, thereby
preserving the patency of the vasculature and surrounding tissue (265). Plasmin, the key enzyme
of this system is capable of degrading fibrin into small soluble fragments and thereby removes the
fibrin clot (101). In blood, plasmin is formed by the activation of plasminogen by tissue type
plasminogen activator (tPA), a process in which fibrin acts as a necessary cofactor (133, 266).
Regulation of fibrinolysis occurs at the level of activation by plasminogen activator inhibitors
(PAI) (267), at the level of plasmin by α2-antiplasmin (268) or in response to activation of the
coagulation cascade by factor XIII and TAFI (18, 65, 264). Control of the regulation of
fibrinolysis is important since impairment of fibrinolysis is associated with thrombosis, whereas
excessive fibrinolysis is manifested by a bleeding tendency (132, 269, 270).
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TAFI, the missing link between coagulation and fibrinolysis
A revision of the traditional coagulation cascade, facilitated by the concomitant
discovery of TAFI, provided a better understanding of the mechanism of interaction between
coagulation and fibrinolysis (18, 82). In this revised model, coagulation and fibrinolysis
conspire and the extrinsic- and intrinsic pathways coincide in their attempt to generate the
high concentrations of thrombin required for the activation of TAFI (see chapter 1 for more
details).
Activation of TAFI is mediated by relatively high concentrations of thrombin that are
formed via the intrinsic pathway in a factor XI dependent way and evidence from both in
vitro  and in vivo  experiments suggest that in plasma an intact factor XI (intrinsic) feedback
loop generates sufficient thrombin for the activation of TAFI (64, 65, 99). As described in
chapter 2, the TAFI levels are an important factor in the regulation of fibrinolysis. Since the
TAFI concentration in plasma is well below the Km of the activation reaction of TAFI by
thrombin an increase in the TAFI concentration is accompanied by increased activation of
TAFI and down regulation of fibrinolysis. In agreement with this, a correlation was found
between the TAFI levels in normal individuals and the clot lysis time. This correlation was
not observed when the intrinsic pathway was blocked, indicating the importance of thrombin
formation via the intrinsic pathway for the activation of TAFI (chapter 2). However, in the
presence of the endothelial cell receptor thrombomodulin, much lower concentrations of
thrombin are required for the activation of TAFI due to an increase of the catalytic efficiency
of about 1250 fold (29). Consequently, the contribution of the intrinsic pathway to the
activation of TAFI is less pronounced in the presence of thrombomodulin. Secretion and
activation of TAFI upon stimulation of platelets by thrombin suggests a role for TAFIa in the
early stages of clot formation during platelet plug formation (chapter 6). Regulation of TAFI
activity occurs most likely by a rapid spontaneous decay of TAFIa activity, a process that
involves temperature-dependent conformational instability and results in a half-life of
TAFIa at 37°C of about 10 minutes (19,  35). To date there have been no reports on human
endogenous TAFIa inhibitors.
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TAFI in health and disease
By now there are several indications that TAFI comprises an important regulatory link
between coagulation and fibrinolysis. As mentioned in the previous section TAFI levels in
plasma correlated with the clot lysis times in healthy individuals, indicating the important role of
the TAFI plasma concentration in the regulation of fibrinolysis (chapter 2). In agreement with
this, high TAFI levels were found to be an independent risk factor for venous thrombosis (49) and
men requiring coronary artery bypass grafting because of stable angina pectoris had increased
preoperative TAFI levels (42). Inhibition of TAFIa by the carboxypeptidase inhibitor from
potatoes (CPI) was found to enhance either tPA-induced or endogenous thrombolysis in a
number of different animal models (98-100, 119), suggesting an important therapeutic
application in the treatment of myocardial infarction and stroke. Correlation of TAFI levels in
plasmas with markers of the acute phase response (C-reactive protein and haptoglobin) (42) and
the identification of TAFI as an acute-phase reactant in mice and rats (38, 39) indicate a possible
role for TAFI in inflammatory disease. This suggests that increased TAFI levels during
inflammation contribute to a prothrombotic- and antifibrinolytic state. In addition, a number of
observations suggest a shift towards stimulation of TAFI activation (see chapter 1 for a detailed
discussion). The role of TAFI in inflammation can be two fold. On one hand the increased TAFI
levels might contribute to the inactivation of inflammatory mediators such as anaphylatoxins and
inflammatory peptides such as C3a and C5a. On the other hand, the increased TAFI levels could
contribute to an increased inhibition of fibrinolysis and thereby facilitate the deteriorating effects
inflammatory processes. Which mechanism will prevail will have to be determined in future
studies.
In contrast to high levels of TAFI, a decreased TAFI concentration is considered to promote
bleeding, however compelling evidence for this is still lacking. An acquired partial deficiency of
TAFI was found in patients with acute promyelocytic leukaemia (APL) which was characterized
by severely reduced TAFIa activity (40%) but normal TAFI antigen levels (114). In addition, the
bleeding complications in young haemophilia A patients might be exacerbated by the relatively
low TAFI levels in these youngsters (chapter 8). To date no genetic origin of TAFI deficiency has
been reported and a polymorphism at Ala147Thr was not accompanied by a change in the
enzymatic characteristics of TAFI (43).
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What is the physiological role of TAFI in fibrinolysis?
Activation of TAFI in clot lysis assays results in a prolongation of the clot lysis time in vitro
and inhibition of TAFIa in various in vivo animal models increased both endogenous and tPA-
induced fibrinolysis (18, 98-100, 119). This implies that the physiological role of TAFI in
fibrinolysis is the temporal delay of plasmin formation and thereby prevents the initiation of
fibrinolysis. This temporal delay of fibrinolysis enables the formation of a well-structured fibrin
clot. Clots formed by low concentrations of thrombin are turbid, porous, have thick fibrin fibers
and are highly susceptible to fibrinolysis, whereas clots formed by high concentrations of fibrin
are less turbid, have a tightly knit network of thin fibers and are relatively resistant to fibrinolysis
(271). In addition, cross linking of the fibrin polymers by activated factor XIII renders the clot
more resistant to lysis. Factor XIII is activated, like TAFI, by relatively high concentrations of
thrombin and the formation of fibrinolysis resistant γ-multimers is a slow process that takes hours
to days to be completed (272). This suggests that the physiological role of augmentation of
fibrinolysis by TAFIa resides in the opportunity for factor XIII to stabilize the fibrin clot and
improved structural organization of the clot.
Activation of TAFI: Thrombin or thrombin-thrombomodulin?
Two possible mechanisms have been proposed to mediate the activation of TAFI: high
concentrations of thrombin generated via the intrinsic pathway, and thrombin in complex with
thrombomodulin which requires much lower concentrations of thrombin. The thrombomodulin-
mediated increase in the catalytic efficiency of TAFI activation by three orders of magnitude and
the existence of a similar mechanism for protein C, for which thrombomodulin is considered to
be the physiological cofactor, might argue in favor of thrombin-thrombomodulin as the
physiological activation mechanism for TAFI. On the other hand, the impaired down regulation
of fibrinolysis in haemophilia A patients (chapter 8) and the enhanced endogenous thrombolysis
upon inhibition of factor XI in a rabbit thrombolysis model (99) argues in favor of thrombin
formation via the intrinsic pathway as the physiological mechanism of TAFI activation.
Consideration of the differences between both mechanisms might provide a clue in this apparent
controversy. Besides the concentration of thrombin and the presence or absence of
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thrombomodulin, the most apparent differences are the localization of TAFI activation and the
quantity of TAFIa generated by both mechanisms. Thrombin-thrombomodulin mediated TAFI
activation occurs in the proximity of the endothelial cells and results in a quantitative conversion
of TAFI to TAFIa. Consequently, TAFIa is located outside of the clot where it protects the surface
of the fibrin clot. The surface of the clot is likely to be the primary location where fibrinolysis is
initiated due to increased local concentrations of tPA released by activated endothelial cells in the
proximity of the fibrin clot (273, 274). A less vigorous initiation of fibrinolysis occurs inside the
fibrin clot mediated by circulating tPA that is incorporated in the clot during clot formation. A
massive activation of TAFI, such as mediated by the thrombin-thrombomodulin complex, would
not be very helpful inside a clot since the half life of TAFIa is only 10 min and in contrast to the
situation outside the clot where new zymogen is constantly provided by the circulation, the
supply of new zymogen inside the clot is limited by the porosity of the clot. Instead, thrombin
formation continues after clot formation via the intrinsic pathway (64) and thrombin bound to
fibrin is relatively protected against inhibition by heparin-antithrombin III (275). Thrombin
mediated TAFI activation results in a limited use of zymogen, thereby enabling the generation of
active TAFI for a prolonged period of time. Systemic neutralization of factor XI activity by anti-
factor XI antibodies resulted in an similar increase of endogenous thrombolysis in a rabbit model
compared with incorporation of the anti-factor XI antibodies in the fibrin clot, indicating that
activation of TAFI by thrombin occurs both inside and on the surface of the fibrin clot (99). The
above suggests that the proposed mechanisms for the activation of TAFI are not mutual exclusive
but are in fact complementary to each other. This way, activation of TAFI by thrombin located
on the fibrin surface inhibits the formation of plasmin where it can do most harm, whereas
activation of TAFI by the thrombin-thrombomodulin complex on endothelial cells adjacent to the
clot protect the outside of the clot against the fibrinolytic attack initiated by the release of tPA by
stimulated endothelial cells.
TAFI and the protein C pathway
The function of TAFI in the regulation of fibrinolysis in response to activation of the
coagulation cascade shows a striking similarity between the function of protein C in the
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Figure 1. The thrombomodulin paradox
Specific stimulation of TAFI or protein C activation is dependent on the concentration of
thrombomodulin. At low concentration of thrombomodulin stimulation of TAFI activation results
in down regulation of fibrinolysis and low concentrations of thrombomodulin are therefore
antifibrinolytic. At higher concentration of thrombomodulin the activation of protein C becomes
more pronounced. Down regulation of thrombin formation by activated protein C results in a
decreased activation of TAFI and an up regulation of fibrinolysis. High concentrations of
thrombomodulin are therefore profibrinolytic.
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regulation of the anticoagulant pathway in response to activation of the coagulation cascade.
Both TAFI and protein C are activated by thrombin and for both enzymes the activation is
enhanced by the endothelial cell receptor thrombomodulin about 1250 fold (29, 164). The
presence of a cofactor in the function of TAFI, similar to the role of protein S in the inactivation
of factors Va and VIIIa by activated protein C, has not been established yet but the interaction of
TAFI with plasminogen (28) and fibrin (unpublished observation) suggest that a similar
mechanism might be possible. In addition, the profibrinolytic effect of protein C was attributed
to inhibition of TAFI activation by activated protein C (25). By inactivation of the factors Va and
VIIIa, activated protein C inhibits the formation of thrombin and thereby diminishes the
activation of TAFI.
The role of protein S in fibrinolysis
In addition to the profibrinolytic effect of activated protein C, the profibrinolytic effect of
protein S might be even more pronounced. Protein S is not only profibrinolytic by acting as a
cofactor to activated protein C in decreasing the formation of thrombin and subsequent TAFI
activation (chapter 5), it also decreased the rate of TAFI activation independently of activated
protein C by inhibition of the initial thrombin formation which could be attributed to the APC-
independent anticoagulant function of protein S (chapter 5). In addition, a recent study suggested
that the fibrinolysis resistant, tightly knit network of thin fibers structure of the clot was not
dependent on the total amount of thrombin generated but rather on the initial rate of thrombin
formation (276). Protein S, via its APC-independent anticoagulant activity (199, 202),
predominantly inhibits the initial formation of thrombin and might thereby enhance the
formation of a fibrinolysis susceptible fibrin clot. These effects of protein S on fibrinolysis,
attributed to its APC-independent anticoagulant activity, suggest an unexpected but prominent
role for protein S in the regulation of fibrinolysis.
Thrombomodulin, TAFI and protein C: What is going on?
The profibrinolytic effect of protein C pathway emphasizes the duplicitous role of
thrombomodulin in the regulation of protein C and TAFI activation. On one hand
163
C
H
A
P
T
E
R
9
thrombomodulin down regulates fibrinolysis by stimulation of TAFI activation but on the other
hand thrombomodulin up regulates fibrinolysis by stimulation of protein C activation resulting
in the inhibition of TAFI activation. Distinct domains in thrombomodulin have been identified to
mediate these processes (31, 68). Although activation of both protein C and TAFI occur
simultaneous, the thrombomodulin concentration was found to be the determining factor in the
outcome of the overall effect (chapter 3). The activation of TAFI is predominantly stimulated at
low thrombomodulin concentrations resulting in a down regulation of fibrinolysis whereas at
high thrombomodulin concentrations the activation of protein C becomes more important
resulting in a decrease of TAFI activation and consequently an up regulation of  fibrinolysis
(chapter 3). In analogy with the thrombin paradox in which thrombin is an anticoagulant at low
concentrations but a procoagulant at high concentrations, the thrombomodulin paradox is
postulated in which thrombomodulin is antifibrinolytic at low concentrations but profibrinolytic
at higher concentrations (figure 1). This implies that a procoagulant state due to a high thrombin
concentration becomes more thrombotic when it is accompanied by a down regulation of
fibrinolysis caused by a low thrombomodulin concentration and vice versa an anticoagulant state
due to a low thrombin concentration is more antithrombotic in the presence of high
concentrations of thrombomodulin which up regulates fibrinolysis. However when thrombin and
thrombomodulin are both present at low concentration, fibrin formation is hampered by the
anticoagulant state induced by thrombin, but if fibrin is formed it is protected against lysis due to
the down regulation of fibrinolysis by thrombomodulin. This mechanism ensures stable clot
formation at sites where it is needed such as in the haemostatic plug.
Protein C inhibitor and fibrinolysis
Interestingly, the effects of  protein C inhibitor (PCI), a potent inhibitor of thrombin bound to
thrombomodulin, on the activation of TAFI and the regulation of fibrinolysis were the inverse of
the effects of thrombomodulin and were dependent on the thrombomodulin concentration
(chapter 4).  At low thrombomodulin concentrations PCI predominantly inhibits the activation of
TAFI whereas at higher thrombomodulin concentrations PCI inhibits the generation of APC by
the thrombin-thrombomodulin complex resulting in a stimulation of the activation of TAFI
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Figure 2. The opposite effects of thrombomodulin and PCI on fibrinolysis
The effects of thrombomodulin (TM) and inhibition of the thrombin-thrombomodulin complex by
PCI are different depending on the thrombomodulin concentration. At low concentration,
thrombomodulin stimulates activation of TAFI (antifibrinolytic) and inhibition of thrombin bound
to thrombomodulin by PCI inhibits TAFI activation (profibrinolytic). At high concentrations,
thrombomodulin stimulates activation of protein C (anticoagulant) and TAFI activation is
inhibited by activated protein C (profibrinolytic). Inhibition of the thrombin-thrombomodulin
complex by PCI, at high thrombomodulin concentrations, diminished protein C activation
(procoagulant) whereas the decreased activation of protein C leads to increased activation of
TAFI (antifibrinolytic).
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(figure 2). The inhibition of  TAFI activation by PCI at low thrombomodulin concentrations but
not at high thrombomodulin concentrations demonstrated that relatively low thrombomodulin
concentrations were sufficient to maximally stimulate TAFI activation.  In contrast, protein C
activation was only affected by PCI at high thrombomodulin concentrations suggesting that for
the activation of protein C higher thrombomodulin concentrations were required for maximal
stimulation than for TAFI.
In vivo, thrombomodulin is predominantly located on the surface of endothelial cells but
circulating levels of soluble thrombomodulin which represent the products of limited proteolytic
cleavage of cell surface and/or intracellular thrombomodulin have been implicated in the
activation of TAFI (109). These soluble thrombomodulin fragments circulate at about 5-20 ng/ml
(100-400 pM) in normal adults and are elevated to more than 50 ng/ml in plasma from patients
with diseases accompanied by endothelial cell damage such as disseminated intravascular
coagulation (DIC), diabetes mellitus with angiopathy and systemic lupus erythematosus (109).
Preliminary results indicated that inhibition of PCI by monoclonal antibodies in normal plasma
prolonged the clot lysis time, whereas the monoclonal antibodies had no effect in PCI depleted
plasma. Whether the prolongation of the clot lysis time by inhibition of PCI is indeed mediated
via stimulation of TAFI activation by soluble thrombomodulin remains to be established, but it
supports the hypothesis that the PCI mediated inhibition of thrombin in the presence of low levels
of thrombomodulin prevents a significant effect of soluble thrombomodulin.
The role of the endothelial protein C receptor
Recently, an endothelial cell protein was identified that promoted the activation of protein C
by the thrombin-thrombomodulin complex and was named the endothelial protein C receptor
(EPCR) (277). By stimulating protein C activation, EPCR could enhance the inhibition of TAFI
activation by activated protein C. Interestingly, the tissue distribution of EPCR is the inverse of
that of thrombomodulin (278). This has led to the hypothesis that the EPCR, which binds both
protein C and activated protein C with similar affinity (279) promotes the formation of quaternary
EPCR-protein C-thrombin-thrombomodulin complexes and thereby facilitates the activation of
protein C in the larger vasculature where thrombomodulin is scarce (167). This mechanism,
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although very appealing at first, has one major discrepancy. Binding of a soluble form of EPCR
to activated protein C inhibited the anticoagulant activity of activated protein C (280).
Furthermore, the high affinity of protein C and activated protein C for EPCR (Kd  30 nM) suggests
that upon activation of protein C, activated protein C remains in complex with the receptor (280).
This troubles a straightforward assessment of the role of the EPCR in the regulation of
anticoagulant activity.
Implications of the thrombomodulin paradox, an example
The opposite effects of thrombomodulin on the regulation of fibrinolysis can have
profound implications for the regulation of fibrinolysis throughout the vasculature. In
particular since it is known that the expression of thrombomodulin in the vascular system is
very heterogeneous. The expression of the amount of thrombomodulin on the endothelial
cell is greatly influenced by the composition of the underlying extracellular matrix and the
effective thrombomodulin concentration can rise from less than 1 nM in the large arteries to
more than 100 nM in the capillary beds (166-168). This suggests that the haemostatic
balance of each vascular bed is the net result of the local balance between pro- and
anticoagulant and pro- and antifibrinolytic mechanisms. The fact that congenital or acquired
hypercoagulable states are characterized by thrombotic phenotypes in different parts of the
vasculature imply that coagulation and fibrinolysis are differentially regulated in different
segments of the vascular bed (188). The vasculature in the brain provides a striking example
of this.
The brain is practically void of thrombomodulin and the combination of high tissue
factor expression in the brain and low expression of thrombomodulin suggests that the brain
may have preferentially adapted to guard against hemorrhage as bleeding inside a closed and
rigid cavity such as the skull could be life-threatening (167, 168, 189). Interestingly,
immunolocalization of tPA in the brain revealed that 90% of the tPA positive vessels were
precapillary arterioles and postcapillary venules (7.5 - 300 µm), whereas only 3% of the
capillaries (accounting for 40% of all vessels) were positive, suggesting that tPA containing
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endothelium is distributed mainly in smaller vessels, excluding the capillaries (281).
This illustrates the complexity of the possible interactions and the profound effects of
local environmental factors on the regulation of the balance between coagulation and
fibrinolysis. A thorough evaluation of feasability of the different processes and the effects on
the balance between coagulation and fibrinolysis might turn out to be important for the
evaluation new therapeutic strategies targeted to specific vascular beds.
It’s all about the balance
Coagulation is not just a consecutive order of events that is opposed by another system of
sequential ordered reactions called the fibrinolytic system. In fact the revision of the traditional
“waterfall” or “cascade” model of coagulation was already a first step in abandoning the
traditional one dimensional view on coagulation or fibrinolysis (82, 282, 283). In the new
generation of coagulation models a more multi-dimensional approach on coagulation and
fibrinolysis should be pursued that illustrates the effect of changes of specific reactions on the nett
balance of coagulation and fibrinolysis and in addition implement the possibility for vascular bed
specific adaptations.
In figure 3 a model of coagulation and fibrinolysis is presented that meets these criteria. In this
model, the coagulation and fibrinolytic factors are categorized to their relative contribution to
either pro- or anticoagulant effects and pro- or antifibrinolytic effects. In the “normal” situation,
haemostasis is in balance and is located in the center of the figure. Factors that initiate fibrinolysis
such as uPA and tPA or that are required for fibrinolysis such as plasminogen clearly are
profibrinolytic and have no effect on coagulation. Similarly to the profibrinolytic factors,
inhibitors of fibrinolysis such as TAFI, α2-antiplasmin, PAI and factor XIII are antifibrinolytic
and do not affect coagulation. The coagulation factors promote thrombin formation and are
therefore procoagulant, but by promoting thrombin formation they also increase the activation of
TAFI and are thus also antifibrinolytic. Tissue factor and factor VII(a) form an exception and are
only procoagulant without affecting fibrinolysis. Although an increased concentration of tissue
factor restored the decreased clot lysis times in haemophilia A plasma by increasing the thrombin
formation and the activation of TAFI, this is not observed in normal plasma (chapter 8). In the
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presence of an intact intrinsic pathway of coagulation, thrombin formation initiated by low tissue
factor concentrations is supported by additional thrombin formation via the factor XI (intrinsic)
feedbackloop and clot lysis times in the presence of either low or high concentration of tissue
factor are identical (chapter 8). In agreement with this therapeutical concentrations of fVIIa did
not restore the decreased clot lysis time in haemophilia A plasma and factor VII(a) is therefore not
considered to be antifibrinolytic (unpublished observation). Components of the protein C
pathway and inhibitors of thrombin (such as antithrombin III) or thrombin formation (such as
tissue factor pathway inhibitor) are clearly anticoagulant by their capacity to inhibit thrombin
Figure 3. Haemostasis is a thoroughly controlled balance
Coagulation and fibrinolytic factors are categorized to their relative contribution to either pro-
or anticoagulant effects and pro- or antifibrinolytic effects. In the “normal” situation,
haemostasis is in balance and is located in the center. The balance is maintained by the
different factors of the coagulation cascade and the fibrinolytic system, each pulling the
haemostatic balance towards the direction they represent, as indicated by the springs. The
contribution of the individual factors to the haemostatic equilibrium should be pictured as a
weight pulling on the spring and where the mass of the weight determines the force by which the
spring is pulled. The effect of thrombomodulin on the haemostatic balance is probably best
illustrated when the spring of thrombomodulin is pictured freely rotating between 180° and 270°
(or even 315°). Low concentrations of thrombomodulin, which predominantly stimulate TAFI
activation and are therefore antifibrinolytic would then be represented by the spring located in
the proximity of 180°, whereas at higher concentrations of thrombomodulin the spring rotates
towards 270° (315°) where the thrombomodulin is anticoagulant (profibrinolytic). A shift of the
haemostatic balance towards the right (procoagulant events) or bottom (antifibrinolytic
events) or any combination in between will result in an increased risk for thrombotic
complications, whereas a shift towards the left (anticoagulant events) or the top (profibrinolytic
events) or anywhere in between results in an increased risk for bleeding complications. The
following abbreviations were used: protein C (PC), protein S (PS), tissue factor pathway inhibitor
(TFPI), antithrombin III (ATIII), urine-tupe plasminogen activator (uPA), tissue-type plasminogen
activator (tPA), plasminogen (plg), tissue factor (TF), prothrombin (fII), factor V (fV), (activated)
factor VII (fVII(a)), factor VIII (fVIII), factor IX (fIX), factor X (fX), factor XI (fXI), factor XIII (fXIII),
palsminogen activator inhibitor (PAI), α2-antiplasmin (α2-AP) and thrombomodulin (TM).
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(formation) (chapters 3, 4 and 5 and (284)). Because inhibition of thrombin (formation)
concomitantly results in a decreased activation of TAFI these factors are also classified as
profibrinolytic. This also illustrates why no factor has been identified to be anticoagulant,
without affecting fibrinolysis. Such a substance would have to interfere in the final step of fibrin
formation by thrombin without affecting thrombin’s enzymatic activity towards other substrates
such as TAFI. Fibrin(ogen) is probably the best factor to represent both procoagulant and
profibrinolytic properties. Fibrinogen is an essential component of the procoagulant response
and decreased fibrinogen levels contribute to a bleeding diathesis. On the other hand fibrin or
anticoagulant procoagulant
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partially degraded fibrin, is profibrinolytic by serving as a template for tPA and plasminogen
thereby promoting the formation of plasmin. Finally, thrombomodulin has both antifibrinolytic
and anticoagulant effects depending on its concentration (chapter 3 and 4).
The haemostatic balance in health and disease
Most of the coagulation factors have been identified as a risk factor for thrombosis when
present at increased concentrations. Deficiencies of either components of the anticoagulant
protein C pathway or the fibrinolytic system are known to coincide with severe thrombotic
complications. Often, the thrombotic tendency of a risk factor is explained by the simple fact that
more thrombin is formed without acknowledging the secondary underlaying antifibrinolytic
effect of thrombin that is contributing to the prothrombotic phenotype (figure 3). Deficiencies of
protein C or protein S but also factor VLeiden, in which the inactivation of factor Va by activated
protein C is severely compromised due to a mutation in factor V (Arg506Gln), resulted in a large
increase of the activation of TAFI (chapters 3, 4 and 5). Although the increased activation of
TAFI is in this case not the primary cause of thrombosis, it does contribute to disturb the
haemostatic balance. On the other hand increased activation of TAFI might also be the primary
cause of thrombosis such as was recently suggested for the increased thrombotic risk associated
with elevated factor XI levels (95), which was attributed to additional thrombin formation by the
intrinsic pathway resulting in a prolonged activation of TAFI, and of course the thrombotic risk
associated with elevated TAFI levels (49).
In contrast, the bleeding complications caused by a deficiency in one of the coagulation
factors is not only the result of impaired fibrin formation but exacerbated by defective inhibition
of fibrinolysis (figure 4), as was shown in chapter 8 for haemophilia A. In approximately 25% of
the patients with severe haemophilia A inhibitory antibodies directed against factor VIII develop
after multiple transfusions with factor VIII concentrate, indicating a need for alternative
therapeutic strategies (260). Increasing the initial rate of thrombin formation by factor VIIa was
found to be an effective alternative and as shown in chapter 8 increasing the amount of TAFIa
generation by either low concentrations of thrombomodulin or increased concentrations of TAFI
also effectively restored the clot lysis times. In figure 4 it is illustrated that factor VII(a) and TAFI
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work in different directions each partly compensating the deficiency of factor VIII. It may turn
out that the combination of factor VII(a) and TAFI will be a more effective replacement of factor
VIII than factor VIIa alone.
Other substrates for TAFIa than fibrin
One of the mysteries that remain to be solved is why the carboxy-terminal lysines on fibrin are
such a good substrate for TAFIa but not for carboxypeptidase N, whereas in contrast to
carboxypeptidase N, TAFIa actually prefers carboxy-terminal arginines over lysines on small
synthetic substrates (13, 28, 50). This suggests that additional enzyme-substrate interactions or
physical structural properties are involved. It is therefore difficult to predict if specific substrates
will be cleaved by TAFIa, but basically all proteins with a carboxy-terminal basic amino acid are
potential substrates for TAFIa. As already mentioned inflammatory mediators such as
anaphylatoxins and inflammatory peptides such as C3a and C5a have to be considered. Inhibition
of plasmin by TAFIa has been demonstrated (137) and recently pancreatic carboxypeptidase B
was shown cleave off the carboxy-terminal lysine of antithrombin III (285). Direct evidence that
these substrates can be cleaved by TAFIa however is still lacking. Both carboxypeptidase N and
TAFIa decreased plasminogen binding to cells but the basic amino acid-containing substrate was
not defined (50). Endostatin is actually the first non-fibrin substrate identified for TAFIa
(chapter 7).
Endostatin is a 20 kD carboxy-terminal fragment of collagen XVIII that inhibits endothelial
cell proliferation and angiogenesis (286). Endostatin stimulated tPA-mediated plasminogen
activation and removal of its carboxy-terminal lysine residue by TAFIa abrogated the stimulation
of plasmin formation and the capacity of endostatin to inhibit tumor growth (chapter 7). This
suggests that stimulation of plasmin formation is the mechanism by which endostatin mediates
its anti-angiogenic effect. Indeed many other fibrinolytic factors have been reported to promote
or suppress angiogenesis (247). In fact, angiogenesis bears numerous similarities to coagulation
and fibrinolysis (247, 255). The formation of a fibrin rich provisional extracellular matrix,
initiated by tissue factor on stimulated endothelial cells and in the subendothelial matrix, is
essential for the adhesion and proliferation of endothelial cells, whereas degradation of the matrix
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Figure 4. The haemostatic balance in haemophilia
The deficiency of either factor VIII (haemophilia A), factor IX (haemophilia B) or factor XI
(haemophilia C) is indicated by the snapped spring in the lower right corner. Consequently, the
formation of thrombin is impaired and the haemostatic balance shift to the left. Due to the
decreased thrombin formation via the intrinsic pathway the activation of TAFI is diminished and
the haemostatic balance is shifted to the top. This positions the haemostatic balance in the
upper left of the figure, the area designated to be associated with bleeding complications.
Administration of purified factor concentrate results, according to our model, in the
replacement of the snapped spring by a new one. Administration of TAFI or factor VIIa each
partially compensates the shift of the haemostatic balance caused by the deficient factor.
Although low concentrations of thrombomodulin can compensate the shift in the haemostatic
balance, high concentrations of thrombomodulin exacerbate the bleeding complications. The
abbreviations used are explained in the legend to figure 3.
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is necessary for endothelial cell growth and migration (255). This indicates the need for thorough
regulation of controlled matrix formation and breakdown in close proximity of each other.
Disturbances of this balance, either by promoting or inhibiting matrix formation or degradation,
will result in an inhibition of angiogenesis. By providing a template for plasminogen and tPA, a
role normally accomplished by partially degraded fibrin, endostatin accelerates matrix
degradation and inhibits angiogenesis. In agreement with this, also continuous systemic
treatment of mice with tPA, pancreatic carboxypeptidase B or fibrin degradation products (FDP)
inhibited tumor growth in mice (chapter 7 and (255)) and indicates that modulation of
plasminogen activation by TAFIa might have profound effects on tumor growth and
angiogenesis.
Notwithstanding the identification of new substrate(s) for TAFIa in the future, the
identification of TAFI as missing link in the regulation of coagulation and fibrinolysis initiated
a new concept in the regulation of coagulation and fibrinolysis and contributed to a better
understanding of the haemostatic mechanism.
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Haemostase
Hartinfarct en beroerte zijn het gevolg van trombi (bloed stolsels) die belangrijke vaten
afsluiten en daardoor weefsel beschadiging van hart of hersenen veroorzaken. Op den duur
worden dergelijke trombi in het lichaam opgelost door het fibrinolytisch systeem, een stelsel van
enzymen dat de belangrijkste component van een trombus, namelijk fibrine oplost. Bij het
ontstaan van een trombus speelt het bloedstollingssysteem een belangrijke rol. Dit systeem
bestaat uit een reeks van stollingsfactoren die elkaar kunnen activeren. Het systeem komt op gang
als bij beschadiging van de vaatwand weefsel factor in contact komt met het bloed. Het resultaat
van het stollingsproces is de vorming van trombine, een enzym dat in staat is fibrinogeen in
fibrine om te zetten. Onlangs is gebleken dat trombine zelf een mechanisme opgang brengt dat
ervoor zorgt dat het fibrine niet meteen wordt opgelost door het fibrinolytische systeem.
Trombine maakt niet alleen het stolsel, maar beschermt het dus ook. Volgens onze theorie wordt
deze beschermende werking vooral veroorzaakt door activatie van trombine activeerbare
fibrinolyse inhibitor (TAFI) door trombine. Het trombine dat voor de activatie van TAFI nodig
is ontstaat via een bepaalde route in het stollingssysteem waarin stollingsfactor XI een essentiële
rol speelt. Trombine kan deze route zelf op gang brengen door activatie van factor XI. Wanneer
we dit mechanisme zouden kunnen remmen, door bijvoorbeeld de vorming van trombine nodig
voor de activatie van TAFI te remmen, de activatie van TAFI door trombine te verhinderen of
door de werking van het geactiveerde TAFI te verminderen, zou dat tot gevolg hebben dat het
stolsel niet beschermd wordt tegen fibrinolyse en dus sneller zou oplossen. Hierdoor zou na een
hartinfarct of beroerte de bloed doorstroming weer sneller op gang gebracht kunnen worden
waardoor de schade aan weefsels door afsluiting van het bloedvat door een trombi wordt
verminderd.
Doel van de studie
Dit onderzoek is in eerste instantie gericht op het mechanisme van de beschermende werking
van trombine op een trombi. De vraag is hoe die trombine vorming tot stand komt en hoe, via de
activatie van TAFI door trombine, het stolsel beschermd wordt tegen afbraak.  In dit proefschrift
is beschreven hoe de trombine vorming tot stand komt die leidt tot activatie van TAFI en
bescherming van het fibrinestolsel tegen fibrinolyse.
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TAFI
TAFI (trombine activeerbare fibrinolyse inhibitor) remt de fibrinolyse door het verwijderen
van carboxy-terminale lysines van fibrine die essentieel zijn voor de binding van plasminogeen
aan fibrine en de activatie van plasminogeen. TAFI wordt geactiveerd door trombine gevormd
door de stollingscascade. Relatief hoge concentraties trombine zijn nodig voor de activatie van
TAFI. Eerder is aangetoond dat deze hoge concentraties trombine gevormd worden door een
amplificatie loop in de intrinsieke weg van de stollingscascade. Deze loop wordt opgestart
doordat trombine factor XI kan activeren, resulterend in additionele trombine vorming via de
intrinsieke weg.
TAFI bepalingen
In hoofdstuk 2 worden specifieke assays beschreven die zijn ontwikkeld voor de bepaling van
TAFI in humaan plasma: een sandwich ELISA voor de bepaling van het TAFI antigeen en een
activiteitsassay voor de bepaling van de activiteit van TAFIa in plasma. In een groep gezonde
vrijwilligers werden TAFI antigeen en TAFI activiteit bepaald. De verkregen waarden lieten
grote individuele verschillen zien en er was een significante correlatie tussen de TAFI waarden
en de individuele clot lysis tijden in deze personen. Indien de clot lysis tijden werden gemeten in
de aanwezigheid van een antilichaam dat de activatie van factor XI remt was er geen correlatie
te zien met TAFI antigeen en activiteit. Dit betekent dat ook in de individuele plasma monsters
de intrinsieke amplificatie loop van essentieel belang is voor de activatie van TAFI. Tevens is de
concentratie TAFI aanwezig in het plasma van zeer grote invloed op de clot lysis tijd.
De rol van het proteïne C systeem
Het proteïne C systeem is een natuurlijk mechanisme dat de vorming van trombine door de
stollingscascade afremt. Proteïne C wordt geactiveerd door trombine dat aan trombomoduline is
gebonden, een receptor op het oppervlak van endotheel cellen, de cellen die de binnenkant van
het bloedvat bekleden. Trombomoduline versterkt niet alleen de activatie van proteïne C door
trombine maar ook de activatie van TAFI door trombine. Aangezien actief proteïne C de
trombine vorming remt door de inactivatie van factor Va en VIIIa, is het de vraag wat het effect
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is van trombomoduline op de activatie van TAFI aangezien TAFI ook door trombine geactiveerd
wordt. Met behulp van de in hoofdstuk 2 beschreven ontwikkelde activiteitsassay voor TAFIa in
plasma zijn in hoofdstuk 3 de karakteristieken van de TAFI activatie bepaald bij verschillende
trombomoduline concentraties. Het blijkt dat als er maar weinig trombomoduline aanwezig is
vooral de activatie van TAFI gestimuleerd wordt terwijl bij hogere concentraties
trombomoduline de activatie van proteïne C belangrijker wordt waardoor de trombine vorming
en dus ook de activatie van TAFI geremd wordt. Dit betekent dat remming van fibrinolyse of juist
stimulatie van fibrinolyse mede afhankelijk is van de hoeveelheid trombomoduline op de
endotheel cel. Aangezien in het lichaam de concentratie van trombomoduline sterk afhankelijk
is van de diameter van het bloedvat en het bestudeerde weefsel zal de fibrinolyse of verschillende
plaatsen in het lichaam anders gereguleerd worden. Het besef dat deze verschillen mogelijk zijn
draagt bij aan een beter begrip waarom een stolsel juist op een specifieke plaats gevormd wordt
en wat de beste bijbehorende methode van behandeling is.
Proteïne C inhibitor
Recentelijk is PCI (proteïne C inhibitor) geïdentificeerd als een zeer goede remmer van het
trombine in complex met trombomoduline. Aangezien TAFI ook geactiveerd wordt door het
trombine-trombomoduline complex kan PCI mogelijk werken als een remmer van de TAFI
activatie. Aan de andere kant kan PCI ook de activatie van proteïne C door trombine in complex
met trombomoduline remmen waardoor de vorming van trombine niet geremd wordt en er dus
meer TAFI geactiveerd kan worden. In hoofdstuk 4 is beschreven dat beide processen kunnen
optreden afhankelijk van de concentratie van trombomoduline. Bij lage concentraties
trombomoduline, als trombomoduline voornamelijk de activatie van TAFI stimuleert, remt PCI
de activatie van TAFI, terwijl bij hogere concentraties trombomoduline, als de activatie van
TAFI geremd is door activatie van proteïne C, remt PCI de activatie van proteïne C en stimuleert
daarmee de activatie van TAFI. Het effect van PCI op de fibrinolyse is dus als het ware het
omgekeerde van het effect van trombomoduline.
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Proteïne S
Proteïne  S is een cofactor in de inactivatie van factor Va en VIIIa door geactiveerd proteïne C
(APC), maar heeft daarnaast ook een APC onafhankelijke anticoagulante functie. In hoofdstuk 5
is beschreven dat bij hogere trombomoduline concentraties proteïne S voor de remming van
TAFI activatie door APC een essentieel onderdeel van het proteïne C systeem is. Echter ook bij
lage concentraties trombomoduline remt proteïne S de activatie van TAFI onafhankelijk van
proteïne C. Deze remming is toegescheven aan de APC onafhankelijke anticoagulante functie
van proteïne S.
TAFI in bloedplaatjes
De vorming van een prop van geactiveerde en geaggregeerde bloedplaatjes vormt de eerste
stap in het stelpen van een bloeding. De bloedplaatjes prop wordt daarna verstevigd door een
netwerk van fibrine draden die gevormd worden door het stollingssysteem. Tijdens de activatie
van bloedplaatjes worden verschillende substanties uitgescheiden door de plaatjes die bijdragen
aan de vorming van de prop en het fibrine netwerk. In hoofdstuk 6 is beschreven dat TAFI ook
in bloedplaatjes aanwezig is en wordt uitgescheiden na activatie van de plaatjes. Dit betekent dat
TAFI mogelijk ook een rol speelt tijdens de vroege fase van stolselvorming.
TAFI in angiogenese en tumor groei
Angiogenese is de vorming van nieuwe bloedvaatjes. Vooral voor de groei van tumoren is
angiogenese belangrijk om de tumor van voldoende zuurstof en voedingsstoffen te voor zien. Een
veelbelovende behandeling van tumoren is dan ook de behandeling met remmers van
angiogenese. Endostatine is zo’n remmer van angiogenese echter het werkingsmechanisme is
nog niet bekend. In hoofdstuk 7 wordt een mogelijk mechanisme beschreven. Endostatine bevat
een carboxy-terminale lysine die belangrijk is voor de binding en activatie van plasminogeen.
Verwijdering van deze lysine door actief TAFI remde niet alleen de stimulatie van plasmine
vorming door endostatine maar ook de anti-angiogene werking van endostatine. Aangezien
stolling en fibrinolyse belangrijke processen zijn die zorgen voor de vorming en afbraak van de
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extra cellulaire matrix waarlangs de bloedvaatjes gaan groeien, zal verstoring van de balans
tussen stolling en fibrinolyse dit proces remmen. Dit duidt op een mogelijke rol voor TAFI in
angiogenese en tumor groei.
Hemofilie A
In hoofdstuk 8 wordt de rol van TAFI in hemofilie A beschreven. Hemofilie A is een
deficiëntie in stollingsfactor VIII waardoor de trombine vorming via de intrinsieke route is
verstoord. Aangezien activatie van TAFI afhankelijk is van de trombine vorming via deze route
is in hemofilie A de activatie van TAFI ook verstoord. Dit betekent dat de bloedingscomplicaties
in patiënten met hemofilie A niet alleen veroorzaakt worden door een verstoorde stolselvorming
maar ook doordat een stolsel nadat het eenmaal is gevormd niet beschermd is tegen afbraak door
het fibrinolytische systeem. Door toevoeging van extra TAFI of door toevoeging van lage
concentraties trombomoduline kon de activatie van TAFI worden vergroot en dit resulteerde in
een normalisatie van de clot lysis tijd in hemofilie A patiënten.
Conclusie
De vorming van trombine door het intrinsieke stollingssysteem en de activatie van TAFI zijn
belangrijk voor de bescherming van een bloedstolsel tegen vroegtijdige afbraak. De regulatie van
TAFI activatie is een complex proces waarin met vele andere factoren rekening gehouden moet
worden. Echter door een beter inzicht in deze processen te krijgen is het mogelijk om nieuwe
therapeutische strategieën te bedenken  of om bestaande behandelingsmethodes te verbeteren.
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